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Introduction
injuries where there is a risk of transmission of infection frequently present in emergency 
departments, sexual assault units, occupational health departments and primary care 
settings. Bloodborne virus (BBV) infections  such as hepatitis B (HBV), hepatitis C (HCV) 
and human immunodeficiency virus (HiV) are of particular concern because of the potential 
long-term health effects for people who become infected, the anxiety experienced by the 
injured persons,  and the increase in their prevalence in the population in recent decades. 
the appropriate management of such injuries, in the emergency and follow-up periods, 
has important implications in terms of minimising the risk of transmission of BBVs and in 
allaying the psychological impact on the injured person.
Many emergency departments and occupational health departments throughout ireland 
have developed guidelines for the management of injuries where there is a risk of BBV 
transmission. However, these guidelines differ in their scope (e.g. all BBVs versus HiV; all 
exposures versus occupational or sexual), their level of detail, and recommended actions, 
such as testing schedules and the use of post-exposure prophylaxis (PEP). the development 
of these guidelines was prompted by the idea of having standardised guidelines on the 
management of these injuries that could be used in all relevant settings throughout the 
country and that would be based on best available evidence and expert opinion.
Purpose and scope
the purpose of these guidelines is to provide comprehensive guidance on the appropriate 
management of injuries where there is a risk of transmission of BBVs and other infections. 
the guidelines are intended for use as follows:
Setting: Any medical setting where the patient first presents with the injury, for example, a 
hospital emergency department or occupational health department, a general practice, a 
dental practice, a Garda occupational health department, a clinic for sexually transmitted 
infections or a sexual assault treatment unit (SAtU).
Patient population: Members of the public in a healthcare or community setting; healthcare 
workers (HCW) or other workers (e.g. members of the Garda or defence forces) in an 
occupational setting; adults and children; both recipients and sources of injuries.
Type of injury: Needlestick or other sharps injury, sexual exposure, human bites, exposure 
of broken skin or of mucous membranes. these guidelines do not cover injuries where the 
source is an animal.
Time: Emergency management on first presentation, and also arrangements for any 
necessary follow-up.
Content
the guidelines cover the following aspects of management: first aid, risk assessment, 
testing, treatment (including PEP for HBV and HiV), counselling and follow-up, records and 
documentation. Although the focus is mainly on BBVs, the management of other risks is 
also covered in brief.
BaCkGround to the GuIdelInes
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The main questions covered by the guidelines are:
• What first aid treatment should be administered?
• Is the exposure significant?
○ What materials are significant for BBVs?
○ What injuries are significant for BBVs?
• How to assess the risk of transmission of BBVs?
○ What is the level of risk of HBV, HCV or HIV?
○ What factors in the injury increase the risk of transmission?
• How should the source be investigated?
• How should the recipient be investigated?
• What blood tests should be done and when?
•  Who should receive HBV vaccine and/or hepatitis B specific immunoglobulin (HBIG)?
•  When is HIV PEP indicated and what treatment protocol should be used?
•  How should HCV exposure be managed?
•  What reassurance can be given to the recipient?
•  What precautions are advised?
•  What follow-up is needed?
the content is arranged as follows:
1. Main body of text – a summary protocol for case management from presentation to 
discharge.
2. Appendices – stand-alone flow charts and tables; data collection forms; template 
letters and information leaflets; detailed discussion and evidence base for specific 
aspects of assessment or treatment.
Methods
Working group
the working group that developed the guidelines is a sub-committee of the Scientific 
Advisory Committee (SAC) of the Health Protection Surveillance Centre (HPSC), and 
included professionals with the relevant expertise and experience, and target users of the 
guidelines. the disciplines represented were dentistry, emergency medicine, infection 
prevention and control nursing, infectious diseases, medical microbiology, occupational 
medicine (hospital and Garda), and public health medicine. the members were chosen 
to represent a professional body or because of their individual expertise. the irish College 
of General Practitioners (iCGP) was unable to provide a representative but agreed to be 
available for consultation during the course of the guidelines development. the members of 
the working group and the organisations they represented are listed on page 10.
Search protocol
in developing the recommendations in these guidelines various sources of guidance were 
reviewed. initially, existing guidelines for the management of needlestick injuries, bites, 
and other blood and sexual exposures were reviewed. these included policies and standard 
operating procedures from emergency departments, occupational health departments, 
infectious diseases services and community health care settings in ireland. Guidelines from 
several Uk services were also reviewed. Existing irish guidelines on immunisation and the 
prevention of transmission of bloodborne viruses were included in this review. international 
documents were also examined, e.g. National institute for Health and Clinical Excellence 
(NiCE) guidelines, Centers for Disease Control and Prevention (CDC) sources and reviews 
from the Cochrane Database of Systematic Reviews. information which was deemed 
relevant for the purpose of developing these guidelines was extracted from these sources by 
working group members, and then discussed at the working group meetings to ensure that 
the guidance selected was appropriate for use in various settings throughout ireland. 
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in order to provide information for patients and their practitioners on the possible risk of 
transmission following different exposures, comprehensive reviews of reliable published 
resources were conducted by the working group members. A new detailed systematic review 
was not considered necessary, as it was felt by committee members that this would only 
replicate reviews which have already been published elsewhere, and would not have been 
feasible within the time allowed for the development of these guidelines. instead, available 
published resources were thoroughly reviewed, and their recommendations were appraised 
by the working group in terms of the reliability of the source, as well as their applicability 
and operability within irish healthcare settings. 
Where insufficient evidence or guidance was available from these sources, or where there 
were discrepancies in the information or recommendations from several reliable sources, 
evidence was sought from original research published in journal articles. Searches were 
conducted using appropriate MeSH search terms to find the available evidence, and this 
was further appraised by the working group. the MeSH headings included: hepatitis B; 
hepatitis B virus; hepatitis C; hepatitis C virus; HiV; transmission; needlestick injuries; bites, 
human; mucous membrane; sexually transmitted diseases; viral. We searched in MEDliNE, 
and Embase, and conducted detailed searches in the BMJ, the lancet, and other core 
journals relevant to the transmission of HiV, HBV and HCV e.g. AiDS, Clinical infectious 
Diseases, infection Control and Hospital Epidemiology, occupational Medicine, American 
Journal of Epidemiology, Journal of the American Dental Association. Articles relating to 
perinatal or vertical transmission were excluded, as were articles not in English, and articles 
which were not available in full for review. 
A recognised limitation during the development of these guidelines was that, in some areas, 
clear evidence from research was not available. Where discrepancies or gaps existed in the 
available guidance and evidence, expert opinion was sought, both from within ireland, and 
abroad. For example, in considering the risks from exposure to saliva following an injury 
such as a human bite, extensive consultation with international oral health experts was 
conducted. 
Consultation
the consultation exercise was carried out as follows:
the draft document was sent to the HPSC SAC in october 2011 and to key stakeholder 
groups and individuals for consultation in December 2011
the draft document was placed on the HPSC website for general consultation in December 
2011. A notice about this posting appeared in the HPSC monthly on-line bulletin, Epi-
insight, in January 2012
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all those who kindly shared these documents with us and allowed us to use extracts from the 
documents:
•  Beaumont Hospital, Dublin - Occupational Health Department
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Guideline Revisions 
June 2018 
Dolutegravir prescribing information amended regarding pregnancy and women of childbearing 
potential. 
2016
The guidelines were reviewed and where appropriate revised and updated by the HPSC SAC 
working group and the HSE Sexual Health and Crisis Pregnancy Programme (Dr. Fiona Lyons, 
Clinical Lead and Ms. Caroline Hurley, Project Manager) in 2016. The revision process was 
approved by the HPSC SAC. The scope and purpose of the guidelines remain the same.
The HPSC SAC working group and the HSE Sexual Health and Crisis Pregnancy Programme would 
like to acknowledge the contribution of the following individuals to the revision process: Dr. Wendy 
Ferguson, Rotunda Hospital Dublin; Prof. Karina Butler, OLCHC, Dublin; Ms. Sinead Kelly, St. 
James’s Hospital, Dublin; Dr. Greg Martin, Dr. Steeven’s Hospital, Dublin and Ms. Niamh Murphy, 
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Summary of changes:
1)  Revision of recommendations in relation to the need for HIV PEP following exposure to HIV in 
the setting of effective antiretroviral therapy
2) Inclusion of dolutegravir as an option for HIV PEP
3) Increased emphasis on the management of cases following sexual exposure
4) Inclusion of Ulipristal Acetate (ellaOne) in the emergency hormonal contraception appendix.
Publication Date: September 2016 
Revision Date: September 2018. Interim updates will be made as required.
2014
In 2014 raltegravir replaced Kaletra as the second agent with Truvada for HIV PEP.
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the GuIdelInes
1. Introduction
1.1   these guidelines are intended for use in emergency medical settings where a patient first presents 
with an injury (including needlestick or other sharps injury, sexual exposure, human bite, exposure 
of broken skin or of mucous membranes) where there is a risk of transmission of infection, in 
particular bloodborne viruses (BBV). these guidelines are relevant to injuries occurring to members 
of the public in a community setting and also to injuries sustained occupationally (such as to 
healthcare workers (HCW) or members of the Garda).
1.2   the terms “recipient” and “source” will be used throughout these guidelines:
 Recipient: the person who sustains the injury
  Source: the source of the potentially infected material, e.g. the person on whom the sharp was 
used, the person who bites, or the source of the blood or body fluid.
1.3    the BBVs considered in these guidelines are hepatitis B virus (HBV), hepatitis C virus (HCV) and 
human immunodeficiency virus (HiV).
2. Initial assessment
See appendices 1-6: 
• Patient management form
• Flow chart for management of injuries
• Algorithm for needlestick/sharps exposure
• Algorithm for mucous membrane exposure
• Algorithm for sexual exposure
• Algorithm for human bite exposure
Note: If the recipient is a healthcare worker (HCW), they should not manage the incident 
themselves. Another appropriate health professional should take over responsibility.
2.1   Urgent first aid treatment should be administered if required. Urgent assessment should be made 
regarding the need for HiV post-exposure prophylaxis (PEP). (See appendix 7 for HiV PEP) 
2.2  Initial wound care
 2.2.1  For contaminated needlestick injuries, sharps injuries or human bites:
   Encourage the wound to bleed.
   the recipient should not suck the injury site.
    irrigate the wound thoroughly with running water and soap. A nailbrush should not be used.
   Dry, and cover the wound with a waterproof dressing if necessary.
 2.2.2  For contamination of the conjunctiva or mucous membranes:
    immediately irrigate the area with copious amounts of normal saline or water. For a splash to 
the eye, this irrigation should be done before and after removal of contact lenses.
 2.2.3  Full clinical assessment should be carried out
    Examine for signs of infection, foreign bodies, damage to blood vessels, nerves, tendons, 
joints or bones (this is particularly important for human bites).
   Assess whether the injury has broken the skin.
2.3 Complete the Patient Management Form (appendix 1):
•  Document who was injured, how, when and the type of injury.
•  Record vaccination status (hepatitis B, tetanus), underlying medical conditions including 
immunosuppression, medications, and allergies.
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2.4 Decide if a significant exposure has occurred.
 2.4.1  Assessment of significance of exposure
   A significant exposure involves both a high-risk material and a significant injury.
 2.4.2  High-risk materials (i.e. significant risk of transmission of BBVs):
    Blood, body fluids containing visible blood, semen and vaginal secretions represent a risk of transmission 
of HBV, HCV or HiV, if the source is infected.1
   (See appendices 21-26 for information about HBV, HCV and HiV)
    outside the body, HCV and HiV significantly decline in infectivity within a few hours. HBV can remain 
infectious for a week or more.
 2.4.3  Low-risk materials (i.e. no significant risk of transmission of BBVs):
    Contamination with faeces, nasal secretions, saliva*, sputum, sweat, tears, urine, and vomitus, unless they 
contain blood, represents a negligible risk of HBV, HCV or HiV transmission. 
    *if the injury is serious (e.g. extensive or deep tissue bite) HBV transmission may be a risk, even if there is 
no visible blood in the saliva. in this situation, HBV vaccine with or without HBiG may be indicated (see 
appendix 6 for algorithm for human bite exposure, appendix 8 for HBV PEP and appendix 18 for discussion 
of human bite injuries and saliva).
 2.4.4  Other materials:
   the risk of transmission of BBVs from exposure (e.g. splash) to the following fluids is unknown:
    Cerebrospinal fluid, synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, breast milk and amniotic 
fluid. if the source has a high blood viral load, the viral load in other fluids, such as amniotic fluid, is also 
likely to be high.
 2.4.5  Significant injuries include: 
    •  Percutaneous injuries 
   •  Human bites which break the skin, i.e. involving a breach of the epidermis, not just bruising or 
indentation of the skin (see appendix 18 for discussion of human bite injuries). 
   •  Exposure of broken skin to blood or body fluids.
   •  Exposure of mucous membranes (including the eye) to blood or body fluids, e.g. by splashing.
   •  Sexual exposure (unprotected). 
 2.4.6  Non-significant injuries include:
   •  Superficial graze not breaking the skin.
   •  Exposure of intact, undamaged skin to blood or body fluids.
   •  Exposure to sterile or uncontaminated sharps.
 2.4.7  Non-significant exposure
    if the incident involves exposure to a low-risk material or a non-significant injury, no further testing or 
examination is required. The patient should be reassured and discharged. the patient should be given 
an information leaflet (appendix 27) and a discharge letter (appendix 35) to give to their GP, indicating 
that no significant exposure occurred, outlining any testing or treatment carried out, and indicating if any 
follow-on care is needed, such as HBV vaccination or wound care.
The following sections relate only to 
significant exposures
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The remainder of the guidelines relate 
only to significant exposures
3. Assessing the risk of transmission of infection
3.1  Risk assessment - bloodborne viruses
  (See appendices 21 to 26 for information about HBV, HCV and HiV)
  Where a significant exposure has occurred, a risk assessment should be carried out to 
estimate the risks of transmission of HBV, HCV and HiV. this should take account of the 
following:
 •  the infectious status (HBV, HCV, HiV), if known, of the source.
 •  if the source is unknown or refuses testing, information may be available about whether 
the source has risk factors for BBVs (such as: people who inject drugs (PWiD), prisoner, 
commercial sex worker (CSW), men who have sex with men (MSM), born in an endemic 
country (see appendices 22, 24, 26 for maps), sexual partner with a risk factor). 
 •  knowledge of the background prevalence of BBVs in the population and in risk groups 
may be helpful. knowledge of the prevalence of PWiD in the local population may also be 
helpful.
 •  the nature of the exposure, including the type of injury and the type of material involved.
 •  the HBV vaccination status of the recipient.
 •  the infectious status (HBV, HCV, HiV), if known, of the recipient.
3.2  Factors increasing the risk of transmission of BBV infection:
 •  Deep percutaneous injuries
 •  Visible blood on injuring device
 •  Hollow needle from source patient artery or vein
 •  large bore needle
 •  Visible blood (of the biter) in mouth of biter 
 •  Blood containing a high viral load of HBV, HCV or HiV
 •  the presence of HBeAg in source
 •  Higher volume of material
 •  Personal protective equipment, e.g. gloves, goggles, not worn (HCWs)
 • Sexual exposure due to aggravated sexual intercourse
 • Sexual exposure in men who have sex with men
 • Sexual exposure in the presence of concurrent STIs.
3.3  Investigation of source
 (See Appendix 29: Checklist: Testing of source person or recipient)
  in the case of a significant exposure, every effort should be made to ascertain the HBV, HCV 
and HiV status of the source.
 3.3.1    If the source is known
  Where the incident occurred in a hospital and the source is a patient in the hospital, the 
consultation with the source should be carried out by a member of his/her treating team. 
When the incident occurred outside the hospital, the consultation and blood testing of the 
source should be carried out by another suitably qualified health professional e.g. primary 
care provider, prison healthcare team.
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 Explain to the source in simple language exactly what has happened.
 Ask if they are known to be infected with HBV, HCV or HiV.
  Ask if they have risk factors for BBVs, e.g. PWiD, CSW, MSM, born in an endemic country (see maps 
in appendices 22, 24, 26), sexual partner with a risk factor.
  •  if their BBV status is unknown, request permission from the source, either directly or through their 
doctor, to take a blood sample for testing for HBV (hepatitis B surface antigen - HBsAg), HCV 
(antibody to hepatitis C - anti-HCV) and HiV (HiV antigen/antibody - Ag/Ab). 
 •  if the recipient is known to be HBV immune, then the source need not be tested for HBV. 
 •  if the source is HBsAg positive, then hepatitis B e-antigen (HBeAg), antibody to HBeAg (anti-HBe) 
and HBV viral load should be carried out to estimate the risk of transmission.
 •  if the source is anti-HCV positive, a HCV ribonucleic acid (RNA) test, and viral load if RNA positive, 
should be carried out as soon as possible. 
 •  if the source is HiV Ag/Ab positive, a HiV viral load should be done to estimate the risk of 
transmission. 
  Where the source is considered likely to be in the window period for a BBV, they should be advised to 
have repeat testing at 3 months. in such situations, discuss emergency management of the recipient 
with a HiV/iD specialist, see section 3.4.
  informed consent must be obtained for this testing (see below). Explain why the tests are being 
done, exactly what tests will be carried out, and the implications for them if a test result is positive. 
the source must be informed that they are free to refuse to provide a sample or to have this testing 
carried out. An information leaflet should be provided (appendix 30 ). if the source refuses consent, 
this fact should be recorded by the health professional.
  the source should be told that the result will be provided by the testing laboratory to their 
nominated doctor (general practitioner (GP) and/or consultant) and that the recipient will also be 
told the result. the confidential nature of the testing process should be emphasised. if, as a result 
of the outcome of this testing, follow-up care is necessary for the source person (e.g. referral to an 
infectious diseases consultant), this is the responsibility of the hospital consultant if the source is a 
patient in hospital, or the source person’s GP. if the source is not registered with a GP, then it is the 
responsibility of the doctor who ordered the test to ensure that appropriate follow-up is arranged.
  the laboratory should be advised to expect an urgent blood sample and asked to provide the 
results as soon as possible. the sample may need to be sent by courier.  the sample (10mls of 
clotted blood) should be marked “Urgent. Possible bloodborne virus exposure – source” and 
should indicate to whom results should be sent with contact details clearly stated. if an RNA test is 
required, arrangements should be made with the testing laboratory. A second blood sample will be 
required. Results of source blood tests should be available from the laboratory to allow a decision to 
be made as soon as possible. in some situations, the urgency with which the blood test is taken and 
sent to the laboratory is dictated by the circumstances and risk assessment. if a delay is likely and 
the source is high-risk, consider whether HiV PEP should be started while waiting for the HiV test 
result. the laboratory should be asked to retain part of the sample for storage for two years. 
 3.3.2 Informed consent          
  the components of a legally valid consent are that it must be given by a person with the capacity 
to consent, it must be given voluntarily and not under any duress or coercion and the person must 
be given sufficient information to allow them to make a decision. Fully informed consent requires 
a clinician to disclose to the person the reason for the test or procedure, the benefits and all of the 
material risks associated with the test or procedure together with the consequences of having or not 
having the test or procedure and the person understands the information that has been provided, 
and has been given an opportunity to consider and weigh it up in order to make a decision. informed 
consent for HiV testing does not need to include written consent.
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  3.3.3 If the source is unknown or known but refuses testing 
  Assess the risk based on any available information, including the circumstances of the 
exposure and the epidemiological likelihood of BBV in the source (prevalence of BBVs 
in the population, known risk environment such as prison, or risk behaviours if source is 
known). the use of HiV PEP is unlikely to be justified in the majority of such exposures 
but HBV immunisation may be appropriate, see appendix 7.
  
  Where the source is deemed to be high risk for a BBV and there is likely to be a delay 
in obtaining consent or results, initiation of HBV immunisation and HiV PEP may be 
indicated while further information is being obtained. See 4.1.
  Consent is required by a clinician who treats, examines, tests or operates on a 
person and to do so without that person’s consent would result in that clinician/
nurse committing an unlawful act.  there are exceptions to this principle, usually in 
exceptional or emergency cases where the treatment is necessary to save the life of or 
preserve the health of a person. to ensure the greatest level of protection to persons 
taking samples, where consent is not forthcoming, an application to Court should be 
made. this can be made at very short notice.
  
  If a blood sample from the source is available to be tested (e.g. it may have been taken 
for another purpose previously), is it acceptable to test it for bloodborne viruses, even if 
the source has refused consent or is unconscious or deceased?
  Under irish law, informed consent to testing should be obtained from the source prior 
to carrying out the test. Where this is not available, the permission of the Court to test 
should be obtained, save in exceptional circumstances where the treatment is necessary 
to save the life of or preserve the health of a person and there would not be sufficient 
time in which to make an application to Court. An application can be made to Court at 
very short notice.
  if a decision is taken to test the sample, the source person should be informed unless to 
do so would, in the doctor’s opinion, be harmful to the individual’s mental or physical 
health.
  If the source person is unconscious, is it acceptable to take a blood sample from them 
for testing?
  Under irish law, informed consent to testing should be obtained from the source prior 
to carrying out the test. Where this is not available, the permission of the Court to test 
should be obtained, save in exceptional circumstances where the treatment is necessary 
to save the life of or preserve the health of a person and there would not be sufficient 
time in which to make an application to Court. An application can be made to Court at 
very short notice.
  if a sample is taken from an unconscious person, they should be informed as soon as 
they regain consciousness unless to do so would, in the doctor’s opinion, be harmful to 
the individual’s mental or physical health.
  If the source person is deceased, is it acceptable to take a blood sample from them for 
testing?
  the position in relation to taking a sample from a deceased person is unclear. if consent 
from the next of kin is not forthcoming and in order to ensure the greatest level of 
protection to the person taking a sample, an application should be made to the Court for 
permission to take the sample. this can be made at very short notice
3.4  Assessing the recipient
 (See Appendix 29: Checklist: Testing of source person or recipient)
  in the case of a significant exposure:
  obtain details of HBV immunisation status if possible, including number of doses, dates, 
post-vaccination anti-HBs level.
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  Ask if they have a HBV vaccination record card (HCWs, Garda and prison personnel are likely to 
have these).
  Ask if they know their infectious status in relation to HBV, HCV or HiV.
  Explain why the tests are being done, exactly what tests will be carried out, and the 
implications for them if a test result is positive.
  informed consent should be obtained and documented before testing is carried out (see 3.3.2). 
An information leaflet should be provided (appendix 28).
  Request HBsAg, antibody to hepatitis B core antigen (anti-HBc), anti-HCV and HiV Ag/Ab. 
Where there has been sexual exposure request syphilis serology. if the recipient is documented 
to have an adequate response to HBV vaccine, it is not necessary to test for HBsAg. See 
appendix 9 for testing schedule, including baseline tests and follow-up testing as indicated. 
See appendix 10 for interpretation of HBV results.
  
  if the recipient was previously vaccinated but the anti-HBs level post-vaccination is unknown, 
and hepatitis B immunoglobulin (HBiG) administration (in addition to vaccine booster) is now 
being considered, it may be helpful to do an antibody to HBsAg (anti-HBs) test. if the anti-
HBs level is ≥10miU/ml, HBiG is not indicated. if anti-HBs is <10miU/ml, the result is of no 
assistance in making the decision about administering HBiG, as antibody level declines over 
time after vaccination but the person may still be protected due to immune memory. in this 
situation, assessment of other factors such as the severity of the exposure may assist in making 
the decision about HBiG (see appendix 8).
  Some of the sample should be retained in the laboratory for storage for two years.
  if the source tests negative for HBV, HCV and HiV, the recipient can be reassured and testing 
of the recipient is not required. Where the source tests negative for blood borne viruses but is 
considered high risk and within the window period, discuss further management with a HiV/iD 
specialist as soon as possible, ideally within 72 hours. HiV PEP may be indicated in exceptional 
circumstances.
4. Treatment of recipient following a significant exposure
4.1  the actions to be taken will depend on the outcome of the risk assessment. 
  if the source blood test results are available and indicate that the source is negative for HBsAg, 
anti-HCV and HiV Ag/Ab, and the investigation has identified no obvious risk factors for BBVs 
in the source (i.e. unlikely that source is in window period for infection), then no further follow-
up of the recipient is required. they can be reassured and discharged. 
  However, even if it is deemed that there has been no risk from the current incident, if the 
recipient has not completed a course of HBV vaccination and may be at risk of HBV infection in 
the future, they should be encouraged to be vaccinated. 
  Where the source tests negative for blood borne viruses but is considered high risk and within 
the window period, discuss further management with a HiV/iD specialist as soon as possible, 
ideally within 72 hours. HiV PEP may be indicated in exceptional circumstances.
  testing of the source may not be possible or may be delayed. Some actions (below) may need 
to be taken immediately and without having the results of source testing. 
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The following actions should be considered when the source is infected or potentially 
infected with a BBV:
4.2 Hepatitis B post-exposure prophylaxis
  Post-exposure, HBV vaccine is highly effective at preventing infection, provided that the 
vaccine is administered preferably within 48 hours but up to 7 days post-exposure. Due to 
the safety profile of HBV vaccine and the infectivity of HBV, a low threshold for initiating HBV 
vaccination is recommended (appendices 8 and 11 –  HBV PEP and Hepatitis B vaccine).2 
in general, HBV vaccination should be offered to all patients who have had a significant 
exposure, unless they are already immune due to vaccination or past infection. 
  the first dose of vaccine should be given in the health care setting where the person 
first presents. Give the patient a HBV vaccination record card with the first dose entered 
(appendix 12). Arrangements should be made for further doses of vaccine to be delivered 
either by the GP, occupational health service, Sti/GUM clinic or infectious diseases clinic as 
appropriate. if the GP has any queries with regard to such follow-up, they should seek advice 
from their department of public health or infectious diseases service.
  HBiG, in addition to HBV vaccine, may be used in limited circumstances to confer passive 
immunity after exposure to HBV (appendix 13). HBiG provides short-term protection (3-6 
months). HBiG should generally only be given to non-immune patients who have had 
a significant exposure to a known HBsAg positive patient or to a known non-responder 
to vaccine who has had exposure to a HBsAg positive source or to an unknown source, 
following a risk assessment (appendix 8). HBiG should ideally be given within 48 hours of 
exposure but not later than 1 week after exposure.
 the recipient should be tested for HBsAg at baseline, 6 weeks and 3 months (appendix 9).
  if the recipient was previously vaccinated, with a documented post-vaccination anti-HBs 
level of ≥10miU/ml, they are likely to have long-term protection against HBV infection. No 
further action is required from the point of view of HBV PEP and no follow-up testing is 
required (appendix 8). 
4.3  Hepatitis C
  Currently there is no recommended post-exposure prophylaxis for HCV.3 However, treatment 
of early infection has been shown to be successful, therefore follow-up monitoring for 
evidence of HCV infection should be carried out (see appendix 14 for treatment of acute 
hepatitis C).
  if a significant risk of exposure to HCV has occurred, i.e. the source is known or likely to be 
HCV positive, testing of the recipient for HCV Ag or RNA, and for anti-HCV should be carried 
out at 6 weeks and 3 months (appendix 9). there is limited data on the performance of HCV 
Ag testing in the setting of acute HCV infection. it is recommended that you discuss with 
your local laboratory and ensure that they are aware of the clinical scenario. if the recipient 
HCV Ag or RNA test is positive, the patient should be referred immediately to an appropriate 
specialist for assessment.
4.4 HIV post-exposure prophylaxis
 (See appendix 7 for detailed protocol for HIV PEP)
  HiV PEP should only be considered in patients who present within 72 hours with a 
significant exposure to either a known HiV positive person or a suspected high-risk source, 
where the overall risk of transmission is >1:1000 (see appendix 7 table 2).
  PEP should not be offered where testing has shown that the source is HiV negative, or if the 
risk assessment has concluded that HiV infection of the source is unlikely, where the overall 
risk of transmission is >1:1000 (see appendix 7 table 2).
  if the HiV status of the source is unknown, a careful risk assessment should be carried out. 
PEP is unlikely to be justified in the majority of such exposures.4
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  if the source is known to be HiV infected and the exposure is significant, see table 3 Appendix 
7 for recommendations on HiV PEP.  Where PEP is indicated it should be started as soon as 
possible, ideally within an hour of exposure.4 PEP should not be offered if more than 72 hours 
has elapsed since the exposure. A 3-5 day starter pack of antiretroviral medications should 
be supplied to the patient. An urgent referral should be arranged to an appropriate clinician 
specialising in HiV treatment or a clinician with significant experience in managing HiV PEP. 
Ensure that the first appointment is scheduled before the finish of the PEP starter pack. An 
information leaflet should be given to the patient (appendix 31). All emergency departments 
and occupational health departments should have arrangements in place for timely access 
to starter packs of PEP. Where there is concern about information from the source in relation 
to HiV treatment or presence of resistance virus the source’s HiV physician or a HiV specialist 
should be consulted as soon as possible, and within 72 hours.  the total duration of HiV PEP 
is 28 days.
  local arrangements should be put in place so that relevant information on the source can be 
made available to the clinician caring for the recipient.
  PEP should be discontinued immediately if a HiV test on the source is found to be negative 
(unless the risk assessment indicates that there is a high likelihood that the source is in the 
window period and on the advice of a HiV/iD specialist). 
4.5 Tetanus
  Depending on the circumstances of the injury, tetanus immunisation should be considered. 
  See appendix 15 re risk assessment for the use of tetanus vaccine and tetanus 
immunoglobulin (tiG).
4.6 Antibiotic treatment
  Prophylactic antibiotics are not routinely recommended for needlestick injuries, although 
each wound should be assessed individually. Antibiotic prophylaxis is indicated after human 
bites, especially to the hand (see appendices 6 and 18). 
5.  Specific injuries and settings
5.1  Occupational exposure
  See appendices 3 and 4 for algorithms for management of needlestick and mucous 
membrane exposures, and appendix 17 for discussion of occupational exposure.
5.2 Sexual exposure
  if a sexual assault has occurred, the recipient should be offered referral to the nearest sexual 
assault treatment unit (SAtU) for further management. 
  in cases of sexual exposure which do not involve assault, the following actions should be 
taken in the emergency department:
  •  Assess the need for HiV PEP (see above and appendix 7)
  •  offer HBV vaccination unless known to be immune. Consider HBiG (see appendix 8)
  •  take blood for baseline BBV testing (see appendix 9), including syphilis
  •  Consider emergency contraception (appendix 16) and give information leaflet (appendix 32)
 •  Advise safe sex (i.e. condoms) for 3 months
  •  Arrange follow-up within 3-5 days in iD/genitourinary medicine (GUM) clinic or with other 
appropriate HiV treating clinician if HiV PEP starter pack commenced
  • Give the recipient an information leaflet (appendix 33)
 •  Refer to sexually transmitted infection (STI)/GUM clinic in 2 weeks time (appendix 34)
 See appendix 5 for algorithm for management of sexual exposure.
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5.3 Human bites
  Following a human bite, an individual risk assessment is required, taking account of the extent of 
the injury, the HBV immunisation status of the recipient and the BBV status of the source and the 
recipient. With the exception of a deep bite wound sustained from a source who is infected or has 
risk factors for HBV, in a recipient who is not HBV immune, the risk of BBV transmission is negligible. 
A recipient of a bite that breaches the skin but with no visible source blood does not require any 
follow-up from the point of view of HiV and HCV. 
  HBV vaccination should be advised for an unvaccinated recipient following a percutaneous 
or mucous membrane exposure to saliva from a source who is HBV infected or high-risk but 
of unknown sero-status (see appendix 8). HBiG may also be indicated, depending on the risk 
assessment, but generally only if the source is HBV positive. HiV PEP would almost never be 
indicated except in extreme circumstances.
  See appendix 6 for algorithm for management of human bites and appendix 18 for a detailed 
discussion of the risks of human bites.
5.4 Community acquired needlestick injury
  injuries from discarded needles and syringes in public places create considerable anxiety regarding 
the possible transmission of bloodborne pathogens. While these injuries pose less of a risk than that 
resulting from a needlestick injury in health-care settings, the perception of risk often results in the 
necessity for evaluation, testing and counselling of the injured person.2  Management of such injuries 
includes acute wound care and consideration of the need for prophylactic management, based on a 
detailed risk assessment.
  HBV is the most stable of the major bloodborne viral pathogens and can survive in the environment 
for 1 week or longer. it is advisable to administer a full course of HBV vaccine to those susceptible 
to HBV infection. HBiG is not usually required unless the needle comes from a known HBV positive 
source and a risk assessment identifies a significant risk of HBV transmission (appendix 8). the 
likelihood of transmission of other bloodborne viruses such as HCV or HiV is very remote.2 
  in general PEP for HiV is not recommended but should be considered in high-risk situations – 
based on location (e.g. prisons) and likely source (e.g. PWiD, insulin injection), the presence of 
fresh blood, the amount of blood, the type of needle involved (e.g. large bore, hollow), and depth of 
penetration.5,6,7
  See appendix 3 for algorithm for needlestick/sharps exposure and appendix 19 for a detailed review 
of community needlestick injuries.
5.5 Injury in dental practice
  Protocols should be in place in the dental setting to prevent avoidable exposures and to minimise 
risk. these protocols should include the safe use of equipment, the use of personal protective 
equipment, training, re-training and induction, the need for vaccination, the need for documentary 
evidence of immunity and what to do in case of an accident.  A responsible person should be 
appointed to manage such incidents. it is vitally important that the practice identifies in advance 
an appropriate unit to which to refer an injured person. the legislation which covers this area is the 
Safety, Health and Welfare at Work Act 2005 (and 2007 Regulations). 
 Emergency management of an injury
 1.  immediate wound hygiene should be carried out.
 2.  if a significant exposure has occurred, i.e. a bite, or an injury from a used needle or from a used 
sharp, immediate referral should take place to the appropriate unit (emergency department or 
infectious disease specialist or occupational health specialist) where a definitive risk assessment 
is carried out.
 3.  the management of the recipient (injured party) is directly based on risk assessment of the 
source. the information to assist the appropriate unit in making this assessment should 
be provided by the practice using the on-Site Assessment Form (appendix 20) which is 
downloadable from the iDA website (www.dentist.ie). Copies of this form should be readily 
available in all practices to facilitate speedy referral.  
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 4.  the source must be informed before they leave the practice that an injury has occurred and 
the on-Site Assessment Form should be completed in their presence. the source should 
be asked if they have any relevant medical history or risk factors for bloodborne viruses. 
they should be asked if their medical history and contact phone number can be passed on 
to the medical team that will treat the recipient. the source should also be informed that 
they may be contacted by the recipient’s treating doctors and asked to provide a blood test. 
they should be reassured that all information will be treated with strict confidentiality by 
the recipient’s treating doctors, and that where necessary appropriate follow-up care will be 
offered to them. the source should be informed that the results of their blood tests may have 
to be disclosed to the recipient.
 5.  the use of information put on the on-Site Assessment Form must comply with data 
protection legislation. 
 6.  Contact details of the responsible person (from the dental practice) both during and after 
hours must be made available to the appropriate unit. 
5.6 Injury in primary care medical practice
  the management of injuries in the primary care medical practice setting should be dealt with 
broadly along the same lines as in a dental practice. Where there is relevant expertise within a 
medical practice then it may be more appropriate to deal with the injury and follow-up within that 
practice.
6.  Information and follow-up of recipient
6.1 Information
  All recipients, whether or not the exposure is significant, should receive appropriate information. 
if no significant exposure has occurred, no follow-up is required and no precautions need be 
taken. the patient should be reassured, given an information leaflet and discharged (appendix 
27). 
  if a significant exposure has occurred, the recipient should receive information about the level of 
risk, the testing required, the implications of a positive result, the implications of treatment, the 
precautions required and the arrangements for follow-up. An information leaflet should be given 
(appendix 28). if the recipient has particular concerns, formal counselling may be arranged.
6.2 Precautions
  if a significant exposure has occurred, the recipient should be advised to take certain precautions, 
depending on the exposure and actions taken: 
  •  Adopt safe sex practices (i.e. use condoms) for 3 months
  •  If planning to donate blood, tissue, breast milk, sperm or organs, the person should inform the 
relevant donation agency about the exposure incident and follow their recommendations 
  •  Seek expert advice regarding pregnancy or breast-feeding
  •  In the absence of infection, healthcare and other workers need not be subject to any 
modification of their work practices
  •  No restrictions are necessary in relation to participation in contact sports
  •  Do not share toothbrushes, razors or needles
  these precautions should be outlined in written form, e.g. a leaflet (appendix 28).
6.3  Follow-up
  Where a significant exposure has occurred, follow-up may be required for the following:
  •  Blood tests and feedback of results
  •  Monitoring for clinical evidence of HBV, HCV or HIV infection. If evidence of infection occurs, an 
urgent referral should be made to an appropriate specialist.
  •  Completion of HBV vaccination course
  •  HIV PEP
  •  Ongoing counselling
  •  STI screen
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  Arrangements should be made for follow-up by the appropriate service and the recipient 
clearly advised about this. this will depend on the circumstances of the incident and the type 
of injury.
  if the person has been started on HiV PEP, they should be monitored by a clinician  
specialising in HiV treatment or a clinician with significant experience in managing HiV PEP. 
An urgent referral should be made to ensure that they are first seen by this specialist before 
the starter pack of antiretroviral medication is finished. the referral pathway to this specialist 
should be clearly defined in each region and a written note given to the patient clearly stating 
where they should go (appendices 31, 34).
  For recipients not prescribed HiV PEP:
  •  Healthcare staff who have received an occupational injury should be referred to their 
occupational health department for follow-up. if they have no occupational health 
department, they should go to their own GP for follow-up if required (appendix 35).
  •  Members of the public should be referred to their own GP, an STI/ID/GUM/SATU service or 
their own occupational health service (appendix 35).
 7.  Records/documentation
7.1  Patient management form
  All parts of the patient management form should be completed (appendix 1) and the form 
retained in the service where the consultation took place.
7.2  Recording of medication
  Details of all medications prescribed, administered and supplied (e.g. PEP, antibiotics, 
vaccines) should be recorded in the appropriate patient record (e.g. hospital chart, 
occupational health department medical record). For vaccines and immunoglobulin products, 
the batch number and expiry date should be recorded.
7.3  Notifiable diseases
  HBV, HCV and HiV are notifiable diseases and should be notified by the attending doctor 
to the director of public health (DPH)/medical officer of health (MoH) (see appendix 36 re 
details of DPHs). A notification form may be downloaded from:    
http://www.hpsc.ie/hpsc/NotifiableDiseases/NotificationForms/
7.4  Occupational exposures
  if the injury occurred in the workplace setting, the appropriate report forms should be 
completed and management informed.
  if, as a result of a work related injury, the employee is absent from work for more than 3 
consecutive days, the employer must report the injury using the iR1 form available from the 
Health and Safety Authority (HSA).
  Under the Safety, Health and Welfare at Work (Biological Agents) Regulations 1994 and 
amendment Regulations 1998, the employer must inform the HSA of any work related 
accident or incident which may have resulted in the release of a biological agent and 
which could cause severe human infection/human illness e.g. a percutaneous injury with a 
contaminated sharp where the source patient is known or found to be positive for hepatitis B, 
hepatitis C or HiV. the iR3 Report of Dangerous occurrence Form may be used to report the 
incident to the HSA, available at www.hsa.ie.
7.5  Risk management forms for hospital
  Where the injury relates to an incident that occurred in a hospital setting, appropriate risk 
management forms should be completed.
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Glossary of abbreviations and terms 
Abbreviations
Ab  Antibody
Ag Antigen
AiDS  Acquired immunodeficiency Syndrome
Alt  Alanine aminotransferase
Anti-HBc  Antibody to hepatitis B core antigen
Anti-HBe  Antibody to hepatitis B e antigen
Anti-HBs  Antibody to hepatitis B surface antigen
Anti-HCV  Antibody to hepatitis C virus
BBV  Bloodborne virus. e.g. HiV, HBV, HCV
CANSi  Community acquired needlestick injury
CDC  Centers for Disease Control and Prevention (Atlanta, USA)
CSW  Commercial sex worker
DtaP  Diphtheria, tetanus and acellular pertussis vaccine
DPH  Director of public health
DNA  Deoxyribonucleic acid
ECDC  European Centre for Disease Prevention and Control
EiA  Enzyme-linked immunoassay
EPP  Exposure-prone procedure
EU  European Union
GP  General practitioner
GUM  Genitourinary medicine
HAARt  Highly active antiretroviral therapy
HBeAg  Hepatitis B e antigen
HBiG  Hepatitis B specific immunoglobulin
HBsAg  Hepatitis B surface antigen
HBV  Hepatitis B virus
HCC  Hepatocellular carcinoma
HCV  Hepatitis C virus
HCW  Healthcare worker
Hib Haemophilus influenzae b
HiV  Human immunodeficiency virus
HPSC  Health Protection Surveillance Centre
HSE  Health Service Executive
iBtS  irish Blood transfusion Service
iCGP  irish College of General Practitioners
iD  infectious diseases
iPV inactivated polio virus vaccine
iM  intramuscular
iU  international units
MoH  Medical officer of health
MSM  Men who have sex with men
n/a  not available; not applicable
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NiAC  National immunisation Advisory Committee
NiCE  National institute for Health and Clinical Excellence
NVRl  National Virus Reference laboratory
oHD  occupational Health Department
oHP  occupational Health Physician
PCR  Polymerase chain reaction
PEP  Post-exposure prophylaxis
PEPSE Post-exposure prophylaxis for sexual exposure
PWiD  People/person who injects drugs
RCPi  Royal College of Physicians of ireland
RNA  Ribonucleic acid
Roi  Republic of ireland
SAtU Sexual Assault treatment Unit
StD  Sexually transmitted disease
Sti  Sexually transmitted infection
SVR  Sustained virological response
td tetanus, low-dose diphtheria
tdap tetanus, low dose diphtheria and low-dose acellular pertussis vaccine
tiG  tetanus immunoglobulin
UNAiDS  Joint United Nations Programme on HiV/AiDS
UPSi  Unprotected sexual intercourse
WHo  World Health organization
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Terms
•   Endemic: The constant presence of a disease or infectious agent within a given geographic area 
or population group; may also refer to the usual prevalence of a given disease within such area 
or group.
•   Exposure incident: A specific exposure to the eye, mouth, other mucous membrane, nonintact 
skin, or parenteral exposure to blood or other potentially infectious materials. Examples of 
an exposure incident include blood spattering into the eyes, splashing into the mouth or a 
puncture by a blood-contaminated needle.
•   Fight bite: A fight bite or closed fist injury is a laceration to the “knuckle” (MCP joint) of the 
hand of someone who punches another person in the mouth.
•   Parenteral: Piercing the skin barrier or mucous membranes e.g. by needlestick.
•   Percutaneous: An exposure through the skin (e.g.  a needlestick or cut with a sharp object) 
or contact of non-intact skin (e.g.  exposed skin that is chapped, abraded, or afflicted with 
dermatitis) with blood, tissue, or other body fluids that are potentially infectious.
•   Post-exposure prophylaxis (PEP): The administration of a drug to prevent the development 
of an infection after the patient has been exposed to the infection, e.g.  HiV PEP involves 
administration of antiretroviral drugs to HiV-negative persons who have been exposed to HiV in 
an effort to prevent establishment of infection. HBV PEP involves the administration of hepatitis 
B vaccine and/or hepatitis B specific immunoglobulin after exposure.
•   Recipient: The person who sustains the injury. In the case of a bloodborne virus exposure 
incident, the recipient is exposed to blood or body fluids of someone else, who is known as the 
source.
•   Risk factors: An aspect of personal behaviour or lifestyle, an environmental exposure, or an 
inborn or inherited characteristic that is associated with an increased occurrence of disease.
•   Seroprevalence: The level of a pathogen in a population, as measured in blood serum.
•   Sharps: Any items that have the potential to puncture the skin and inoculate the recipient with 
infectious material.
•   Source individual: The source of the potentially infectious material, e.g.  the person on whom 
the sharp was used, the person who bites, or the source of the blood or body fluid.
•   Standard Precautions: Standard Precautions are the minimum infection prevention practices 
that apply to all patient care, regardless of suspected or confirmed infection status of the 
patient, in any setting where healthcare is delivered. Standard Precautions include: 1) hand 
hygiene, 2) use of personal protective equipment (e.g. gloves, gowns, masks), 3) safe injection 
practices, 4) safe handling of potentially contaminated equipment or surfaces in the patient 
environment, and 5) respiratory hygiene/cough etiquette.
•   Sustained virological response (SVR) (for hepatitis C treatment): The absence of detectable 
hepatitis C RNA in the serum as shown by a qualitative hepatitis C RNA assay with lower limit 
of detection of 50 iU/ml or less at 24 weeks after the end of treatment.
•   Toxoid: is a modified bacterial toxin that has been rendered non-toxic but has the ability to 
stimulate the formation of antitoxin.
•   Window period: The time interval after infection during which serological assays for antigen 
and/or antibody are negative.
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Bloodborne Virus Exposure • Patient Management Form
Reporting time:          __ __ : __ __ Reporting date:            __ __ / __ __  / __ __
Doctor name: Doctor signature:
 
Details of injury (date, time, place etc.)
 
Nature of material (e.g. blood, saliva, semen etc.)
if Not blood, was fluid blood stained  Yes   No  
HEALTHCARE ExPOSURES (Consider using local form if applicable)
Area where exposure occured
Was this an ‘exposure prone procedure’?  Yes   No  
Were gloves worn at the time of the injury?  Yes   No  
instrument (if any) which caused the injury
What was the instrument originally intended for?
Did the instrument have a safety mechanism?  Yes   No 
Was the safety mechanism activated ?   Yes   No 
Past Medical History (incl. immunosuppression)
Is recipient known to have HBV, HCV, or HIV?  No   Yes   Detail below  
Medications
Allergies
if female Pregnant   Breastfeeding  
Hepatitis B Vaccination
1 dose 2 doses Full course Year
Antibody result if known
Tetanus
Date of last vaccination       __ __ / __ __  / __ __    Number of doses
  
RECIPIENT DETAILS
ASSESSMENT OF ExPOSURE RISK
Name
Address
Gender  M ¨  F ¨ Date of birth     __ __ / __ __  / __ __
MRN
tel no. Mobile
occupation
Work address
  GP name and address and telephone number
Needlestick/sharp injury 
 Hollow bore needle    Solid Needle 
 Visible blood present 
 Device had been directly in source artery or vein 
 other sharp      Describe___________________________________
Severity of needlestick or sharp injury
 Superficial - source scratch, no blood appeared 
 Moderate - penetrated skin and blood appeared 
 Deep - puncture, with or without blood appearance 
Human bite    Skin breached    
Splash 
 intact skin    Non-intact skin 
 Mucous membrane    Eye 
Sexual exposure 
Receptive anal  insertive anal 
Receptive oral   insertive oral 
Receptive vaginal    insertive vaginal 
Condom used/ condom intact   Ejaculated 
if sexual assault, consider referral to a sexual assault treatment
unit or social worker 
other injury   (describe in “Details of injury” box)
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Overall, is exposure significant? (see section 2.4)      Yes ¨  No ¨
if exposure is considered significant
Is source known?  Yes   No 
if yes, iD number    e.g. source hospital MRN or laboratory number
(Health care institution to assign an iD number by which the recipient and source can be confidentially linked)
  
  
  
  
  
  
DECISION
RECIPIENT MANAGEMENT CHECKLIST
FOLLOW-UP ARRANGEMENTS
If exposure is considered significant, proceed.
If unsure how to proceed, discuss with senior 
doctor in the Emergency Department or in 
Infectious Diseases.
 
if no, no further follow up is required
Reassured 
Patient information leaflet provided (appendix 27)  
Discharged 
First aid given  Yes    No   (see section 2)
Recipient bloods taken (appendix 9) Yes    No 
For testing         For storage only  
Appropriately labeled “Possible BBV exposure - Recipient”  
 test Date  Result
HBsAg  ______________  _______
Anti-HBc ______________ _______
Anti-HCV ______________ _______
HiV Ag/Ab ______________  _______
Syphilis (sexual exposures only) ______________ _______
Pregnancy  ______________ _______
informed consent received for testing   Yes    No  
(see Checklist, appendix 29)
Following sexual assault  Yes
Social worker referral    
Sexual assault unit referral   
Emergency contraception  
Garda notification if patient agrees   
Treatment record, including PEP  Yes
HBV vaccination given (appendices 8 & 11)   
HBiG required (appendix 8)   
HBiG given   
HiV PEP offered (appendix 7)   
HiV PEP accepted (HiV PEP should be discontinued 
immediately if the source is found to be HiV negative)  
Considered interactions between PEP and other medication 
(Consult BNF, pharmacist, www.hiv-druginteractions.org,   
product insert)   
HiV PEP information leaflet given (appendix 31)   
Baseline bloods taken (FBC, lFts, Renal, Bone profile)  
Urinalysis for proteinuria (in renal impairment, give first dose of 
truvada and discuss with an iD consultant. isentress can be given)  
time between exposure and starting HiV PEP    ______  hours
Number of days of HiV PEP given     ______   days
HiV PEP drugs prescribed (name of drugs) _________________________
____________________________________________________________________
tetanus vaccine given (appendix 15)   
tetanus immunoglobulin (tiG)   
Examined wound for infection  
Antibiotics prescribed  
Note: Record details of medication/ vaccines in patient’s chart
    
  
  
Precautions advised during follow-up period – 3 months
(appendix 28)
Avoid unprotected sexual practices   
Seek expert advice regarding pregnancy or breastfeeding   
Discussed
Compliance with medication   
Possible adverse reactions and how to manage them   
No modification to work practices   
No restrictions to sports   
importance of advising relevant agency if donating blood,  
blood products, organ donation, other donation  
Follow-up referral for:  Name of service
(Please use the standard referral forms—  
appendices 34 & 35)
test results  _________________
Further testing (6/52, 3/12) (appendix 9)  _________________
Vaccinations _________________
HiV PEP (urgent, in 3-5 days — appointment to be
arranged in iD or HiV clinic, or in the occupational
health department (if appropriate)). _________________
Counselling _________________
Sti screen  _________________
Patient information leaflet regarding significant exposures 
provided (appendix 28)   
t
o
o
l
k
it
t
o
o
l
k
it
-30-
eMI Guidelines - Appendix 1  Patient management form (reviewed May 2016)
  
  Do not give this part of the form to the recipient if it contains confidential information that the recipient has not 
themselves provided.
in these circumstances, local plans must be made so that the form can be forwarded to the iD clinic when the recipient is being referred
iD number      e.g. source hospital MRN or laboratory number
(Health care institution to assign an iD number by which the recipient and source can be confidentially linked)
Source: Any risk factors for BBV?  Yes    No    Unknown  
PWiD  
Prisoner   
Born in an endemic country            
(Refer to maps in appendices 22, 24, 26)
Recipient of blood/ blood products   (pre August 1973 HBV, pre oct 1985 HiV, pre oct 1991 HCV)
High risk sexual behaviour
 MSM (men who have sex with men  
 CSW (commercial sex worker)  
 Multiple sexual partners  
 Partner with BBV  
Was source consent received for testing?  Yes      No  
implications of testing discussed with source  Yes     No  
Consent sought from source to disclose test results to recipient  Yes      No  
Source information leaflet provided (appendix 30)  Yes      No  
Reason for not testing source person serology (if applicable)
Unknown source    Refused    Dead    Unable to give consent  
Discharged/ not available    Next of kin not available   
  
  
  
  
ASSESSMENT OF SOURCE INFECTIVITY (SEE SECTION 3.3)
INFORMATION ON SOURCE
Is source immunosuppressed?   Yes      No     Unknown   
HBV 
HBsAg:  Positive       Negative       Unknown   
if positive:  HBeAg positive     Viral load_________
if negative:  Date of last negative test________ 
HCV 
Anti-HCV:  Positive       Negative       Unknown    
if positive:  RNA positive     Viral load_________ 
if negative:  Date of last negative test__________
HiV 
HiV Ag/Ab:  Positive       Negative       Unknown   
if positive:  Viral load________   CD4 count__________ 
What ART now?_____________________
if negative: Date of last negative test_________
if unknown serology, test the following:   Date sent  Result:
HBsAg
if HBsAg positive:  HBeAg
 Anti-HBe
 Viral load
Anti-HCV
if Anti-HCV positive:  RNA
 Viral load
HIV Ag/Ab
if HiV Ag or Ab positive: Viral load
t
o
o
l
k
it
t
o
o
l
k
it
-31-
eMI Guidelines - Appendix 2  Flow chart for management of injuries (reviewed May 2016)
 
Management of injuries where there is risk of 
bloodborne virus (BBV) transmission
Exposure incident
needlestick, sharps, bite, 
splash, sexual 
(algorithms - appendices 3-6)
Initial wound management
Wound: Encourage bleeding, 
wash, don’t scrub, cover. 
Eye splash: irrigate with water
Is exposure significant?
i.e. high risk material AND 
significant injury (see side panel)
Assess BBV status of source 
(HBV, HCV, HIV – appendices 
21-26)
No further action. 
Reassure and 
discharge
(information leaflet 
appendix 27)
Source known: test 
for BBVs or confirm 
previous results, with 
consent 
(Section 3.3.1)
(appendices 29 and 30)
Source unknown or 
does not consent: 
assess risk based on 
circumstances and 
likelihood of BBV 
(Section 3.3.3)
Assess BBV status of recipient 
History of HBV vaccination, 
previous tests for BBVs. 
take blood to test for BBVs or 
store (appendices 9 and 29 )
Clinical management of 
recipient based on risk 
assessment 
(appendices 7 and 8)
Information and follow-up
level of risk, precautions, follow-up 
for tests, vaccination, PEP, 
information, Sti screen
(information leaflet appendix 28)
High risk materials: 
blood, semen, vaginal 
secretions, body fluids with 
visible blood
Low risk materials:  
urine, nasal secretions, 
saliva*, sputum, faeces, 
vomit, sweat, tears – unless 
visible blood
Significant injury: 
percutaneous, human bite* 
with skin broken, exposure 
of broken skin or mucous 
membrane to blood or body 
fluids, sexual exposure 
(unprotected) 
*if human bite with no visible 
blood, only risk is HBV.
Non-significant injury: 
superficial graze, exposure of 
intact skin, exposure to sterile 
sharps
Source testing:   
HBsAg, anti-HCV, HiV Ag/
Ab. if HBsAg positive, test 
HBeAg, anti-HBe and viral 
load. if anti-HCV positive, test 
HCV RNA and viral load. if 
HiV positive, test viral load
Recipient testing:  
HBsAg, anti-HBc, anti-HCV, 
HiV Ag/Ab, ±anti-HBs
Clinical management 
of recipient may include: 
HBV PEP (vaccine ± HBiG); 
HiV PEP; Emergency 
contraception; tetanus; 
antibiotics
Follow-up/referral may be: 
GP, occupational Health, iD, 
SAtU, Sti/GUM
No
Yes
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Information and Follow-up 
level of risk, precautions, follow-up for further testing (appendix 9), vaccination, PEP. Give information leaflets (appendices 28 & 31)
No risk of HBV/HCV/HIV 
transmission. Reassure.
Give patient information 
leaflet (appendix 27) 
and discharge letter 
(appendix 35). 
Advise GP/occupational 
health follow-up
(Section 2.4.7)
NO
YES
 
See HBV PEP table 
(appendix 8)
  
there is currently no PEP 
available for HCV, but if 
seroconversion occurs, 
early treatment is highly 
effective (appendix 14)
Wound management: encourage bleeding, wash 
Was the exposure significant – i.e. skin breached and a high risk material? (Section 2.4)
Assess BBV risk of source (Section 3.3). If source known, test for BBVs or confirm previous results (with 
consent). If source unknown or does not consent, assess risk based on circumstances and likelihood of BBV
Assess BBV status of recipient (HBV vaccination, previous BBV tests, baseline bloods (Section 3.4 and 
appendix 9)). Clinical management of recipient based on risk assessment (Section 4)
HIV PEP is recommended if the source is known HIV+ with a detectable viral load, and the injury is within 
the past 72 hrs. See appendix 7 for further information and indications on use of PEP, and follow checklist on 
patient management form appendix 1.
HiV PEP may also be considered where the following criteria are met:
•   Source is unknown but from a high prevalence group or area (e.g. needle and syringe discarded in a location 
where PWiD are known to inject)(see appendices 7 & 19 for factors associated with increased risk)
•   Injury within the past 72 hrs
•   There is a high likelihood that the needle has been left there in the past couple of days
in such rare circumstances, and only if all the above criteria are met, should PEP be considered. 
if these criteria are not met, HiV PEP is Not indicated.
if there is no information available about the likely source of the needle or how long it was there, PEP would 
not be routinely recommended, but could be discussed with the recipient & consider truvada alone.
HIVHBV
Management of BBV risk following exposure to needlestick/sharps in 
occupational (appendix 17) or community setting (appendix 19)
Complete patient management form (appendix 1)
HCV
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Information and Follow-up 
level of risk, precautions, follow-up for further testing (appendix 9), vaccination, PEP. Give information leaflet (appendices 28 & 31)
No risk of HBV/HCV/HIV 
transmission. Reassure.
Give patient information 
leaflet (appendix 27) 
and discharge letter 
(appendix 35). 
Advise GP/occupational 
health follow-up
NO
YES
  
See HBV PEP table 
(appendix 8)
 
there is currently no PEP 
available for HCV, but if 
seroconversion occurs, 
early treatment is highly 
effective (appendix 14)
Wound (or eye, mouth) irrigation 
Was the fluid a high risk material? (Section 2.4)
Assess BBV risk of source (Section 3.3). If source known, test for BBVs or confirm previous results (with 
consent).  If source unknown or does not consent, assess risk based on circumstances and likelihood of BBV
Assess BBV status of recipient (HBV vaccination, previous BBV tests, baseline bloods 
(Section 3.4 & appendix 9).  Clinical management of recipient based on risk assessment (Section 4)
HiV PEP should only be considered where the following criteria are met:
•  Injury  within the past 72 hours
•  Splash from high risk material to non-intact skin, eye or mouth
•  Source is known HIV-positive with a detectable viral load
if these criteria are not met, HiV PEP is Not indicated
See appendix 7 (HiV PEP)
HIV
Management of BBV risk following exposure of mucous membrane or broken skin 
in occupational or community setting
Complete patient management form (appendix 1)
HBV HCV
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Information and Follow-up
Ensure patient is clear about follow-up plan. Advise regarding safer sex until after the window period. Give written information (appendices 28 & 33).
No risk of HBV/HCV/HIV 
transmission. Reassure. 
No further follow-up 
required. Give patient info 
leaflet (appendix 27) and 
discharge to GP (appendix 
35)
NO
  
there is currently no 
PEP available for HCV, 
but if seroconversion 
occurs, early 
treatment is highly 
effective (appendix 14)
See HBV PEP table 
(appendix 8) 
Follow appendix 7 for details 
on HiV PEP and use the 
management checklist in 
the patient management 
form (appendix 1). outside 
of these recommendations, 
HiV PEP should not 
be prescribed without 
discussion with an iD/HiV 
specialist, where it may be 
considered in rare extreme 
cases.
Consider need for emergency contraception (appendix 16) / SATU referral (appendix 36) / risk of other STIs
Was the exposure significant? (i.e. exposure to blood/semen/vaginal secretions)
Assess BBV risk of source (Section 3.3). If source known, test for BBVs or confirm previous results with consent. 
If source unknown or does not consent, consider if high risk group e.g. PWID/MSM/CSW/endemic country (Section 3.1)
Assess BBV status of recipient (HBV vaccination, previous BBV tests, baseline bloods (Section 3.4 and appendix 9))
Clinical management of recipient based on risk assessment (Section 4)
HIV positive Unknown HIV status
EXPOSURE TYPE HIV VL unknown/detectable HIV VL undetectable
From high prevalence
country / risk-group
From low prevalence
country / group
RECEPTIVE ANAL SEX RECoMMENDED
Not RECoMMENDED
Provided source has  confirmed 
HIV VL<200c/ml for >6 months
RECoMMENDED Not RECoMMENDED 
INSERTIVE ANAL SEX RECoMMENDED Not RECoMMENDED CoNSiDER* Not RECoMMENDED
RECEPTIVE VAGINAL SEX RECoMMENDED Not RECoMMENDED CoNSiDER* Not RECoMMENDED
INSERTIVE VAGINAL SEX CoNSiDER& Not RECoMMENDED CoNSiDER* Not RECoMMENDED
FELLATIO WITH EJACULATION Not RECoMMENDED Not RECoMMENDED Not RECoMMENDED Not RECoMMENDED
FELLATIO WITHOUT EJACULATION Not RECoMMENDED Not RECoMMENDED Not RECoMMENDED Not RECoMMENDED
SPLASH OF SEMEN INTO EYE Not RECoMMENDED Not RECoMMENDED Not RECoMMENDED Not RECoMMENDED
CUNNILINGUS Not RECoMMENDED Not RECoMMENDED Not RECoMMENDED Not RECoMMENDED
Source HIV status 
Table adapted from BASHH PEPSE 2015
Do not give/consider PEP if more than 72 hours since the exposure
Management of BBV risk following sexual exposure 
Complete BBV patient management form (appendix 1)
YES
HBV HCV
* Prevalence of HiV within communities may change these recommendations from consider to recommend in areas/groups of particular high HiV prevalence 
& Where source HiV viral load is high (e.g. recent seroconversion) or where there is evidence of genital ulceration
toolkit
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Information and Follow-up 
level of risk, precautions, follow-up for further testing (appendix 9), vaccination, PEP. Give information leaflets (appendices 28 & 31)
No risk of HCV/HIV 
transmission. No 
further follow-up 
required for HCV or 
HIV. HBV follow-up 
as per HBV PEP table 
(appendix 8) as it is 
theoretically possible 
that HBV can be 
transmitted through a 
deep tissue bloodless 
bite.  Manage as per 
table and  patient will 
need HBsAg (but not 
HIV/HCV) level at 6 
weeks and 3 months if 
not HBV immune.
NO YES Follow-up 
required for HBV, 
HCV and HIV 
Oral antibiotic (Augmentin if not penicillin allergic) + wound irrigation (If ‘fight bite’ – refer for washout) + tetanus prophylaxis (appendix 15)
Was biter (source) bleeding from mouth prior to bite?
Consider risk to biter if bitten person’s blood gets in biter’s mouth
to date there have only been a handful of reports of BBV transmission from human bites and few of these were 
convincing. All cases involved deep bites where there was blood in the mouth of the biter, and where the biter had high 
viral loads. thus the absolute risk is not known - deemed to be possible but extremely rare.
HIV
Management of BBV risk following human bite breaching skin – or ‘fight bite’ (closed fist injury-
see appendix 18)  There is no risk of BBV transmission if the skin is not breached. Complete BBV patient management form (appendix 1)
Assess BBV risk of source (Section 3.3). if source known, test for BBVs or confirm previous results (with consent).  
if source unknown or does not consent, is it likely that they are from a high risk group e.g. PWiD/MSM/CSW/endemic 
country (Section 3.1)?
HiV PEP should only be prescribed where all the following criteria are met: 
1. it is within 72 hours of the injury
2. there was deep tissue injury
3. the biter was, with complete certainty, bleeding from their mouth prior to the bite
4.  the biter is known to be HiV positive and is either not on ARt or not virologically suppressed on ARt. Where 
the biter is on ARt with an undetectable viral load for >/= 6 months, PEP is Not indicated. 
if all 4 criteria are met, HiV PEP is indicated. Follow the management steps for HiV PEP prescription as 
outlined in the management checklist on the patient management form (appendix 1), and in appendix 7 (HiV 
PEP). outside of this, HiV PEP should not be prescribed without discussion with an iD/HiV specialist, where it 
may be considered in rare extreme cases.
Assess BBV status of recipient (HBV vaccination, previous BBV tests, baseline bloods (Section 3.4 and appendix 9))
Clinical management of recipient based on risk assessment (Section 4)
  
See Hepatitis B PEP table 
(Appendix 8). 
  
there is currently no 
PEP available for HCV, 
but if seroconversion 
occurs, early treatment 
is highly effective 
(appendix 14)
HBV HCV
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HIV Post-ExPosurE ProPHylaxIs (PEP)
Key points
1. Only consider PEP if within 72 hours of exposure
2. The first dose of PEP should be given as soon as possible - within 2 hours if possible
3. Assess risk based on type of exposure and what is known about source (consider risk of HBV and HCV also – see
relevant appendices)
4. Test source if feasible
5. Discuss with senior doctor in emergency medicine or HIV specialist if unsure how to proceed
6. If PEP indicated:
a. Counsel
b. Test blood and urine
c. Prescribe starter pack
d. Arrange follow up at ID or GUM clinic before starter pack runs out
e. Advise no unprotected sex for 3 months
7. Complete the patient management form  (appendix 1) – it will serve as a checklist
Introduction
The use of post-exposure prophylaxis (PEP) against HIV infection dates back to the early 1990s, when only limited 
antiviral treatment for chronic infection was available. Prophylaxis was primarily used after occupational exposures.1 
A case–control study published in 1997 showed that health care workers who received zidovudine after needlestick 
exposures were 81% less likely to undergo seroconversion to positivity for HIV.2 Generally, combination therapies are 
prescribed nowadays, so current HIV PEP may be more effective. However, PEP is not a guarantee of protection.
After exposure to HIV through sexual contact or injecting drug use, antiretroviral therapy may also be administered 
for prophylaxis against infection. No efficacy data are available for this strategy, but substantial safety and feasibility 
data have led to its widespread acceptance.1 
General principles
HIV PEP should only be considered in patients who present within 72 hours with a significant exposure from either a 
known HIV positive person or a suspected high risk source. The first dose of PEP should be given as soon as possible - 
within 2 hours if possible.
PEP should not be offered where testing has shown that the source is HIV negative, or if the risk assessment has 
concluded that HIV infection of the source is unlikely.
If the HIV status of the source is unknown, a careful risk assessment should be carried out. PEP is unlikely to be 
justified in the majority of such exposures.3
Risk assessment
The risk of an individual acquiring HIV following an exposure is dependent upon the risk that the source is HIV-
positive where unknown, and the risk of infection following a specific exposure from an HIV-positive individual.4
Risk of HIV transmission = risk that source is HIV-positive x risk of exposure*
(*including co-factors such as sexually transmitted infections, high HIV viral load and bleeding).4
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Table 1 Risk of HIV transmission per exposure from a known HIV-positive individual not on ART 
(Adapted from BASHH UK Guideline for use of HIV PEPSE 20154 – source references omitted from table)
Type of exposure Estimated risk of HIV transmission per exposure from a known HIV-positive individual not on ART
Receptive anal intercourse 1 in 90 
      Receptive anal intercourse with ejaculation 1 in 65 
      Receptive anal intercourse no ejaculation 1 in 170 
Insertive anal intercourse 1 in 666
      Insertive anal intercourse not circumcised 1 in 161
     Insertive anal intercourse and circumcised 1 in 909
Receptive vaginal intercourse 1 in 1000
Insertive vaginal intercourse 1 in 1,219
Semen splash to eye <1 in 10,000
Receptive oral sex (giving fellatio) <1 in 10,000
Insertive oral sex (receiving fellatio) <1 in 10,000
Blood transfusion (one unit) 1 in 1
Needlestick injury 1 in 333
Sharing injecting equipment (includes chemsex) 1 in 149
Human bite <1 in 10,000
NB: All sexually related risk probabilities are for unprotected sexual exposure; it is assumed similar risks will exist where condom 
failure has occurred
The table above is simply a guide. There are a number of factors that may increase the risk of 
transmission such as high viral load in the source, and intercurrent STIs, e.g. syphilis. 
The overall number of HIV cases in the UK diagnosed in HCWs following occupational exposures is 
five documented cases and 31 probable cases, eight of these probable cases being diagnosed prior to 
1997.5
Table 2  Estimated risk of HIV transmission by type of exposure where source HIV status is 
unknown
Type of exposure Population group 
(% HIV prevalence) 
Risk of HIV transmission - source 
HIV status unknown 
Rounded off estimated 
risk per exposure 
(compared with risk if 
source known HIV+) 
Receptive anal sex 
MSM* 
MSM in Ireland 
(8%)6
8/100 x 1/90 = 1/1125  1/1000 (1/90)
Insertive anal sex MSM* MSM in Ireland 
(8%)6
8/100 x 1/666 = 1/8325 (overall)
8/100 x 1/161 = 1/2012 (not 
circumcised)
1/8000 (1/666)
1/2000 (1/161)
Receptive oral sex 
MSM* 
MSM in Ireland 
(8%)6
8/100 x 1/10,000 = 1/125,000 1/100,000 (<1/10,000)
Receptive vaginal sex Heterosexuals in 
Ireland (0.15%)7,% 
0.15/100 x 1/1000 = 1/666,666 1/700,000 (1/1000)
NSI† from unknown non 
high risk hospital pt 
Heterosexuals in 
Ireland (0.15%)7,%
0.15/100 x 1/333 = 1/222,000 1/200,000 (1/333)
NSI† from community 
source 
PWID‡ in Ireland
(5 to10%)8,9,§,& 
5/100 x 1/333 = 1/6660 to
10/100 x 1/333 = 1/3330
1/7000 to 1/3000 
(1/333)
*MSM=men who have sex with men
% Of note, the prevalence of diagnosed HIV varies geographically in Ireland with crude prevalence of 2.0/1000 amongst 17-78 year olds 
in Dublin. (Patients Accessing Ambulatory Care for HIV-infection: Epidemiology and Prevalence Assessment. Tuite H et al. Ir Med J. 
2015 Jul-Aug;108(7):199-202).
†NSI=needlestick injury
‡PWID=people who inject drugs 
§ Personal communications: Dr Shay Keating, Drug Treatment Centre Board and Dr Jean Long, Alcohol and Drug Research Unit, 
Health Research Board.
& Of note there has been an increase in the number of recent HIV infections diagnosed amongst PWID in Dublin 
(http://www.hpsc.ie/A-Z/HIVSTIs/HIVandAIDS/HIVPeoplewhoinjectdrugs/MainBody,15231,en.html)
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It is generally recommended that HIV PEP is only offered when the estimated transmission risk is 1 in 
1000 or greater, but all cases are considered on a case-by-case basis.4 PEP can be considered in those 
with a risk of between 1 in 1,000 and 1 in 10,000 only in very exceptional circumstances.
Table 3 HIV PEP recommendations by type of exposure and source status 
(Adapted from BASHH UK Guideline 20154 – modified to take account of higher prevalence of HIV in PWID population in Ireland compared to 
UK. The last two rows are not contained in the BASHH Guideline table)
Source HIV status
HIV positive Unknown HIV Status
HIV VL unknown / 
detectable
HIV VL 
undetectable
From high prevalence 
country / risk-group*
From low prevalence 
country / group
Receptive anal sex Recommend Not recommended&
Provided source has confirmed 
HIV Vl<200c/ml for >6 months 
Recommend Not recommended
Insertive anal sex Recommend Not recommended& Consider† Not recommended
Receptive vaginal sex Recommend Not recommended& Consider† Not recommended
Insertive vaginal sex Consider% Not recommended& Consider† Not recommended
Fellatio with ejaculation ‡ Not recommended** Not recommended Not recommended Not recommended
Fellatio without ejaculation‡ Not recommended Not recommended Not recommended Not recommended
Splash of semen into eye Not recommended Not recommended Not recommended Not recommended
Cunnilingus Not recommended Not recommended Not recommended Not recommended
Sharing of injecting 
equipment
Recommend Not recommended Consider† Not recommended
Human bite§ Consider in very limited 
circumstances*** 
(see Bite algorithm, 
appendix 6)
Not recommended Not recommended Not recommended
Needlestick from a discarded 
needle in the community
Consider in very limited 
circumstances*** (see 
Needlestick/Sharps 
algorithm, appendix 3)
Not recommended
Needlestick direct from 
source***
Recommend Not recommended Consider† Not recommended
Blood splash to non-intact 
skin, eye or mouth***
Consider Not recommended Not recommended Not recommended
* High prevalence groups within this recommendation are those where there is a significant likelihood of the source individual being HIV-
positive. Within Ireland at present, this is likely to be men who have sex with men, and individuals who have immigrated from areas of high 
HIV prevalence (particularly sub-Saharan Africa) (See map of global HIV prevalence, appendix 26)
&  Provided source’s HIV viral load is undetectable for >/= 6 months. Where there is uncertainty about results or medication adherence, PEP 
should be offered
† More detailed knowledge of local prevalence of HIV within communities may change these recommendations from consider to recommend in 
areas/groups of particularly high HIV prevalence
%Where source HIV viral load is high (e.g. recent seroconversion) or where there is evidence of genital ulceration
‡PEP is not recommended for individuals receiving fellatio, i.e. inserting their penis into another’s oral cavity
**Consider where recent seroconversion or evidence of oropharyngeal ulceration or trauma.
§A bite is assumed to constitute breakage of the skin with passage of blood
***Denotes parts of table that differ from BASHH Guideline
Estimating probability that source is HIV positive
In the case of a significant exposure, every effort should be made to ascertain the HIV status of the source.
If the source is known, the exposure should be outlined to the source and consent requested for blood to test 
for HIV Ag/Ab (and HBsAg, anti-HBc and anti-HCV)(appendices 29 & 30).
•  The source is considered HIV negative if there is a recent HIV negative result within the past 3 months plus
no clinical indication of a retroviral/ seroconversion-like illness, and source is not considered to be at high
risk of infection.
•  The source is considered HIV positive if they have a positive HIV result, or a physician has diagnosed HIV or
the source self-reports a diagnosis of HIV. A low or undetectable HIV viral load greatly diminishes but does
not completely eliminate the risk of transmission. PEP should be discussed with the treating ID consultant
if the source is on anti HIV medication. If not contactable, commence standard PEP.
If the exposure involves a source person with either unknown HIV status or unknown identity it is not 
possible to give reassurance that the risk of HIV infection is zero. However, it may be possible to estimate 
risk, e.g. is the source from a high risk group such as PWID, MSM or from a country of high prevalence. 
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(See appendices 25 & 26 on HIV epidemiology and risk of transmission, and maps of global HIV prevalence and 
prevalence in PWID).
Counselling
If the risk of HIV is estimated to be high and PEP is being considered, the recipient should receive counselling on 
the risks and benefits of PEP. The counselling should cover:
•  The estimated HIV risk
•   The potentially serious adverse reactions to PEP which must be balanced against the risk of HIV infection
•   The possible requirement to inform insurer of a positive test result, as is applicable for an existing policy or for a 
new application 
•   The benefits of early identification versus the implications of a positive result
•   The window period.
Give the recipient an information leaflet about significant exposures (appendix 28).
Decision not to give PEP
If PEP is not to be given, explain why. Arrange for follow-up to be carried out by a GP, occupational health service or 
STI clinic as appropriate (appendix 35). 
Decision to give PEP
If a decision is taken to prescribe PEP, the recipient should be advised:
•   How to take the medication
•   The importance of adhering to the prescribed medication
•   The expected side effects
•   That only a starter pack is being prescribed.
Give the recipient a HIV PEP information leaflet (appendix 31)
Baseline investigations of recipient prior to prescribing HIV PEP
Baseline investigations prior to prescribing PEP are outlined in table 4. Blood samples should be labelled “Possible 
BBV exposure – recipient”.
Table 4  Baseline recipient investigations prior to prescribing PEP 
Safety bloods FBC, U&E, LFTs, Bone profile Must be reviewed 
prior to discharge 
home
Pregnancy test Urine strip
Urinalysis Dipstick for proteinuria
HIV testing HIV Ag/Ab
Hepatitis HBsAg, anti-HBc, anti-HCV 
Syphilis If sexual exposure
Prescribing HIV PEP 
Key points
•  Discuss with senior doctor in emergency medicine or infectious diseases if unsure how to proceed. 
•  Only start PEP within 72 hours of the risk event. 
•  The first dose of PEP should be given as soon as possible - within 2 hours if possible. It is not necessary to wait for 
blood results on the recipient (table 4) or the source.
•  Ensure baseline safety bloods are within normal limits before discharge. If there is renal impairment or 
proteinuria, see special prescribing situations below.
•  In general, dolutegravir should not be used in early pregnancy or in women of childbearing potential.
•  PEP should be discontinued immediately if a HIV test on the source is found to be negative, unless the source is 
at high risk of recent infection, in which case, continuation of PEP should only be on the explicit advice of a HIV 
physician.
•  It is important to note that antiretrovirals are unlicensed in Ireland for PEP. However, there are no licensed 
alternatives and they are widely used internationally and accepted as best practice.
Drug-drug Interactions
Overall the drugs chosen for HIV PEP pose a relatively low risk for drug-drug interactions but as with all prescribing, 
complete a full medication history (including herbal remedies, vitamins/minerals, over the counter medicines and 
recreational drugs) before prescribing HIV PEP.
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Truvada: There are no significant drug-drug interactions with Truvada.
Raltegravir: Advise patient to stop antacids and multivitamins (products containing metal cations e.g. magnesium/
aluminium, which can reduce the absorption of raltegravir) during PEP. Prescribe a PPI/H2 antagonist if required.
Increase the dose of raltegravir to 800mg 12 hourly if co-administration with rifampicin is required. Other 
cytochrome P450 inducers can be used with the standard dose of raltegravir.
Dolutegravir: Advise patients to take calcium and iron supplements, multivitamins and aluminium and magnesium 
containing antacids (which reduce the absorption of dolutegravir) at least 2 hours after or 6 hours before 
Dolutegravir.
Increase the dose of dolutegravir to 50mg 12 hourly if co-administration with rifampicin, phenytoin, phenobarbital, 
carbamazepine, oxcarbazepine or St. John’s Wort is required.
Dolutegravir increases the concentration of metformin and a dose adjustment should be considered when starting 
and stopping dolutegravir to maintain glycaemic control.
Dolutegravir is contra-indicated with dofetilide due to potential life-threatening toxicity caused by high dofetilide 
concentrations.
Additional resources include the product insert for the drug, the British National Formularly, 
www.hiv-druginteractions.org and www.medicines.ie.
Medications - Adults
Standard 3-5 day Starter Pack (ED/SATU): 
Truvada® (tenofovir/emtricitabine) one blue tablet daily, plus Isentress® 400mg (raltegravir) 1 pink tablet twice 
daily, a total of 3 tablets/day. 
 
Truvada®
PLUS
Isentress®
Once daily 
Morning 
Evening 
Truvada® should be taken with food as this improves tenofovir absorption and may reduce nausea. If patients have 
difficulty in swallowing, Truvada® can be dispersed in approximately 100ml of water or orange juice and taken 
immediately. Isentress® tablets however, should be swallowed whole and not chewed, broken or crushed (Isentress® 
SmPC, www.medicines.ie)
All medications must be reviewed by an ID/HIV specialist or a clinician with significant experience in managing HIV 
PEP before the starter pack runs out. A leaflet explaining the contents of the pack, the possible side effects and brief 
advice on how to deal with them should be provided to the patient (appendix 31). 
Standard Regimen STI/ID clinic: 
Truvada® (tenofovir/emtricitabine) one blue tablet daily, plus Isentress® 400mg (raltegravir) 1 pink tablet twice 
daily, a total of 3 tablets/day. 
Or  (Note: In general, dolutegravir is not recommended in early pregnancy or in women of childbearing potential)
Truvada® (tenofovir/emtricitabine) one blue tablet daily, plus Tivicay® 50mg (dolutegravir) one yellow tablet once 
daily, a total of 2 tablets/day. (Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV post-exposure 
prophylaxis in gay and bisexual men. McAllister J et al. Available at http://programme.aids2016.org/Abstract/
Abstract/1203)
Truvada®
PLUS
Isentress®
OR
Tivicay®
Once daily 
Morning 
Once daily 
Evening 
Patients who have been started on the standard starter pack, may continue on this regimen to complete the 4 weeks of 
treatment or may have the Isentress® switched to Tivicay® when they attend the ID/HIV or STI clinic for follow-up. The 
decision will be dictated by a number of factors, including potential drug-drug interactions between Tivicay® and other 
concomitant medications. 
EMI Guidelines - Appendix 7   HIV Post-exposure prophylaxis (PEP) (updated June 2018)
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Truvada® should be taken with food as this improves tenofovir absorption and may reduce nausea. If patients have 
difficulty in swallowing, Truvada® can be dispersed in approximately 100ml of water or orange juice and taken 
immediately. Isentress® tablets, however should be swallowed whole and not chewed, broken or crushed. Tivicay® can be 
taken with or without food. 
Potential Side Effects: 
Truvada® and Isentress®: GI side effects are common. Headache is common. Severe side effects are uncommon, but 
include rash, renal impairment and hepatoxicity. Patients experiencing side effects should contact their doctor. Tivicay®: 
Headache, dizziness and GI disturbance are reported as very common side effects. Insomnia, abnormal dreams, 
depression, rash, pruritus, elevations in ALT and CK are reported as common side effects. Patients experiencing side 
effects should contact their doctor. Further information on dosing and potential side effects and drug-drug interactions 
can be found in the relevant summary of product characteristics (Truvada® SmPC, Isentress® SmPC and Tivicay® SmPC 
all available at www.medicines.ie)
Special Prescribing situations
1.    Source is known to be HIV positive and on antiretroviral drugs: Discuss with ID/HIV specialist. If not contactable, 
commence standard starter pack and ensure follow up with ID/HIV specialist urgently.
2.  Renal impairment or proteinuria: Give first dose of Truvada® and discuss with ID/HIV specialist regarding the need 
for dose adjustment. Isentress®can be given. Tivicay® may alter creatinine excretion leading to an increase in serum 
creatinine but does not cause renal impairment or need to be dose adjusted in renal impairment.
3.  Pregnancy: If indicated, commence same PEP.  In general, dolutegravir is not recommended in early pregnancy or in 
women of childbearing potential. Ensure urgent specialist follow up
4.  Breastfeeding: Breastfeeding is generally not recommended while taking PEP. If the patient is currently 
breastfeeding or considering breastfeeding, this should be discussed with an obstetrician or an ID/HIV specialist. 
5.    Patients unable to tolerate 3-drug PEP: In exceptional circumstances the regimen can be switched to Truvada® 
alone. This should always be discussed first with an ID/HIV specialist.
Precautions
Advise the recipient to adopt safe sex practices (i.e. use condoms) for 3 months. See section 6.2 of main guidelines 
regarding precautions.
Follow-up
A recipient started on HIV PEP should be monitored by a clinician specialising in HIV treatment or a clinician with 
significant experience in managing HIV PEP. An urgent referral should be made to ensure that this visit takes place 
before the starter pack runs out (appendix 34). Note: Starter packs are not used in paediatrics. The doctor should 
complete the patient management form (appendix 1). This will serve as a referral form for the specialist clinic. Follow-up 
arrangements should be recorded in the patient’s notes.
Medications - Children 
(Adapted from Post Exposure Prophylaxis (PEP) Guidelines for children and adolescents potentially exposed to HIV. Our lady’s Children’s 
Hospital, Crumlin, February 2016) 
The risk assessment should be as per adults. The treatment is outlined below.
Counsel and advise the family, and provide information leaflets outlining side effects of medication. 
1.  Young people from 10 years of age and over 35Kg who are able to swallow tablets should receive PEP as for adults: 
Raltegravir 400mg (Isentress®) 1 tablet twice daily + Truvada® 1 tablet daily.
2.  Young people 10 years of age or older with renal insufficiency should not receive Tenofovir and should therefore be 
given : Raltegravir 400mg (Isentress®) 1 tablet twice daily + fixed dose combination of Lamivudine 150mg/Zidovudine 
300mg (Combivir®) 1 tablet twice daily.
3.  Tenofovir TDF should be avoided in the context of renal impairment at any age if at all possible (seek expert advice).
4.  Although Raltegravir is currently licensed in children younger than 6 years and weighing>11Kg, experience of use in 
children in this age group is limited. Kaletra® remains an alternative in children under 6 years of age with chewable 
Raltegravir as first line. (seek expert advice). 
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Regimens 
Accurate weight and height measurements should be used to calculate doses.
Surface area calculation:
Paediatric starter packs are not in use and not recommended as drugs are dispensed according to the 
individual’s body surface area. It is recommended that all centres with paediatric units should have 
paediatric HIV PEP preparations in stock or have formal arrangements in place whereby the drugs can 
be promptly sourced from another centre.
Table 5  Suggested PEP regimens10 (see dosing Table 2 below)
Age (years) Preferred PEP Alternative PEP Notes
10+ Raltegravir (Isentress®) + 
Truvada® (emtrictabine 200mg 
/ tenofovir disoproxil fumarate 
(TDF) 300mg 
NB if under 35KG, we would 
recommend age and weight 
appropriate dosing of raltegravir 
+ TDF + Lamivudine
1. Raltegravir  (Isentress®) +
Lamividune 150mg/ Zidovudine
300mg (Combivir®) combined
tablet
As  per adult guideline with an 
alternative for Tenofovir in those 
with renal insufficiency
6-9 Raltegravir (Isentress®) 
+ Lamivudine (Epivir®) +
Zidovudine (Retrovir®)
1. Kaletra® (lopinavir/Ritonavir)
+ Lamivudine (Epivir®) +
Zidovudine (Retrovir®)
2. Raltegravir (Isentress®) or
Kaletra® (Lopinavir/Ritonavir)
+ Tenofovir TDF (Viread®) +
Lamivudine (Epivir®)
Adult dose of Raltegravir 
for children >25Kg. Note 
the chewable formulation of 
raltegravir is not bioequivalent 
to the tablets (See table of 
preparations available below)
2- <6 Raltegravir (Isentress®) 
+ Lamivudine (Epivir®) +
Zidovudine (Retrovir®)
1. Kaletra® (Lopinavir/Ritonavir)
+ Lamivudine (Epivir®) +
Zidovudine (Retrovir®)
2. Raltegravir (Isentress®) or
Kaletra® (Lopinavir/Ritonavir)
+ Tenofovir TDF + Lamivudine
(Epivir®)
Use Raltegravir (Isentress® 
chewable tablets) when available 
<2 Kaletra® (Lopinavir/Ritonavir) 
+ Lamivudine (Epivir®) +
Zidovudine (Retrovir®)
Liquid formulations
EMI Guidelines - Appendix 7  HIV Post-exposure prophylaxis (PEP) (updated June 2018)
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Table 6: HIV PEP Drugs, Doses and Side Effects10
Dosing is correct as per date of guideline publication but for updated dosing see CHIVA ART dosing table http://www.chiva.org.uk/
Generally, medicines are well tolerated with the exception of minor, initial gastrointestinal disturbance and possible headache. 
Drug Formulation Dose Potential   Side Effects*
Raltegravir (RAL)
(Isentress®)
Note: Formulations are not 
bioequivalent; use chewable 
tablets for children 11-25Kg and 
children >25Kg who cannot 
swallow tablets
Tablet: 400mg
Chewable Tablet: 25mg, 
100mg (can be chewed or 
swallowed)
Tablet:
From 25Kg 400mg BD
Chewable Tablet:
11-14Kg: 75mg BD
14-20Kg: 100mg BD
20-28Kg: 150mg BD
28-40Kg: 200mg BD
>40Kg: 300mg BD
Take with or without food.
Rash, nausea, hepatitis
Zidovudine (AZT, ZDV) 
(Retrovir®)
Capsule:100mg
Liquid:10mg/mL
Capsule or liquid:
180mg/m²/Dose BD to a maximum 
dose of 250mg BD (max. 300mg BD 
when used in combination products)
Preferably on an empty stomach. If 
nausea occurs can be taken with food.
Granulocytopenia and/or 
anaemia, nausea, headache, 
myopathy, hepatitis, 
neuropathy
Lamivudine (3TC)
(Epivir®)
Tablet: 150mg
Liquid:10mg/mL
Tablet or Liquid:
4mg/Kg/dose BD to a maximum of 
150mg BD
Take with or without food.
Peripheral neuropathy, 
nausea, diarrhoea, headache
Truvada® 
Do not use if known renal 
impairment
Combined tablet:
(Tenofovir TDF 300mg / 
Emtricitabine  FTC 200mg)
Combined tablet:
>35Kg: 1 tablet daily
Headache nausea, 
vomiting, diarrhoea, renal 
tubular, dysfunction bone 
demineralization
Tenofovir TDF
(Viread®)
Note: 300mg Tenofovir 
disoproxil fumarate (TDF) = 
245mg Tenofovir disoproxil (TD)
All doses expressed as TDF
Tablet TDF (TD)
300mg (245mg)
For paediatric use: 
the tablet: TDF (TD) 300mg 
(245mg) disperses in 10mL 
water within 5 minutes
Tablet:
>35Kg: 1 tablet daily
2-12 years: 
8mg (6.5mg)/Kg once daily
10-12Kg: 80mg(66mg)= 2.7mL
12-14Kg: 100mg(83mg)= 3.4mL
14-17Kg:120mg(99mg)= 4mL
Do not use if known renal 
impairment
Continued:
Tenofovir TDF 
(Viread®)
Note: 300mg Tenofovir 
disoproxil fumarate = 245mg 
Tenofovir disoproxil (TD)
All does expressed as TDF(TD)
Tablet: TDF (TD)
300mg (245mg)
For paediatric use: 
the tablet: TDF (TD) 300mg 
(245mg) disperses in 10mL 
water within 5 minutes
Continued:
17-19Kg:140mg(116mg)= 4.7mL
19-22Kg:160mg(132mg)= 5.4mL
22-24Kg: 180mg(149mg)= 6.1mL
24-27Kg: 200mg(165mg)= 6.7mL
27-29Kg: 220mg(182mg)= 7.4mL
29-32Kg: 240mg(198mg)=8.1mL
32-34Kg: 260mg(215mg)= 8.8mL
34-35Kg: 280mg(231mg)= 9.4mL
≥35Kg: 300mg(245mg)= 10mL
The dose can be diluted in orange juice 
to improve taste 
Do not use if known renal 
impairment
Combivir® Combined tablet:
Lamivudine 150mg (3TC) / 
Zidovudine (ZDV) 300mg
Combined tablet:
>30Kg: 1 tablet twice daily
As for ZDV and 3TC
Kaletra®
2 adult tablets = 4 paediatric 
tablets = 5mL of liquid
All doses are based on 
Lopinavir (LPV)
Liquid:
Lopinavir (LPV) 80mg/ 
Ritonavir (RTV) 20mg per mL
Paediatric tablet:
(pale yellow)
Lopinavir (LPV)100mg/ 
Ritonavir (RTV) 25mg
Adult tablet:
(yellow)
Lopinavir (LPV)200mg/ 
Ritonavir (RTV) 50mg
Liquid:
300mg/m²/dose BD
Dose in mls = (300 x BSA) / 80
Paediatric tablet:
15-25Kg: 2 tablets BD
25-35Kg: 3 Tablets BD
>35Kg: 4 Tablets BD
Adult tablet:
>35Kg: 2 Tablets BD
Diarrhoea, abdominal pain, 
nausea, vomiting, headache
*This list of side effects is not exhaustive – refer to product datasheet for detailed information on side effects, interactions with other medicines and other 
cautions for use.
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6) Hepatitis B post-exposure prophylaxis
Hepatitis B vaccine is highly effective in preventing acute infection after exposure if given within 7 days and preferably within 48 hours. 
Hepatitis B immunoglobulin (HBIG) is only indicated where the source is known HBsAg positive, or where the recipient is a known non-responder to HBV vaccine and the source is 
known to be high risk. HBIG should ideally be given within 48 hours but not later than 7 days after exposure.
Exposure type 1. Needlestick injury
2. Bite with breach of skin
3. Sexual exposure
4. Mucosal exposure to blood or body fluids containing blood
Recipient
vaccination 
status 
Recipient unvaccinated 
against HBV
Recipient not fully 
vaccinated against HBV (<3 
doses)
Recipient fully vaccinated 
against HBV but
anti-HBs unknown4
Recipient documented non- 
responder to HBV vaccine
Recipient known 
responder 
to HBV vaccine,
i.e. anti-HBs≥10 mIU/ml
Source known to be 
HBsAg positive
Give HBiG1
Start accelerated2 HBV 
vaccine course
Recommend vaccination be 
completed
Give HBV vaccine dose. Test 
recipient anti-HBs urgently
Consider HBiG1 if <10 miU/ml 
(Urgent consult to iD/GUM 
specialist)
Recommend vaccination be 
completed
Give HBV vaccine dose. Test 
recipient anti-HBs urgently
Consider HBiG1 if <10 miU/ml 
(Urgent consult to iD/GUM 
specialist)
Give HBiG1 plus HBV vaccine dose
Urgent iD/GUM referral for 
alternative vaccination strategy 
No need for further
vaccine dose
Source HBV status 
unknown but potential 
high risk, ie from 
country of high or
intermediate 
prevalence3 
Make every effort to test 
source 
Start accelerated2 HBV 
vaccine course 
Recommend vaccination be 
completed
Make every effort to test 
source 
Give HBV vaccine dose
Recommend vaccination be 
completed
Make every effort to test 
source 
Give HBV vaccine dose
Make every effort to test source 
Give HBV vaccine dose
Consider HBiG1 (Urgent consult to 
iD/GUM specialist)
Urgent iD/GUM referral for 
alternative vaccination strategy 
No need for further
vaccine dose
Source HBV status 
unknown -  no high 
risk features, ie normal 
population risk5
Start accelerated2 HBV 
vaccine course
Recommend vaccination be 
completed
Give HBV vaccine dose 
Recommend vaccination be 
completed
Give HBV vaccine dose Make every effort to test source 
Give HBV vaccine dose
Urgent iD/GUM referral for 
alternative vaccination strategy 
No need for further
vaccine dose
Source HBsAg negative Routine (opportunistic) HBV 
vaccination course
Routine (opportunistic) HBV 
vaccination course
No need for further
vaccine dose
Routine iD/GUM referral for 
alternative vaccination strategy
No need for further
vaccine dose
1For bite with no visible blood, risk assess or seek urgent iD specialist advice re giving HBiG
 2An accelerated vaccine course consists of doses at 0, 1 and 2 months. A booster dose is given at 12 months to those at continuing risk. the standard course is 0, 1 and 6 months.
 3 Africa, Asia, Central and South America, Central and Eastern Europe. Refer to CDC map: http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm or 
appendices 21 & 22
4 if the recipient was fully vaccinated as an infant, no further testing or booster dose of HBV vaccine is required. Universal infant HBV vaccination commenced in ireland in September 2008.
5 People who inject drugs in ireland have only a 2% risk of being HBsAg positive and are thus not considered to be high risk. the prevalence in the general population is ≤0.1%
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testInG of reCIPIent
1. this section does not cover testing of the recipient for the purpose of monitoring HiV PEP 
treatment.
2. if a significant exposure has occurred, BBV testing of the recipient at baseline and over a 
period of follow-up is indicated. if no significant exposure has occurred, then no recipient 
testing is required.
3. if test results on the source are available and show that the source is negative for HBV, HCV 
and HiV, and the source is not considered to be at high-risk for recent infection, then testing of 
the recipient is not required.
4. informed consent should be obtained from the recipient before any testing is carried out 
(appendices 28 & 29).
5. Baseline testing is to reflect the recipient’s current status - not to test for infection related to 
the current exposure. 
Testing of recipient where a significant exposure has occurred
Time of test Status of source
1. BBV status unknown OR
2. Negative but high-risk OR
3. Positive for HBV, HCV or HIV
Negative for HBV, HCV 
and HIV AND not high-
risk
Baseline HBsAg†
Anti-HBc
Anti-HCV
HiV Ag/Ab
For sexual exposure Syphilis serology
Follow up testing is not 
required but baseline 
testing may be offered in 
an opportunistic way.
2 weeks Sti testing for sexual exposures
6 weeks HBsAg†
Anti-HCV 
HCV Ag or RNA *
HiV Ag/Ab
For sexual exposure Syphilis serology
3 months HBsAg†
Anti-HCV 
HCV Ag or RNA
HiV Ag/Ab
For sexual exposure Syphilis serology
† if recipient documented to have an adequate response to HBV vaccine, it is not necessary to test for HBsAg
* liaise with local lab in relation to whether Ag or RNA testing is being performed and ensure that the laboratory is aware of the 
clinical scenario
Anti-HBs testing: 
if the recipient was previously vaccinated but anti-HBs level post-vaccination is unknown, and 
HBiG administration (in addition to vaccine booster) is now being considered, it may be helpful to 
do an anti-HBs test at baseline. if the anti-HBs is ≥10miU/ml, HBiG is not indicated. if anti-HBs 
is <10miU/ml, the result is of no assistance in making the decision about administering HBiG, 
as antibody level declines over time after vaccination but the person may still be protected due 
to immune memory. in this situation, assessment of other factors such as the severity of the 
exposure may assist in making the decision about HBiG.
if recipient initiates a course of HBV vaccination, an anti-HBs test should be carried out 2 months 
after completion of the course of vaccination.
Sample and accompanying information
For serology samples 10mls of clotted blood is required. Where RNA testing is also being 
performed, an EDtA sample may be required. Please check with your laboratory what type of 
eMI Guidelines - Appendix 9   Testing of recipient  (updated May 2016)
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sample is required and if there is a requirement to deliver samples within a timeframe from time 
of collection.  the request form should include the following information:
•  label: “Possible BBV exposure – recipient”
•  test and retain for 2 years  
•  list the tests requested (as per table)
•  Give the details and contact number (preferably mobile number) of the healthcare 
professional to whom the results should be sent
Negative test results
if all these tests are negative, no further testing is needed.
Positive test results
if any of the test results are positive, a referral to an appropriate specialist should be made 
(appendix 34).
Testing of needles
testing of needles or sharps for the presence of BBVs is not recommended.
 
eMI Guidelines - Appendix 9   Testing of recipient  (updated May 2016)
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InterPretatIon of hBV results
(Adapted from immunisation Guidelines for ireland. 2013 Edition. Chapter 9 - Hepatitis B, updated September 2015.  
 National immunisation Advisory Committee, RCPi)
HBsAg HBeAg Anti-HBe Anti-HBc IgM Anti-HBc total Anti-HBs Interpretation
Neg Neg Neg Neg Neg Neg Susceptible to HBV
PoS PoS Neg PoS/Neg PoS/Neg Neg Acute HBV infection 
Neg Neg Neg PoS PoS1 Neg Recent HBV infection (HBsAg 
window)
PoS PoS Neg WEAk PoS/ Neg PoS Neg Chronic HBV infection2
PoS Neg PoS/Neg WEAk PoS/ Neg PoS Neg HBeAg neg chronic HBV infection3
Neg Neg PoS/Neg Neg PoS* PoS/Neg Resolved HBV infection
Neg Neg Neg Neg Neg PoS Response to hepatitis B vaccine
Notes
1 Anti-HBc detected in two assays
2 Follow up sample required to confirm chronic HBV infection
3 Follow up sample required and also HBV DNA viral investigations may be required
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hePatItIs B VaCCIne
HBV vaccine contains recombinant HBsAg, derived from yeast cells, adsorbed onto aluminium hydroxide 
adjuvant. the vaccine is effective at preventing infection in individuals who produce specific antibodies to 
HBsAg (anti-HBs). However, around 10-15% of adults fail to respond or have a poor response to 3 doses 
of vaccine. Poor response is associated with age over 40 years, male gender, obesity and smoking. lower 
seroconversion rates have also been reported in those with alcoholic liver disease. Patients who are 
immunocompromised or have chronic renal failure may respond less well and may require larger or more 
frequent doses of vaccine.
HBV vaccine is used for pre-exposure and post-exposure protection and provides long-term protection. 
Pre-exposure prophylaxis: Since 2008, all infants are offered HBV vaccine as part of the routine 
childhood immunisation schedule at 2, 4 and 6 months of age. in addition, HBV vaccine is recommended 
for those who are at increased risk of infection because of their occupation, close contact with cases, 
medical conditions, or lifestyle factors such as injecting drug use, and sexual behaviour.
Vaccine efficacy studies have shown that 90-100% of vaccinated persons who develop anti-HBs ≥10miU/
ml after a primary series are protected from HBV infection. 
Post-exposure: HBV vaccine is highly effective at preventing infection, provided that the vaccine is 
administered preferably within 48 hours but up to 7 days post-exposure. 
Specific hepatitis B immunoglobulin (HBiG) is available for passive protection and, when indicated, is 
normally used in combination with HBV vaccine to confer passive/active immunity after exposure. it 
should be administered according to the manufacturer’s guidelines and should ideally be given within 
48 hours of exposure but not later than a week after exposure. HBiG provides short-term protection (3-6 
months) (see appendix 13)
Schedule and dosage:
the basic HBV immunisation schedule consists of three doses of vaccine at 0, 1 and 6 months. Alternative 
accelerated schedules exist (e.g. 0, 1 and 2 months; 0, 7 and 21 days – see manufacturer’s guidelines) if 
more rapid protection is required. these should be followed by a dose of vaccine at 12 months to complete 
the course.
Currently licensed vaccines contain different concentrations of antigen. the appropriate manufacturer’s 
dosage should be adhered to. Higher doses of vaccine should be used for adult patients with chronic 
renal failure, and considered for other immunosuppressed adults.
Administration: the vaccine is given intramuscularly in the deltoid region and not in the gluteal region. in 
the case of infants, the vaccine may be given in the anterolateral thigh. 
Contraindications: the vaccine is contraindicated in a person who has had an anaphylactic reaction to 
preceding doses of a HBV-containing vaccine or any of its constituents. 
Pregnancy and breastfeeding: Pregnancy is not a contraindication to HBV vaccination. No adverse effect 
on the developing foetus has been observed when pregnant women have been immunised against HBV. 
Breastfeeding is not a contraindication to HBV immunisation. 
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Adverse reactions: HBV vaccine is generally well tolerated. the commonest reactions are soreness and 
redness at the injection site. Fever, rash, malaise and influenza-like symptoms are less commonly reported 
after vaccination.
Post-vaccination testing: Routine post-vaccination testing for anti-HBs is recommended 2 months after 
completing the course of vaccination for persons who are at continuing risk of HBV exposure. Following 
primary vaccination, it is preferable to achieve anti-HBs levels above 100miU/ml although levels above 
10miU/ml are generally accepted as protecting against infection. Anti-HBs titre often declines post-
vaccination but a rapid anamnestic response develops after exposure to the virus.
Reference
Royal College of Physicians of ireland, National immunisation Advisory Committee. immunisation Guidelines for ireland 2013. Chapter 
9 - Hepatitis B (updated 17th September 2015). Available from: http://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/.
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hePatItIs B VaCCInatIon 
PatIent reCord Card
A downloadable version of this card can be found at www.emitoolkit.ie
Patient Record Card
Patient MRN: 
Patient Name: 
Healthcare Facility: 
Vaccine 1 Date: 
Next vaccine dose due: 
Vaccine 2 Date: 
Next vaccine dose due: 
Vaccine 3 Date: 
Return for Blood test on:  
Post Vaccination Anti-HBs titre level:
It is important that all doses of vaccine are administered
Please keep safe and bring card with you for hospital appointments 
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Vaccine 1 Date: 
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Post Vaccination Anti-HBs titre level:
It is important that all doses of vaccine are administered
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hePatItIs B IMMunoGloBulIn (hBIG)
if HBiG is indicated (see appendix 8 re HBV PEP), it should be administered according to the 
manufacturer’s guidelines. it should ideally be given within 48 hours of exposure but not later than 1 week 
after exposure.
Hepatect CP® (Biotest Pharm GmbH) 50 units/ml is the HBiG product available in ireland. 
the dose for post-exposure prophylaxis in adults is 500 units (10 ml). For children, the dose is 8 units (0.16 
ml)/kg. 
Hepatect CP® should be infused intravenously at an initial rate of 0.1 ml/kg/hour for 10 minutes. if 
tolerated, the rate of administration may gradually be increased to a maximum of 1 ml/kg/hour.
Do not dilute Hepatect CP® or mix Hepatect CP® with any fluid.
the first dose of HBV vaccine can be given on the same day as HBiG but at a different site.
theoretical risk of infection
According to the  Hepatect CP® Summary of Product Characteristics (SPC) (http://www.hpra.ie/
homepage/medicines/medicines-information/find-a-medicine/results/item?pano=PA0592/005/004&s
pcpara=6.0&t=HEPAtECt%20CP):
 “Standard measures to prevent infections resulting from the use of medicinal products prepared from 
human blood or plasma include selection of donors, screening of individual donations and plasma pools 
for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/
removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are 
administered, the possibility of transmitting infective agents cannot be totally excluded. this also applies 
to unknown or emerging viruses and other pathogens.
the measures taken are considered effective for enveloped viruses such as HiV, HBV and HCV. the 
measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.
there is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission 
with immunoglobulins and it is also assumed that the antibody content makes an important contribution 
to the viral safety.
it is strongly recommended that every time that  Hepatect CP® is administered to a patient, the name and 
batch number of the product are recorded in order to maintain a link between the patient and the batch of 
the product.”
Reference
Royal College of Physicians of ireland, National immunisation Advisory Committee. immunisation Guidelines for ireland 2013 . 
Available from:http://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/
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 ManaGeMent of aCute hePatItIs C
Currently there is no recommended post-exposure prophylaxis for HCV. However, treatment 
of early infection has been shown to be successful.
A review of 17 published studies on therapy of acute hepatitis C was carried out by Alberti et al.1  
Almost all of these studies were small in size, uncontrolled and highly heterogeneous in respect 
of patient features, dose and duration of treatment, follow-up evaluation, and criteria used 
to define efficacy and safety. However, the authors concluded that the pooled results strongly 
support the benefit of interferon therapy in reducing chronicity of acute hepatitis C, a finding 
that was confirmed by a formal meta-analysis of several randomised controlled trials of acute 
hepatitis C treatment. the pooled data from 17 studies showed a sustained virological response 
(SVR) of 62% (range 37-100%) in the treated patients, compared with 12% (range 0-20%) in 
untreated individuals. 
in the United kingdom, the surveillance system for occupational exposures to BBVs in healthcare 
workers (HCWs)has reported that, of 10 HCWs who received treatment for acute HCV, all had 
achieved an SVR.2  
in a review article on acute hepatitis C, Maheshwari et al state that, despite the absence of large 
randomised trials, it is reasonable to conclude that early treatment could reduce the chronicity 
of HCV infection.3 However, several issues of therapy are unresolved, such as: which patients to 
treat, when to start treatment and what regimen is optimal.
Recommendation:
•   It is essential that patients who develop acute hepatitis C infection are diagnosed as soon as 
possible to allow for early treatment. therefore, a HCV Ag or HCV RNA test on the recipient is 
carried out at six weeks and three months after the exposure incident. 
•   The recipient should also be counselled for symptoms suggestive of acute infection, e.g. fever, 
abdominal pain, vomiting, dark urine, yellow eyes. 
•   A person with symptoms suggestive of hepatitis, or a positive HCV RNA or Ag result, should be 
evaluated immediately by an appropriate specialist.
•   The patient should be advised to avoid unprotected sexual contact.
References    
1. Alberti A, Boccato S, Vario A, Benvegnu l. therapy of acute hepatitis C. Hepatology 2002;36:S195-S200.
2. Health Protection Agency Centre for infections, National Public Health Service for Wales, CDSC Northern 
ireland and Health Protection Scotland. Eye of the Needle. Surveillance of significant occupational exposure to 
bloodborne viruses in healthcare workers. November 2008.
3. Maheshwari A, Ray S, thuluvath PJ. Acute hepatitis C. lancet 2008;372:321-32
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tetanus  
(Adapted from Royal College of Physicians of ireland, National immunisation Advisory Committee. 
immunisation Guidelines for ireland 2013. Chapter 21 - tetanus (updated 25th August 2015).  Available from: 
http://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter21.pdf)
Prophylaxis for tetanus-prone wounds
the following wounds are considered tetanus-prone:
•  Wounds contaminated with soil, faeces, saliva or foreign bodies
•  Puncture wounds*, avulsions, burns or crush injuries
•  Wounds or burns requiring surgical treatment which is delayed for more than 6 hours
•  Compound fractures
Note: occasionally, apparently trivial injuries can result in tetanus.
*Needlestick injuries in healthcare settings are unlikely to pose a risk of tetanus.
Risk assessment of wounds for use of vaccination and tetanus immunoglobulin (TIG)  
Vaccination status Clean wound Tetanus prone wound
Fully immunised 
(5 doses of tetanus vaccine at 
appropriate intervals) 
Nil Nil Consider tiG*
Primary immunisation and age 
appropriate boosters complete Nil Nil Consider tiG
*
Primary immunisation or age 
appropriate boosters incomplete
Age appropriate 
tetanus vaccine and 
complete vaccine 
schedule
Age appropriate 
tetanus vaccine 
and complete 
vaccine schedule
tiG
Unimmunised or unknown vaccine 
status
Age appropriate 
tetanus vaccine and 
complete vaccine 
schedule
Age appropriate 
tetanus vaccine 
and complete 
vaccine schedule
tiG
* Consider tiG for fully vaccinated patients who are immunocompromised 
 
Important:
If both TIG plus a vaccine are to be given, administer at separate sites.
Refer to GP for follow-up vaccines.
Batch numbers and expiry dates must be recorded for all vaccines given.
This information MUST be communicated to the patient’s GP so that:
•  Duplication of vaccination does not occur
•  Full records may be passed onto the relevant agencies in order that a full nationwide database 
is kept of batch numbers and expiry dates of vaccines given to children.
Specific anti-tetanus immunoglobulin
Indications
Prophylaxis with tiG is recommended for those with tetanus-prone wounds who:
•   have not received at least 3 doses of tetanus toxoid and their last dose within 10 years (see table 
above)
or
•   are immunocompromised, even if fully immunised (see Chapter 3 of Immunisation Guidelines for 
ireland 2013).
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Dose and route of administration
Prevention
250 units (1ml) intramuscularly into the anterolateral thigh.
the single dose of tiG is doubled to 500 units (2ml) when any of the following situations exist:
•  The injury occurred more than 24 hours previously
•  The patient weights more than 90kg
•  The wound is heavily contaminated
•  The wound is infected or involves a fracture
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PresCrIBInG InforMatIon for eMerGenCy 
horMonal ContraCePtIon (eC)  
Please note that the provision of family planning services is not considered within the normal remit of 
the Emergency Department. However, there are situations where emergency hormonal contraception is 
considered appropriate. 
When should emergency hormonal contraception be considered?
1)    in females presenting for post-exposure prophylaxis (or consideration of same) following potential 
sexual exposure to HiV.
2)   in females presenting for assessment following sexual assault.
Please note that insertion of a copper iUD is a more effective form of emergency contraception. Copper 
iUDs are available at Family Planning and Well Woman Clinics. Advice on how to obtain an iUD should 
be offered to all women attending for emergency contraception even if presenting within 72 hrs of 
unprotected sexual intercourse (UPSi).
1. Emergency Contraceptive Pill (ECP): Ulipristal Acetate (ellaOne®)
How does ulipristal acetate (UPA) prevent pregnancy? 
UPA is a progesterone receptor modulator and the primary mechanism of action is thought to be 
inhibition or delay of ovulation.1 if administered immediately before ovulation UPA has been shown to 
suppress growth of lead follicles.2, 3 there is evidence3 to suggest that UPA can prevent ovulation after the 
lH surge has started, delaying follicular rupture until up to 5 days later. Administration of UPA at the time 
of the lH peak or after has been shown to be ineffective in delaying follicular rupture.3
Although there have been studies that have shown an endometrial effect,4, 5 the contribution of these 
endometrial changes to the efficacy of UPA (e.g. by inhibiting implantation) is as yet unknown.
there is currently a lack of evidence on the effect of UPA if inadvertently administered after implantation 
has occurred, but there have been no associated adverse outcomes in the small numbers of inadvertent 
pregnancies that have been reported to date.1 
it is important to remember that women must not consider themselves protected against pregnancy 
for subsequent acts of intercourse. therefore, after using emergency contraception, women should be 
advised to use a reliable barrier method until her next menstrual period.
When can ulipristal acetate (UPA) be given?
UPA should be given as soon as possible after UPSi. The efficacy of UPA has been demonstrated up to 
120 hours after UPSI 1, 6, 7 and there is no apparent decline in efficacy within that time period.6
No data are available on the efficacy of ellaone when taken more than 120 hours (5 days) after 
unprotected intercourse.
What is the dose?
A single dose of UPA 30mg tablet is given orally.1
if vomiting occurs within 3 hours of ellaone intake, another tablet should be taken.1
the SPC (summary of product characteristics) states that concomitant use of ellaone with CYP3A4 
inducers is not recommended due to interaction (e.g. rifampicin, phenytoin, phenobarbital, 
carbamazepine, efavirenz, fosphenytoine, nevirapine, oxcarbazepine, primidone, rifabutine, St John’s 
wort/Hypericum perforatum, long term use of ritonavir). 1
the FSRH Guidelines (2011) do not currently support doubling the dose of UPA when using drugs that 
may reduce UPA’s efficacy.8
Contraindications to using ulipristal acetate (UPA)
Although there has been limited inclusion of under-18s in clinical trials of UPA, age is not listed as a 
contraindication within the SPC.1
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1)  the SPC states that contraindications to use include a hypersensitivity to UPA or any of the other 
components, and also pregnancy.1
2)  Use is not recommended in women with severe asthma insufficiently controlled by oral glucocorticoids. 
3)  in addition the SPC advises caution in women with hepatic dysfunction, hereditary problems of galactose 
intolerance, the lapp lactase deficiency or glucose-galactose malabsorption.1
4)  the SPC states that after intake of UPA, breastfeeding is not recommended for up to 36 hours.1
Ulipristal Acetate (ellaOne®) emergency contraception is available, over the counter, without prescription 
to women over 16 years of age. 
Please refer to the Faculty of Sexual and Reproductive Healthcare website     
http://www.fsrh.org/searchresults.asp?q=ellaone) or the Summary of Product Characteristics   
(http://www.medicines.ie/medicine/15370/SPC/ellaone+30+mg/) for further information. 
2.  Emergency Contraceptive Pill (ECP): Levonorgestrel (NorLevo® or Prevenelle®) 
How does levonorgestrel prevent pregnancy?
the exact mode of action of levonorgestrel in preventing pregnancy following UPSi is not known. if taken 
in the preovulatory phase it will usually inhibit ovulation for 5-7 days, by which time any sperm in the upper 
reproductive tract have lost their fertilising ability. it may also cause endometrial changes that discourage 
implantation.
it is important to remember that women must not consider themselves protected against pregnancy for the 
rest of their cycle following a dose of levonorgestrel. this is particularly important if levonorgestrel has the 
effect of delaying ovulation.
Results from a recent clinical study 9 showed that a 1500 microgram single dose of levonorgestrel (taken 
within 72 hours of UPSi) prevented 82% of expected pregnancies.
When can levonorgestrel be given?
levonorgestrel should be given as soon as possible after UPSi. it is most effective when given within 72 hours 
of UPSi. Efficacy is reduced after this time.10, 11
Use of levonorgestrel between 73 and 120 hours post UPSi may be associated with a reduced expected 
pregnancy rate and may be considered. Use of levonorgestrel after 72 hours is outside of the product licence. 
Women in these circumstance should be offered ellaone or advised to attend a family planning or well woman 
clinic for insertion of a copper iUD. 
What is the dose?
the usual dose of levonorgestrel is 1.5mg stat, given as soon as possible after UPSi.10, 11
it is not necessary to give prophylactic antiemetics routinely with levonorgestrel. Antiemetics can be reserved 
for women who give a history of vomiting when they have taken levonorgestrel in the past or where a woman is 
receiving a second dose because of vomiting within 3 hours of taking levonorgestrel.
the metabolism of levonorgestrel is enhanced by concomitant use of liver enzyme inducers. Drugs suspected 
of having the capacity to reduce the efficacy of levonorgestrel containing medication include barbiturates 
(including primidone), phenytoin, carbamazepine, herbal medicines containing Hypericum perforatum (St. 
John’s Wort), rifampicin, ritonavir, rifabutin, griseofulvin.10, 11
Medicines containing levonorgestrel may increase the risk of cyclosporin toxicity due to possible inhibition of 
cyclosporin metabolism.11 For further information on drug interactions check with a pharmacist or consult the 
British National Formulary, BNF.
in women taking liver enzyme inducers the current recommendation from the Faculty of Family Planning is 
that the women take 3mg levonorgestrel stat.12 they should also be informed of the option of being referred to 
a family planning clinic for insertion of an iUD.
Contraindications to using levonorgestrel
1)  there is no age limit to the use of levonorgestrel, although there is little data on its use in females under 
16 years of age.
2)  the WHo Medical eligibility Criteria for Contraceptive use advises that there are no medical 
contraindications to levonorgestrel.13
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3)  the SPC (summary of product characteristics) for Prevenelle and Norlevo state that levonorgestrel is not 
recommended in patients with severe hepatic dysfunction.10, 11 
4)  Prevenelle and Norlevo contain lactose monohydrate. Patients with rare hereditary problems of galactose 
intolerance, the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.10, 11
5)  Women with severe malabsorption syndromes (such as Crohn’s disease) may experience a reduction in efficacy 
of oral emergency contraception.11
6)  Any women known to have hypersensitivity to levonogestrel or any of the other components of the tablet 
should use levonorgestrel with caution. 
For further information on the Summary of Product Characteristics see:
http://www.medicines.ie/medicine/11933/SPC/Norlevo+1.5mg+tablet/ or      
http://www.medicines.ie/medicine/16228/SPC/Prevenelle+1500+microgram+tablet/ 
Levonorgestrel emergency contraception is available, over the counter, without prescription to women over 16 
years of age. 
(Adapted from Faculty of Sexual & Reproductive Healthcare Clinical Guidance on Emergency Contraception, August 2011, updated January 
2012.14)
Time Frames for Emergency Contraception
MEtHoD tiME FRAME 
Ulipristal acetate 30mg (one tablet) orally As soon as possible but within 5 days (120 hours) of unprotected intercourse or 
expected date of ovulation.15, 16
Single dose of levonorgestrel 1.5 mg. (one tablet) 
orally. 
As soon as possible within 72 hours.10, 11, 17
Some evidence it is of value up to 5 days (120hrs) but the efficacy is uncertain and 
it is not licensed for use after 72 hours.17, 18, 19 
A copper containing intra-uterine device * After 72 hours but within 5 days (120 hours) of unprotected intercourse or ex-
pected date of ovulation.20, 21, 22 
*Available from some family planning and well woman clinics
Source: HSE Recent Rape/Sexual Assault: National Guidelines on Referral and Forensic Clinical Examination in ireland. 3rd edition; 2014.23
For patient information leaflet on emergency contraception, see appendix 32.
eMI Guidelines - Appendix 16 Prescribing information for emergency contraception (updated May 2016)
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oCCuPatIonal Blood or Body fluId 
exPosure
this section relates to workplaces where a risk assessment has indicated that blood and body fluid exposures 
are an occupational hazard. Such occupations include, but are not limited to, the healthcare sector, members 
of An Garda Siochana, and prison personnel.
Each occupational health service should have a local policy for the prevention and management of blood and 
body fluid exposures. this policy should take into account local expertise and local resources, which in turn will 
dictate whether the employee is managed at the initial stage in the occupational health department (oHD), 
local emergency department (ED) or elsewhere.  
in occupations where infectious exposures are recognized as potential hazards, a hierarchical approach to 
management is required and the focus should be on prevention.1 
Employees should be informed of the correct course of action to follow in the event of an occupational blood 
or body fluid exposure at commencement of their employment. Furthermore, employees should be reminded 
that they should not manage these exposures themselves but should report the exposure and follow local 
management arrangements.  
training of employees in the correct use of instruments (including personal protective equipment) is 
recommended.2, 3, 4 While this should reduce the frequency of exposures, unfortunately it will not completely 
eliminate blood and body fluid exposures. Where vaccination is available, it must be provided by the employer. 
At present, this is only available for hepatitis B (see appendix 11, Hepatitis B vaccine). Where an employee 
does not achieve an adequate protective antibody response, they should be counselled regarding the risk of 
exposures to hepatitis B infected blood and the recommended management of such exposures. this should be 
documented. 
the needlestick/sharps exposure algorithm (appendix 3) outlines the initial management of any employee 
who is exposed to blood or body fluids in the course of their work. Further details and relevant background 
information are included elsewhere in the guideline. local resources will dictate where the worker is managed 
at the initial stage i.e oHD, ED or other and where follow-up is carried out i.e. oHD, infectious diseases service.
in addition to the risk of disease transmission, blood and body fluid exposures are a recognised cause of 
distress among recipients, with potential medical and legal ramifications. Anxiety, insomnia and depression 
are frequently reported, while more extreme cases of post-traumatic stress disorder and panic attacks 
have also been described. to minimise this, clear and consistent information should be provided including 
the risks of disease transmission, details of the management and follow-up plan, symptoms suggestive of 
seroconversion illness, likely side effects and potential drug interactions of treatment (where relevant) and any 
workplace/life-style modification that may be indicated (see information leaflets, appendices 28 and 31).  
in all cases, the details of the injury, including the context of the injury and the nature of the device involved, 
should be recorded (appendix 1, patient management form). this information is required both in the initial 
assessment process (see Section 2 of the Guidelines) and to inform future decision making (e.g. purchasing 
policies, training, counselling requirements) regarding preventative measures. in addition, the oHD should be 
able to provide anonymous details of injuries to the Health & Safety Authority and for auditing purposes.
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huMan BIte InJurIes, salIVa and 
transMIssIon of BloodBorne 
VIruses
Summary of BBV transmission risk from exposure to saliva
the risk of BBV transmission from exposure to saliva is very low overall. it is related to the type of 
injury, the type of virus present, and the amount of blood in the saliva. Saliva cannot transmit BBVs 
unless blood is present, although blood can be present without being visible. the risk is increased if 
there is visible blood, poor oral hygiene, or if the source or recipient is immunocompromised. if there 
is a large amount of blood present in the saliva, the risk is similar to the risk from exposure to blood. 
 
With bite cases, an individual risk assessment is required, taking account of the extent of the injury, 
the HBV immunisation status of the injured person and the BBV status of the source and the injured 
person. With the exception of a deep bite wound sustained from a HBV infected, or high-risk, source, 
in a recipient who is not HBV immune, the risk of BBV transmission is negligible. the evidence 
suggests that the risk of transmission from a HiV positive or HCV positive source is minimal to non-
existent. A recipient of a bite that breaches the skin but with no visible source blood does not require 
any follow-up from the point of view of HiV and HCV. 
HBV vaccination should be advised for an unvaccinated recipient following a percutaneous or 
mucous membrane exposure to saliva from a source who is HBV infected or high-risk but of unknown 
sero-status (see appendix 8). HBiG may also be indicated, depending on the risk assessment, but 
generally only if the source is HBV positive. if HBiG is required, it should ideally be given within 48 
hours of exposure, but not later than a week after exposure. HiV PEP would not be indicated except 
in extreme circumstances.
Saliva and bloodborne viruses
Although composed mainly of water (99%), saliva is a complex secretion. Saliva can be considered 
as gland-specific saliva or whole saliva. Whole saliva (mixed saliva) is a mixture of oral fluids 
and includes secretions from both the major and minor salivary glands, in addition to several 
constituents of non-salivary origin, such as gingival crevicular fluid, expectorated bronchial and 
nasal secretions, serum and blood derivatives from oral wounds, bacteria and bacterial products, 
viruses and fungi, desquamated epithelial cells, other cellular components, and food debris. Saliva 
has protective properties and contains a variety of antimicrobial constituents and growth factors.  
in general, complete bloodborne viruses are not secreted into saliva, even though the bloodborne 
viruses HBV, HCV and HiV have all been detected by molecular techniques in saliva of infected 
patients. BBVs get there from blood leakage into the oral cavity, either from soft or hard tissue 
trauma or from periodontal bleeding. Salivary fluids exiting the glands mirror the composition of 
macromolecules in blood. Viral particles usually are too large to filter through the salivary glands 
and into saliva. However, individual components of unassembled viral particles can get through the 
glands, such as hepatitis B surface antigen or DNA, and appear in saliva without the presence of 
blood.  However, transmission can only occur if completely assembled HBV particles are in the saliva.  
No studies are available that prove that HBV is transmitted through saliva in the absence of blood.  
the same holds true for HCV and HiV. The bottom line is that saliva can only transmit BBVs to the 
extent that blood is present. 
However, even when blood is not visible, it can still be present in limited quantities in the saliva 
and therefore saliva is considered a potentially infectious material in any percutaneous or 
mucous membrane exposure by the US CDC and occupational Safety and Health Administration 
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(oSHA). A bite from someone known to have poor gum health, diabetes, immunocompromise, or on 
anticoagulant medication, may increase the risk. Dentists are occupationally exposed to saliva, and 
prior to 1982 when the HBV vaccine was not available and exam gloves were not routinely used, their 
seroprevalence of HBV markers of infection was about 15%. the HCV seroprevalence in dentists is 
about 0.5%, and for HiV it is under 0.025%. therefore, the risk of transmission from percutaneous or 
mucous membrane contact is proportional to the amount of blood in the saliva and the type of virus 
present.
 
Hepatitis B
HBV has been demonstrated in the saliva of HBV infected people and a high correlation has been 
shown between HBV DNA levels in serum and saliva.1,2,3 Saliva has been suggested as a vehicle for 
horizontal transmission of HBV among children. A study of paired saliva and plasma samples from 43 
children with chronic HBV infection found  high levels of HBV DNA (mean 33.9 x 103 iU/ml) in saliva 
of HBeAg positive children but HBV DNA was not detectable in the saliva samples from the HBeAg 
negative children.4
transmission of HBV by human bite has been described and definitively proven by genome sequencing 
of the virus in the carrier and in the bitten person.5
Hepatitis C
HCV has been shown to be frequently present in the saliva of HCV infected people.6,7,8 However, 
epidemiological studies show that infection by contact with contaminated saliva is rare.8 it may be 
that the specific and non-specific defence mechanisms present in saliva could attenuate or abolish 
the infective capacity of viral particles. Saliva of patients with chronic HCV infection contains specific 
igG and igA neutralising antibodies directed against the E1 and E2 surface glycoproteins which could 
block viral adhesion to the host cell.9 there is conflicting evidence about the relationship between the 
presence of the hepatitis C virus in the saliva and the viral load in the blood, with one review suggesting 
a direct relationship8; however, one study found that the presence of HCV in saliva is independent of the 
level of viral load.10
there have been no reports proving the direct transmission of HCV by saliva: the possibility of 
transmission of HCV by a human bite has not been confirmed by molecular studies.8 Data suggest 
that nosocomial transmission of HCV to dental HCWs is unlikely.11  A review of the evidence on HCV 
transmission by saliva8 found that the prevalence of HCV infection among dental health care workers 
exposed to saliva is similar to that for the general population. 
HIV 
Salivary proteins play a role in the inactivation of HiV and preventing its infectivity.12 HiV virus is 
detectable in saliva, especially in immune compromised patients as CD4 count declines and plasma 
viral load increases. in countries where HiV positive patients receive successful anti-viral therapy 
(HAARt), viral load is undetectable in most cases and the risk of oral transmission of HiV is probably 
low to non-existent.
Bite injuries represent a potential means of transmitting HiV. However, HiV transmission by this route 
has been reported rarely.13 the few documented cases of possible HiV transmission following bites were 
in adults exposed to blood-tinged saliva.14
transmission might theoretically occur either through biting or receiving a bite from a HiV-infected 
person. Biting a HiV-infected person, resulting in a break in the skin, exposes the oral mucous 
membranes to infected blood; being bitten by a HiV-infected person exposes non-intact skin to 
saliva. Saliva that is not contaminated with blood contains HiV in much lower titres and constitutes a 
negligible risk. A bite is not considered a risk exposure to either party when the integrity of the skin is 
not disrupted.
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A review of literature on human bites and HiV transmission15 concluded that it is possible for a bite from a 
HiV-infected individual to transmit HiV. the likely risk of transmission is increased if:
•  Blood is present in the oral cavity
•  The bite breaks the skin
•  The bite is associated with a previous injury
•  The biter is IgA deficient.
huMan BIte InJurIes 
(appendix 6, algorithm for management of human bites)
Background
Human bite wounds may result in infection such as cellulitis, osteomyelitis or septic arthritis. Current 
data suggest an infection rate from human bite wounds of the order of 10% to 50%, depending on the 
wound type and location. However, human bite wounds to the hand are associated with infection rates of 
almost 50%. A clenched-fist injury (“fight bite”) is considered the most serious of all human-bite wounds, 
with bites to feet, face, or skin overlying cartilaginous structures, or bites that penetrate deeper than the 
epidermal layer also significant. Human bites in other areas pose no greater risk than animal bites.
Human bites cause more serious infections than dog and cat bites because the human oral flora contains 
multiple species of bacteria. Human bite wound pathogens include aerobic bacteria (such as streptococci, 
s aureus and eikenella corrodens) and anaerobic bacteria (such as fusobacterium, Peptostreptococcus, 
Prevotella, and Porphyomonas spp.16 
Because individuals with human bite wounds have a high-risk of serious bacterial infections close 
assessment of any bite wound is necessary. overall, the risk of transmission of bloodborne viruses by 
human bites is likely to be low (see above). However, a significant risk of transmission must be considered 
following a human bite from a high-risk individual where a breach of the skin occurs and particularly if 
there is blood in the saliva. the risk is highest where the biter is HBV positive.
Pathophysiology
in a closed-fist injury (“fight bite”), forces sufficient to break the skin from striking an opponent’s tooth 
often inoculate the extensor tendon and its sheath. As the hand is flexed at the time of impact, the 
bacterial load is transferred caudally when the hand is opened and the tendon slides back to its relaxed 
state. Resulting contamination cannot be removed readily through normal cleansing and irrigation. 
When a finger is bitten, such as in a chomping-type injury, tendons and their overlying sheaths are 
in close proximity to the skin. the wound may appear to be a minor abrasion-type injury, but careful 
inspection is required to rule out deep injury.
When a tooth strikes the head, even a deep puncture wound may appear innocuous. Deep, subgaleal, 
bacterial contamination is possible. this is especially true in young children who have relatively thin soft 
scalp and forehead tissue.
Frequency, age and sex
in a 4-year retrospective review in the United kingdom, 421 (13%) human bites were identified out of 
3136 case notes in emergency medicine departments. the majority of those bitten were young males, 
with 44% of the males aged 16-25 years. the male-to-female ratio was 3:1. Closed-fist injuries are 
encountered almost exclusively in young males. toddlers frequently bite one another, but injuries usually 
are superficial and low-risk. 
Mortality/Morbidity
the primary concern with human bites of the hand is infection, which can be severe because of spread 
along tendon sheaths and deep into the hand. Surgical incision and drainage may be needed. Resultant 
scarring and tissue damage may compromise normal function of the hand. 
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infection is also the major complication of bites in other areas of the body. Most can be treated 
adequately; however, infections of poorly vascularized structures, such as ear cartilage, may be difficult 
to treat. 
other serious infectious complications such as deep soft tissue infection, septic arthritis, osteomyelitis, 
infectious tenosynovitis, bacteraemia, necrotizing fasciitis, and osteomyelitis of the skull vault have 
been associated with human bites. 
Risk assessment following a human bite17, 18
History
· Circumstances of the injury
· time of injury (after three hours, the bacterial count in a wound increases dramatically)
· Past medical history, including immunocompromised state
· tetanus immunisation status
· Routine or recent medications (especially steroids, anticoagulants)
Examination
· Vital signs: temperature, blood-pressure and heart rate.
· Dimensions of wound, including depth 
· Assess for signs of infection, drainage or tissue loss
· Assess for vascular, neurological or tendon injury
· Photographic documentation (patient’s consent is required)
Special tests – to be considered
· labs: wound swab, blood culture and sensitivities, complete blood cell count with differential, 
HiV, HBV, HCV serological status.
· Cultures for both aerobic and anaerobic bacteria are recommended if the wound shows clinical 
evidence of infection.
· Radiographic: for wounds near a joint or bone - to evaluate for foreign bodies (e.g. tooth 
fragments).
Treatment of human bite wounds
Wound management plays a key role in prevention of infection. the surface should be cleaned and 
lacerations should be irrigated with sterile saline using pressure irrigation.19 Devitalized tissue should 
be debrided. the management of puncture wounds is more controversial. High pressure irrigation into 
a puncture wound should be avoided. 
Clinical findings which indicate infection of bite wounds include erythema, swelling, tenderness, 
purulent drainage, lymphangitis and fever. Wounds which are infected at presentation should 
be swabbed and cultured, and blood cultures should also be taken. infectious diseases/clinical 
microbiology advice should be sought regarding appropriate antimicrobial treatment, and surgical 
opinion should be sought regarding debridement and other surgical interventions. inpatient treatment 
with intravenous antibiotics and surgical input is often required. 
the use of prophylactic antibiotics after human bites to the hand has been shown to reduce the risk of 
infection.20 Prophylactic antibiotics should be given for human bites if any of the following are present: 
•  bite to hand (clenched fist injuries are particularly high-risk), foot, face or ear; 
•  bite through dermis or puncture wound; 
•  moderate-severe wound with crush injury; 
•  wound near bone or joint; 
•  wounds requiring closure; 
•  wounds in areas of impaired venous/lymphatic drainage including post-mastectomy; 
•  immunocompromised hosts (including patients with transplants, HIV, post-splenectomy, cirrhosis or 
diabetes mellitus). 
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 the recommended regimen for prophylaxis of infection is co-amoxiclav 625 mg tds for 3 to 5 days, with 
alternatives for penicillin allergic patients including doxycycline 100 mg bd plus metronidazole 400 mg 
po tds, or ciprofloxacin 500 to 750 mg bd plus metronidazole.19
HBV vaccination should be advised for all unvaccinated recipients of a human bite wound. HBiG may 
also be indicated, depending on the risk assessment, but generally only if the source is HBV positive (see 
appendix 8).
HiV PEP would almost never be indicated following a human bite except in extreme circumstances.
tetanus prophylaxis may be indicated (see appendix 15).
outpatient follow-up of patients with human bites is advised to monitor for any evidence of development 
of infection. 
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CoMMunIty aCquIred needlestICk 
InJurIes
Community acquired needlestick injuries (CANSis) have not been well described, and the evidence base 
on which to recommend management strategies is poor.1 CANSis cover a wide spectrum from criminal 
assault with blood filled syringes to children playing with discarded syringes in public parks.1 
Although community needlestick injuries are a common source of anxiety for the public and for the health 
care providers who treat them, transmission of BBVs in a non-clinical setting is exceedingly rare.2 CANSi 
due to deliberate assault with a blood filled syringe represents a higher risk than average.1 
in contrast to the situation with needlestick injuries in health care workers, the source of blood 
in discarded needles is usually unknown, injury does not occur immediately after needle use, the 
needle rarely contains fresh blood, any virus present has been exposed to drying and environmental 
temperatures, and injuries are usually superficial.3 
the risk of BBV transmission through a needlestick injury from a discarded needle/syringe is likely to 
depend on several factors. these factors include the prevalence of BBVs among PWiD in the particular 
setting, the type of injury sustained, the viability of the particular virus outside the body, how recently the 
needle/syringe has been used, the level of immunity (in the case of HBV) and the availability and use of 
PEP (in the case of HBV and HiV).4 
Reported cases of BBV transmission following a CANSI
there are currently few reported incidents of BBV infections thought to be secondary to a CANSi. A 
case of presumed acute HBV infection was reported in a 4 year old boy in Spain who did not receive 
post-exposure HBV vaccine or HBiG.5 in 2011, a case of acute HBV infection occurring 2 months after a 
CANSi was reported from Australia. the patient had a history of incomplete vaccination and HBV vaccine 
booster was delayed. He did not receive HBiG.2 three cases of HCV seroconversion in adults following 
needlestick injuries in the community have been reported.6, 7 No HiV infections have been reported after a 
CANSi.8
Case series
in a study in an emergency medicine department in Sydney, 124 cases of CANSi were identified over a 
6 year period, of which 120 were described. the median age was 26 years. there was a marked male 
predominance. injuries were work-related in 36% of cases, predominantly police officers and cleaners. 
68% of cases were as a result of exposure to discarded syringes. the source of the blood in the syringe 
was identifiable in only 12% cases. 54% of patients received HBV PEP and 8% received HiV PEP. At 6 
months post-injury there were no HBV, HCV or HiV seroconversions in the 10 patients for whom there was 
follow-up serology.1 
A large study in Montreal of 274 paediatric patients presenting with CANSi between 1988 and 2006 
found no seroconversions.8 of patients who were not known to be immune to HBV, 82.2% received HBiG 
and 92.6% received HBV vaccine. HiV chemoprophylaxis was given to 39% of patients who presented 
after 1997. the most common site of injury was the hand. Most of the injuries were superficial and blood 
was rarely visible on the needle or syringe.8
Several other studies reported the outcome of CANSis in children presenting to emergency departments 
in Edinburgh, Dublin, Melbourne and Birmingham. No cases of seroconversion for BBVs were detected. 
However, compliance with follow-up was generally poor.9, 10, 11, 12
A review of the literature up until September 2007 by the Canadian Paediatric Society yielded 12 case 
series from areas of high prevalence of bloodborne viruses. these involved a total of 483 children with 
follow-up for HiV, 452 for HBV and 265 for HCV. there were no infections. the majority of children 
received HBV prophylaxis, if it was indicated. 130 children received antiretroviral prophylaxis.3  
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Viability of BBVs in the environment
CANSis are likely to carry a considerably smaller risk of BBV transmission than injuries in the 
occupational setting as needles found in the community have been exposed to environmental 
temperatures and drying for an indeterminate period of time .8
Environmental HBV transmission is well documented and relates to its high concentration in blood and 
its ability to maintain infectivity on environmental surfaces.4 HBV has been demonstrated to survive 
in dried blood at room temperature on environmental surfaces for at least 1 week.1 HBV has been 
detected in discarded needles.3 
HCV is thought to be a fragile virus which would be unlikely to survive in the environment, but there 
are little data at this time.3 Support for the potential for environmental HCV transmission comes from 
studies that demonstrate high levels of HCV transmission in health care settings – particularly renal 
dialysis units and wards with immunocompromised patients.4
HiV is a relatively fragile virus and is susceptible to drying. However, survival of HiV for up to 42 days 
in syringes inoculated with the virus has been demonstrated, with duration of survival dependent 
on ambient temperature. one study found no traces of HiV proviral DNA in syringes discarded by 
intravenous drug users, while another study found HiV DNA in visibly contaminated needles and 
syringes from shooting galleries.3  However, the presence of viral DNA is not a direct demonstration of 
viable virus.
Risk of BBV transmission
the risk of transmission of BBVs following CANSis is difficult to estimate. HBV represents the highest 
risk. the likelihood of transmission of HCV or HiV is very remote. 
the risk of BBV transmission following needlestick injuries in the occupational setting has been 
estimated and may be of value in estimating the risk in CANSis:
the risk of acquiring HBV from an occupational needlestick injury when the source is hepatitis B 
surface antigen (HBsAg) positive ranges from 2% to 40%, depending on the source’s level of viremia.3 
the average incidence of anti-HCV seroconversion after accidental percutaneous exposure from a HCV 
positive source is 1.8%.1
the risk of acquisition of HiV from a hollow-bore needle with blood from a known HiV seropositive 
source is between 0.2% and 0.5%, based on prospective studies of occupational needlestick injuries. 
the risk is increased with higher viral inoculum, which is related to the amount of blood introduced 
and the concentration of virus in that blood. the size of the needle, the depth of penetration and 
whether blood was injected are also important considerations. in most reported instances involving 
transmission of HiV, the needlestick injury occurred within seconds or minutes after the needle was 
withdrawn from the source patient.3
Management of CANSI (see appendix 3, algorithm for needlestick exposure)
Risk assessment
Although the actual risk of infection from such an injury is very low, the perception of risk by patients 
results in much anxiety. Evaluation and counselling are needed. 
individualised risk assessment is essential for every case of CANSi as the source is rarely identified. 
However, if the source can be identified, then all attempts should be made to assess their risk factors 
and to test them for BBVs (see section 3.3 investigation of source). 
Post-exposure prophylaxis
hBV:  HBV vaccine with an accelerated schedule should be offered to non- and partially-immune 
recipients. HBiG may occasionally be indicated (see HBV PEP appendix 8).
hCV:  there is no effective post-exposure prophylaxis for HCV. However, treatment of early infection 
has been shown to be effective. Baseline and follow-up testing at 6 weeks and 3 months for HCV 
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would therefore enable early therapeutic intervention following HCV transmission4 (see 
appendix 14 treatment of acute hepatitis C).
hIV: HiV PEP remains an unresolved issue. No studies have directly measured the effectiveness 
of PEP in decreasing the risk of HiV transmission in non-occupational settings .12 the risk of HiV 
transmission, and risks and benefits of antiretroviral prophylaxis should be assessed on a case-
by-case basis, and guided by expert opinion.1  Antiretroviral prophylaxis should be recommended 
only in cases of high-risk.3, 8, 12 (See appendix 7, HiV PEP)
the factors associated with increased risk are:
•  the source is considered likely to have HIV
•  the injury was deep, penetrating
•  the needle was large-bore, hollow lumen
•  the incident involved a needle with visible blood (particularly fresh blood)
•  blood may have been injected. 
BBV testing and follow-up
Follow-up after any significant needlestick injury is essential. the clinician dealing with the 
initial incident should ensure that the patient understands the importance of follow-up, and that 
appropriate arrangements are made. Patients sometimes assume that if blood tests that are 
performed at the time of injury are negative, then there is no possibility of infection and no need 
for further testing.3 if a significant exposure has occurred, testing the recipient for BBVs should 
be carried out at baseline, 6 weeks and 3 months (see appendix 9 testing of recipient). 
Testing of needles and syringes
testing needles and syringes for viruses is not indicated. Results are likely to be negative, but a 
negative result does not rule out the possibility of infection.3
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eMI Guidelines - Appendix 20  On-site assessment form (Dental/Primary care) (reviewed May 2016)
injury in Dental Practice or Primary Care Medical Practice
Form to be given to the recipient’s treating doctor
on-site assessment form for incidents such as needlesticks and human bites where there is a risk of bloodborne virus (BBV) transmission
Reporting time: Reporting date:
Dentist name: Dentist signature:
Responsible person: Contact phone number:
  After hours number:
SOURCE DETAILS
Is the source known?  Yes   No  
Has the source been informed of incident?  Yes   No  
Has the source consented to medical history 
being passed on?    Yes   No  
Has the source consented to testing?  Yes   No  
If consent given, is there a relevant med history?  Yes   No  
if yes - details?  Yes   No  
RECIPIENT DETAILS
Name
Address
Gender  M    F  
Date of birth
telephone number
Mobile
occupation
Work address
  GP name and address and telephone number
ASSESSMENT OF ExPOSURE RISK
 Brief description of injury including date, time and place of injury
 
Nature of material e.g. blood, saliva
if Not blood, was fluid blood stained  Yes   No  
HEALTHCARE ExPOSURES
Area where exposure occured
Was this an ‘exposure prone procedure’?  Yes   No  
Were gloves worn at the time of the injury?  Yes   No  
instrument (if any) which caused the injury
What was the instrument originally intended for?
Did the instrument have a safety mechanism? Yes   No 
Was the safety mechanism activated ?   Yes   No 
Nature of injury
Needlestick  
 Hollow bore needle    Solid Needle 
 Visible blood present 
 Device had been directly in source artery or vein 
other sharps  
Describe
Severity of needlestick or sharp injury
 Superficial - surface scratch, no blood appeared 
 Moderate - penetrated skin and blood appeared 
 Deep - puncture, with or without blood appearance 
Human bite    Skin breached    
Splash 
 intact skin    Non-intact skin 
 Mucous membrane    Eye 
Medical History (incl. immunosuppression)
Specify if recipient known to be positive for HBV, HCV or HiV
Medications
Allergies
if female Pregnant   Breastfeeding  
Hepatitis B Vaccination
1 dose 2 doses Full course Year
Antibody result if known
Tetanus
Date of last vaccination Number of doses
Signed:  _______________________________________________________
Responsible Person
if consent to testing given:
Source first name:  ________________________________________________
Source mobile phone no.: _________________________________________
  
other injury  
Describe
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hepatitis B virus: epidemiology and transmission 
risks
Hepatitis B virus (HBV) infection is a serious and common infectious disease of the liver, affecting millions of people 
throughout the world. the incubation period for HBV is 45-180 days, most commonly 60-90 days.1
Clinical information
Acute infection is clinically recognised in only a small proportion of cases; less that 10% of children and 30-50% of 
adults show icteric disease. in those with clinical illness, the onset is usually insidious, with anorexia, vague abdominal 
discomfort, nausea and vomiting, sometimes arthralgia and rash, often progressing to jaundice. Following acute HBV 
infection, the risk of developing chronic infection varies inversely with age. Chronic HBV infection occurs among about 
90% of infants infected at birth, 25-50% of children infected at 1-5 years of age and about 1-10% of persons infected 
as older children and adults. An estimated 15-25% of persons with chronic HBV infection will die prematurely of either 
cirrhosis or hepatocellular carcinoma.1
Vaccination
HBV can be effectively prevented by vaccination. A safe and effective vaccine has been available since the 1980s. the 
complete vaccine series induces protective antibody levels in more than 95% of infants, children and young adults. 
After age 40, protection following the primary vaccination series drops below 90%. Protection lasts at least 20 years 
and should be lifelong.2 Since 2008, hepatitis B vaccine has been included in the childhood immunisation programme 
in ireland, alongside the targeted immunisation programme for those individuals who are at increased risk of HBV 
because of their occupation, lifestyle or other factors. these include healthcare workers (HCW), prison and security 
personnel, contacts of cases, people who inject drugs, people with certain medical conditions, clients in learning 
disability centres, people with multiple sexual partners, men who have sex with men, prisoners, and travellers to and 
immigrants from HBV endemic areas.3
Transmission
HBV has been found in virtually all body secretions and excretions. However, only blood, body fluids containing visible 
blood, semen and vaginal secretions represent a risk of transmission.4 HBV is transmitted by percutaneous and mucosal 
exposure to infective blood or body fluids. Major modes of HBV transmission include sexual or close household contact 
with an infected person, perinatal mother to infant transmission, injecting drug use and nosocomial exposure.1
Percutaneous exposures that have resulted in HBV transmission include transfusion of unscreened blood or blood 
products, sharing unsterilised injection needles for iV drug use, haemodialysis, acupuncture, tattooing and injuries from 
contaminated sharp instruments sustained by hospital personnel.5
HBV is stable on environmental surfaces for at least 7 days and is 100 times more infectious than HiV. 
Serological markers for HBV
HBsAg: Hepatitis B surface antigen is a marker of infectivity. its presence indicates either acute or chronic infection.
HBeAg: Hepatitis B e antigen is a marker of a high degree of infectivity and correlates with a high level of HBV 
replication.
Anti-HBs: Antibody to hepatitis B surface antigen is a marker of immunity, either an immune response to HBV infection 
or to vaccination.
Anti-HBc: Antibody to hepatitis B core antigen is a marker of HBV infection.
Prevalence of HBV infection in Ireland, Europe and the world
Ireland
the prevalence of HBV in the general population in ireland is low. However, HBV is more prevalent in certain sub-groups 
of the population.6 the prevalence of HBV is higher in injecting drug users, people born in countries of intermediate (2-
7%) or high (>8%) hepatitis B endemicity, MSM, people with multiple sexual partners, household or sexual contracts of 
known cases.7
the prevalence of HBV infection is generally lowest in the blood donor population, followed by the general population, 
then pregnant women, then high-risk groups. to determine the risk of HBV in migrant populations, it is necessary to 
look at data on their country of origin.
the World Health organization has classified ireland as a country of low prevalence for HBV, i.e. prevalence of HBsAg 
<2%.6 the European Centre for Disease Prevention and Control (ECDC) carried out a literature review in 2010 of 
publications dated 2000-2009 on the prevalence of viral hepatitis in Europe.8 it reported that the HBsAg prevalence 
in the general population in ireland is estimated to be 0.1%. ireland and the Netherlands have the lowest prevalence 
of HBV infection in Europe. it also reported that the HBsAg prevalence rates in blood donors and pregnant women in 
ireland are among the lowest rates in Europe. 
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Low risk populations in Ireland
General population
A European HBV seroprevalence study using residual sera showed a low prevalence in irish samples collected in 
2003 (anti-HBc 1.7%, HBsAg 0.1%).9 A national study of oral fluid samples collected by postal survey in 1998-1999 
estimated anti-HBc prevalence in ireland to be 0.51%.10
Blood donors
of 313,019 first time blood donors tested by the iBtS between 1997 and 2015, 34 (0.011%) were found to be HBsAg
positive. (Personal communication, Dr Joan o’Riordan, iBtS, July 2016).
Pregnant women
Routine antenatal testing for HBsAg was introduced in the Rotunda Hospital in 1998. Uptake was almost 100% and 
>16,000 pregnancies were screened between January 1998 and June 2000. this showed a HBsAg prevalence of 4.2% 
in non-EU women and 0.03% in irish women tested.11 Screening of >24,000 pregnant women in the West of ireland 
in 2004-2009 demonstrated a prevalence of HBsAg of 0.21%, and all positive women were thought to be of non-irish 
origin.12
High risk populations in Ireland
Prisoners
A national cross sectional survey of irish prisoners in 1998 showed a prevalence of anti-HBc of 8.7% total, and of 
18.5% in prisoners who were people who inject drugs.13
People who inject drugs
A cross-sectional study of 316 opiate users attending 21 addiction treatment centres in the HSE East was carried out 
between Dec 2001 and Jan 2002. the prevalence of HBsAg was 2% and of anti-HBc was 17%.14
Homeless people
Homeless people also have evidence of increased exposure to HBV, with a prevalence of anti-HBc of 9% in a study 
performed in Dublin in 1999-2000.3
Asylum seekers
Screening of asylum seekers in the HSE eastern region 1999-2003 found a prevalence of HBsAg of 5% .15
Trends in hepatitis B infection in Ireland
Hepatitis B is a notifiable disease in ireland. there was a dramatic increase in annual HBV notifications between 1997 
(31 cases) and 2008 (919 cases), mostly attributable to large numbers of people immigrating to ireland from HBV 
endemic countries. Between 2000 and 2010, 95% of asylum applicants, and 73% of new work permit recipients, 
were from countries with intermediate or high HBV endemicity. the number of hepatitis B cases reported in ireland 
increased by 5% in 2014 with 445 cases (9.7/100,000) compared with 425 cases in 2013. However, there has been 
a general downward trend in the number of reported cases since peak levels in 2008 (n=901).7 the trend (a decline 
since the peak in 2008 with an increase in 2014) correspond to immigration trends in ireland during the same 
period.16 
Between 2010 and 2014, 8% of reported cases of hepatitis B were acute and 92% were chronic. the majority of acute 
cases of hepatitis B were sexually acquired. Where reported, the risk factors for chronic infection included, born in an 
endemic country (69%), sexually acquired (13%) and vertical transmission (5%).16
Hepatitis B infection in Europe
Although there is a decreasing trend in HBV, each year there are between 7,000 and 8,000 newly diagnosed cases of 
HBV in the EU/EEA region.17 there has been a steady downward trend in the reported rates of acute cases in Europe 
that is likely related to the impact of vaccination campaigns.18 99% of countries have integrated HBV into routine 
immunisation (2014).19 the total percentage of people infected with HBV varies between different countries, with 
higher rates in the southern part of Europe. the country with the highest prevalence (>4%) is Romania followed by 
medium prevalence countries (>1-2%), Spain, (parts of) italy, and Greece. Countries with a low prevalence (<1%) 
include Belgium, the Czech Republic, Finland, Germany, ireland, Netherlands, Slovakia and Sweden.17
the most severely affected population groups are people who inject drugs, sex workers, men who have sex with men, 
people living with HiV, inmates, and immigrants from high-endemic regions. in some countries, sexual transmission is 
more common than transmission through household contacts or injecting drug use.17
in 2013, 19,101 cases of hepatitis B infections were reported in 28 EU/EEA member states, a crude rate of 4.4 / 
100,000 population.18  
Maps of HBV prevalence in different population groups by country in Europe are available in the ECDC technical Report .8
Global distribution
the global prevalence of chronic HBV infection (based on % of population HBsAg positive) is as follows20: 
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High prevalence (≥8%): sub-Saharan Africa, South-East Asia, the Eastern Mediterranean countries, south and 
western Pacific islands, the interior of the Amazon basin and certain parts of the Caribbean. 
Moderate prevalence (2–7%): in south-central and south-west Asia, eastern and southern Europe, the Russian 
Federation and most of central and South America. 
low prevalence (<2%): Australia, New Zealand, northern and western Europe, and North America. 
Transmission risks
the hepatitis B virus can survive outside the body for at least 7 days.21 Several factors influence the risk of 
transmission of HBV infection, including the viral load of the source. 
in a healthcare occupational context, the level that is regarded as “high” for a viral load differs in various regions. in 
America and ireland, HCWs who are infected with HBV but have a circulating viral burden <104 genome equivalents/
ml are allowed to continue working unrestricted.22,23 transmission of HBV via a percutaneous route is considered 
unlikely at HBV DNA levels below 107genome equivalents/ml.24
Needlestick injuries
those who are e antigen positive generally have higher viral loads, and the transmission rate of HBV following a 
needlestick injury from a source who is e antigen positive is estimated to be between 30% and 62%.4, 22 the same 
injury with exposure to blood from a source who is e antigen negative is associated with 6-37% risk of serological 
evidence of HBV infection in the recipient.4, 22 Some patients are infected with pre-core mutant viruses. this is 
associated with a high viral load in the absence of the e antigen, and thus is also associated with a high risk of HBV 
transmission.22
the risk from needlestick injuries in the community is more difficult to estimate and the exact incidence of needlestick 
injuries and the transmission rate is unknown. the limited published case reports25, 26 would indicate that there is a 
very low risk of HBV transmission associated with community acquired needlestick injuries.
Other healthcare setting exposures
Spring loaded lancets have been implicated in the transmission of HBV to patients27, as have reusable sub-dermal 
EEG electrodes.28 there is a report of transmission of HBV to a patient during an endoscopic procedure, although no 
biopsies were taken, but bleeding gastric ulceration was identified. the presumed source was HBeAg positive .29
Cleveland et al report that HBV infection prevalence in dentists increases with longer duration in practice.30Although 
rates in a reference control population were not included in this report, increasing prevalence with longer duration of 
practice indicates that there is potential for transmission to dentists during their work.
Other percutaneous exposures
there are case reports documenting the transmission of HBV among butchers.31, 32 these are attributed to small hand 
cuts, and sharing knives, which can carry the virus on the handle. it is also thought that HBV can be transmitted via 
small cuts acquired in barber shops.33
Body fluid exposures
HBV DNA has been detected in body fluids apart from blood, including saliva, urine, nasopharyngeal fluid, semen, 
cervicovaginal fluids and tears.34-37. HBV transmission can occur following exposure to non-intact skin and mucous 
membranes. A case report describes transmission of HBV via broken skin, following contact with saliva and 
nasopharyngeal fluids from the source.38
Human bites
Case reports have documented HBV virus transmission via a human bite, when associated with the skin being broken.39, 
40
Sexual exposures
HBsAg has been found in seminal fluid and vaginal secretions, although concentrations in these fluids are lower 
than in blood.41 the risk of transmission of HBV following sexual exposure depends on the type of exposure, the viral 
load of the source, and the presence of sexually transmitted infections.42 the prevalence of HBV in heterosexuals 
is increased in those with multiple sexual partners42-44, and those who have markers for HiV or syphilis.45 An 
infection rate of 18-44.2% is seen in regular heterosexual partners of HBV infected patients 46-48 in addition, female 
commercial sex workers with a history of having anal intercourse had an increased risk of HBV infection.45
the risk of developing HBV infection is particularly high among men who have sex with men.41, 49 For men who have 
sex with men, the prevalence of HBV infection is increased in those who have a history of an ulcerative sexually 
transmitted infection, chlamydia, gonorrhoea, commercial sex work, or multiple partners.50 there is also a significant 
risk associated with unprotected insertive anal intercourse.51
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6) Hepatitis B transmission risk by exposure type
Exposure Risk per exposure (unless otherwise stated)
Needlestick Healthcare setting, patient known HBeAg (+) = 37-62% risk of serologic evidence of infection in recipient
HBeAg (-) = 23-37% risk of serologic evidence of infection, 1-6% clinical infection4
Healthcare setting, patient unknown, or 
patient known but serology unknown
Requires risk assessment
Community setting 2 case reports only.25, 26 Risk very low. Requires risk assessment. For example, if the local PWiD population has a 
seroprevalence of 50%, the risk from a community acquired needlestick is 12-31%.52 (Note: seroprevalence in PWiD in 
ireland is lower than 50% - see epidemiology section).
other percutaneous 
injuries with blood 
exposure
Healthcare sharp (e.g. lancet) Risk per exposure unknown. 36.8%53 -42%27 developed HBV after repeat exposures. 
Exposure prone procedure by infected 
healthcare worker
transmission rates vary between 6 and 15%54 - most were before standard precautions introduced
transfusion 52-69% transmission if transfused with HBsAg (+) blood55
Human bites Risk negligible in the absence of visible blood. Case reports only. Requires risk assessment. 
Percutaneous exposure to other body fluids (e.g. saliva) Very low risk. Case reports - HBeAg (+) source.38 Requires risk assessment. 
Sexual exposures Heterosexual exposures in general 18%46 – 40%47 - 44.2%48 infection rate seen in regular partners of HBV infected people
increased risk if: multiple partners42, 44, syphilis44, 45, 56, gonorrhoea56, receptive anal intercourse45
Men who have sex with men increased risk of HBV transmission associated with ulcerative Sti, gonorrhoea/chlamydia, sexual partner with HiV/AiDS, 
multiple sexual partners, commercial sex work50, history of insertive anal intercourse51
Receptive oral sex (fellatio) Possible means of transmission57
Risk assessment
• Type/details of injury – as above
• Source status – increased risk with HBeAg, high viral load
• Recipient status – increased risk if immunocompromised 
• For unknown source, consider where injury occurred – community setting versus hospital setting
  if in hospital – consider high-risk ward/patients  
  if in community – consider prevalence of HBV and of PWiD locally
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Prevalence of hepatitis B worldwide
¹ Disease data source: Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and 
endemicity. Vaccine. 2012; 30(12): 2212-2219.
MAP 334. PREVALENCE OF CHRONIC HEPATITIS B VIRUS INFECTION AMONG ADULTS¹
Source: ott JJ, Stevens GA, Groeger J, Wiersma St. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg 
seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-2219.
Prevalence of hepatitis B surface antigen in people who inject drugs 
worldwide 
Source: Reprinted from lancet 2011;378(9791), Nelson Pk, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in 
people who inject drugs: results of systematic reviews, pages 571-83, Copyright (2011), with permission from Elsevier.
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hepatitis C virus: epidemiology and transmission 
risks
Hepatitis C infection is caused by an RNA virus that was first identified in 1989.1 Chronic hepatitis C infection is a major 
cause of chronic liver disease and death throughout the world.2 Approximately 3% of the world’s population is infected 
with hepatitis C virus (HCV).3 Six distinct but related genotypes and multiple subtypes have been identified.1, 4 in 
western Europe genotypes 1a and 1b are most common, followed by genotypes 3 and 2.5
Transmission
HCV is transmitted by blood and now occurs primarily through injecting drug use, and less frequently through sex with 
an infected partner, occupational exposure, and maternal-foetal transmission. in some cases no risk factors can be 
identified.1, 5 transfusion-related HCV infection is rare now since the introduction of routine screening of blood for HCV 
antibodies in the early 1990s.6
Clinical information
in general, acute HCV infection is relatively mild, with only 20-30% of infected persons developing symptoms or 
clinically evident acute infection. in most persons who become infected with HCV, viraemia persists. Antibody to HCV 
(anti-HCV) is present in acute, chronic and resolved infection. HCV RNA/HCV Ag is an indication of HCV viraemia.
Chronic HCV infection is marked by persistence of HCV RNA for at least 6 months after onset of infection. Spontaneous 
resolution after 6 or 12 months of infection is unusual. Between 55 and 85% of those infected develop chronic 
infection.6 Chronically infected people are at risk for progressive liver disease characterised by hepatocellular 
inflammation, hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC). these complications develop only in 
a proportion of patients and only after many years or decades of infection. it has been estimated that up to 20% of 
chronically infected individuals will develop cirrhosis of the liver over a 20 to 25 year period, and that, of patients with 
cirrhosis, approximately 3% to 4% will develop HCC per year. Factors that have been shown to be associated with 
progression of liver fibrosis include older age at infection, male gender, genetic factors, metabolic factors (steatosis, 
diabetes and obesity), co-infection with human immunodeficiency virus (HiV) or hepatitis B, duration of infection, and 
alcohol intake.6
Highly effective all-oral treatment with direct-acting antivirals is now available in ireland. this eradicates the virus in 
over 90% of cases.7
Prevalence of HCV infection in Ireland, Europe and the world
Ireland
A previous study has estimated that the prevalence of chronic HCV infection in ireland is 0.5-1.2% 8. this study took 
undiagnosed cases into account. More recent estimates of levels of undiagnosed hepatitis C in ireland indicate the 
overall prevalence of hepatitis C in ireland is more likely to be between 0.5 and 0.7% (23,000 to 32,000).9 this is 
similar to other countries in northern Europe and in line with the WHo estimate of <1%. However, it is more prevalent 
in certain sub-groups of the population, in particular people who inject drugs (PWiD) and prisoners. HCV may also be 
more prevalent in immigrants to ireland from endemic countries.
Blood donors
of 313,019 first time blood donors tested by the iBtS between 1997 and 2015, 48 (0.015%) were found to be HCV
positive. (Personal communication, Dr Joan o’Riordan, iBtS, July 2016).
Asylum seekers
Screening of asylum seekers in the HSE eastern region 1999-2003 found a prevalence of anti-HCV of 1.5%.10
A reception centre in HSE East, reported that 1% of those tested under the voluntary health screening programme, 
between 2004 and 2012, were positive for chronic HCV infection.11
Prisoners and people who inject drugs
Studies of PWiD in prisons and PWiD attending methadone clinics, specialist addiction treatment centres and GPs 
have estimated the HCV prevalence in this population to be between 62% and 81%.12
A national cross sectional survey of irish prisoners in 1998 showed a prevalence of anti-HCV of 37% of all prisoners, 
and of 81.3% in prisoners who were prisoners who inject drugs.13
More recently, a 2011 prison study found that 54% of prisoners with a history of injecting heroin were anti-HCV positive 
and 41.5% of prisoners with a history of injecting any drugs were anti-HCV positive.14
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Trends in HCV in Ireland
Hepatitis C became a notifiable disease in ireland in 2004. Between 2004 and 2015, 13,478 cases were notified. the 
highest annual number of notifications was in 2007 (n=1539). there has been a significant decrease in recent years and 
678 cases were notified in 2015. two thirds of cases were male and most were young to middle aged adults (median age: 
34 years, mean age: 36.1 years). Where risk factor information was available, over 80% of cases between 2007 and 2015, 
were among people who inject drugs.9
HCV in Europe
in Europe, HCV infection shows a significant increasing trend in reported numbers. Every year there are 27,000 to 29,000 
newly diagnosed cases in the EU/EEA.15
A recent systematic literature review of HCV prevalence in Europe, based on information from 14 countries, reported a 
prevalence range of 0.4-3.5%.16 the prevalence is higher in the southern part of Europe. Countries with high prevalence 
(more than 2%) include italy, Romania and Spain. Medium prevalence was observed in Bulgaria, France, Greece, and 
Poland. Countries with low prevalence (less than 1%) include Belgium, Germany, the Netherlands, Sweden, and the United 
kingdom.15
the most severely affected population groups are people who inject drugs, haemodialysis patients, persons living with 
HiV, inmates, and immigrants from high-endemic regions. Reported numbers are likely to reflect the current testing and 
screening practices in countries rather than the real incidence of infection. the reported number is an underestimate of the 
real occurrence of HCV due to the asymptomatic nature of the infection.15
Maps of HCV prevalence in different population groups by country in Europe are available in the ECDC technical Report.16
Global HCV distribution
the estimated global prevalence of HCV is 2-3% .17, 18 Countries with the highest reported prevalence rates are located in 
Africa and Asia. China has a reported seroprevalence of 3.2%. one community-based survey in india reported an overall 
rate of 0.9%. indonesia’s rate is 2.1% in serosurveys of voluntary blood donors. the seroprevalence in Pakistan is reported 
to range from 2.4% to 6.5%. Egypt has the highest reported seroprevalence rate, 22%.17 Areas of lower prevalence include 
North America, northern and western Europe, and Australia.
the predominant source of new HCV infections in developed countries over the past few decades is injecting drug use. in 
developing countries, unsafe therapeutic injections and transfusions are likely to be the major modes of transmission.17 
Anti-HCV prevalence in PWiD globally varies greatly, from 9.8% to 97.4%.19 (See map, appendix 24).
Transmission risks
Needlestick injuries
there is a wide range of reported estimates for the risk of transmission of HCV after a needlestick or sharps injury from a 
source patient – between 0 and 10%.20-22 the estimated risk from a needlestick injury from a source with detectable HCV 
RNA is 6.1%.23 the risk of developing HCV is greater after an injury with a hollow-bore needle21, or deep injuries24, compared 
with other injuries. Also, one study showed an 11-fold increase in transmission of HCV from source patients with viral load 
>6 log10 copies/ml, compared with source patients with viral load ≤4 log10 copies/ml following percutaneous exposure.24 
the risk of transmission is also influenced by whether the source is co-infected with HiV (see section below).
in cold temperatures, HCV can survive in syringes for many days in laboratory studies.25 the clinical implications of this are 
unknown, but the risk of becoming infected with HCV from an abandoned syringe depends on the prevalence of HCV in 
the local community. there are case reports of HCV transmission from needlestick injuries in the community26, but as the 
exact incidence of injuries in the community is not known, the risk of transmission from such injuries cannot be accurately 
quantified.
Other percutaneous exposures
the risk of acquiring HCV during an operation performed by an infected surgeon is reported to be between 0 and 3.7%. 
27,28,29 in general the risk of contracting HCV following an injury from an unknown source is negligible.30
Sharps in the workplace, other than in the healthcare setting, such as razors and meat slicers have also been implicated in 
the transmission of HCV.31, 32
there is an increased incidence of HCV in those who have a tattoo, with a pooled odds ratio of 2.73 (95% Ci 2.38-3.15). 
large tattoos, and those received in non-professional locations are associated with the greatest risk.33
Splashes/mucocutaneous exposures
Several case reports have been published describing the transmission of HCV following a splash of blood into the eye of the 
recipient.34,35 Also, transmission of HCV has occurred following splashes of infected blood onto broken skin.36 the exact risk 
associated with these exposures is unknown.
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Exposure to saliva (including injuries caused by human bites)
HCV RNA has been demonstrated in saliva.37, 38 Case reports describe transmission of HCV following human bites, but 
precise details of the nature of the bites, and whether blood was present in the mouth of the biter, or whether skin 
was broken at the time of the bite, are not known.39 inoculation with saliva has caused transmission of the virus in 
experimental studies.40, 41
Studies in dentists indicate a low incidence of nosocomial transmission of HCV.42 it is also thought, however, that HCV 
can be transmitted via sharing a toothbrush with an index case.38, 43
Sexual exposures
in general, transmission of HCV via sexual contact is inefficient in stable monogamous heterosexual couples.44 
there is evidence, however, of a low rate of transmission of HCV between discordant heterosexual couples and a 
prevalence of 2-6% of anti-HCV in the non-index partner.44-46 Higher prevalence of anti-HCV has been observed in 
those with multiple sexual partners, in the absence of other risks, such as PWiD or recipients of blood products, as 
further evidence of the plausibility of sexual transmission.47, 48 if a risk is present, it is likely to be very low, and a rate of 
transmission per heterosexual exposure has not been calculated.
Recent outbreaks of acute HCV among HiV-positive MSM who deny PWiD suggest that the epidemiology of HCV 
transmission is changing in this population. in several European countries as well as in the United States and 
Australia, HCV has unexpectedly emerged as an Sti among HiV-positive MSM. longitudinal cohort studies have 
confirmed a marked increase in HCV incidence among HiV-positive MSM, but not HiV-negative MSM, after the year 
2000.49 Studies in Australia, Uk, Switzerland and the Netherlands have reported an incidence of HCV infection 
ranging from 0.6 to 0.9/100 person years in HiV positive MSM who were not PWiD.50
Exposure to other body fluids
HCV RNA has been identified in blood, saliva37, bile51, sweat52, semen53, and cervicovaginal secretions.54 the infective 
potential of cervicovaginal secretions is questioned55, but may increase during menstruation.54
Transmission of infection following exposure to a source with HIV and HCV
the risk of developing HCV infection after simultaneous exposure to HiV and HCV is estimated at 2.8%56 (in this study, 
no one developed HiV after simultaneous exposure). 100% of patients who received an injection drawn from a vial 
contaminated with HiV and HCV developed acute HCV infection, but no one developed HiV.57
HiV and HCV transmission from a patient to a healthcare worker occurred after contact with the patient’s emesis, 
faeces and urine, to non-intact skin on the healthcare worker’s hands.58
A case report describes the transmission of HCV, but not HiV, via a human bite to the hand from a source co-infected 
with HiV and HCV.59 Although the recipient had a wound on his hand prior to the bite, it is not known whether there 
was blood in the mouth of the source at the time of the incident. Studies have not shown an increased incidence of 
HCV RNA in saliva of co-infected patients compared to those infected with only HCV.60
the odds ratio of sexual transmission of HCV increased in women co-infected with HiV or another sexually
transmitted infection (adjusted odds ratio 3.3-3.9) or homosexual men co-infected with HiV (adjusted odds
ratio 4.1-5.7).61
there is an increased incidence of HCV-antibodies in patients who had acquired HiV via heterosexual
transmission, than in those who had developed HiV from a different exposure.62
HiV status does not seem to influence the presence of HCV in semen in men co-infected with HCV and HiV.63 HCV RNA 
is detected more frequently in cervicovaginal fluid from women co-infected with HiV, than in those not infected with 
HiV64, especially if HCV viremia is present, or if HiV RNA is also found in the cervicovaginal secretions.
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Hepatitis C transmission risk by exposure type
Exposure Risk per exposure (unless otherwise stated)
Needlestick Healthcare setting, source patient (serology) 
known
0-10%.20-22 Average 1.8%65
increased risk if - hollow needle21, deep injuries 24, co-infection with HiV56, high viral load.24
Healthcare setting, source patient unknown, 
or unable to test source patient (serology 
unknown)
Unknown source – negligible risk.30
Risk assessment required
Community setting Risk not accurately determined.26 Risk assessment required. if local PWiD population has a seroprevalence of 50-90%, the 
estimated risk of HCV transmission in a community needlestick injury is 1.62%.66 
Exposure prone procedure by infected healthcare worker 0-3.7%.27, 28, 29 Risk may increase to 6% for certain procedures, e.g. open heart surgery.28 Risk assessment required. 
Non healthcare related occupational sharp injuries Risk not accurately determined, but transmission possible.31, 32 Risk assessment required. 
tattoos Risk not accurately determined. Pooled odds ratio 2.73 (95% Ci 2.38-3.15)33
Risk assessment required. increased risk if larger tattoos or tattoos in non-professional locations
Mucous membrane exposure to blood Very low risk. Case reports only.34, 35 Risk assessment required
intact skin exposed to blood No recognised risk
Non-intact skin, body fluid exposure Very low risk. Case report describes transmission of HiV and HCV from co-infected source.58 Risk assessment required. 
Human bite injuries Very low risk.39. Case reports only. Risk assessment required. Possible higher risk of transmission of HCV than HiV if the source 
patient is co-infected with HCV and HiV.60
Sexual exposures Heterosexual exposures in general inefficient transmission61, but transmission possible as seen in stable heterosexual relationships44-46, and in those with history of 
multiple sexual partners.47, 48 Possible increased risk of transmission if source co-infected with HiV61
MSM inefficient transmission.67, 68 Co-infection with HiV increases the risk of transmission61, 69-71
Note: in England, between 1997 and 2007, there were only 14 reported cases of HCV transmission from a patient to a healthcare worker, with a transmission rate calculated as 1.6%.72
  
Risk assessment
• Type/details of injury – as above
• Source status – increased risk with high viral load
• Recipient status – increased risk if immunocompromised 
• For unknown source, consider where injury occurred – community setting versus hospital setting
  if in hospital – consider high-risk ward/patients  
  if in community – consider prevalence of HCV and of PWiD locally
•  Consider where the needle was found and the temperature of environment – longer virus survival in cold temperatures thus potential increased risk of transmission.26
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Prevalence of hepatitis C worldwide 
¹ Disease data source:  Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST.  “Global Epidemiology of Hepatitis C Virus Infection; New Estimates of Age-Specific Antibody to HCV and 
Seroprevalence.”  Hepatology 2013; 57:1333-1342.
MAP 335. DISTRIBUTION OF HEPATITIS C VIRUS INFECTION¹Source: Mohd Hanafiah k, Groeger J, Flaxman AD, Wiersma St. “Global Epidemiology of Hepatitis C Virus infection; New Estimates of 
Age-Sp cific Antibody to HCV and
Seroprevalence.” Hepatology 2013; 57:1333-1342.
Prevalence of anti-hepatitis C among people who inject drugs 
worldwide
Source: Reprinted from lancet 2011;378(9791), Nelson Pk, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and 
hepatitis C in people who inject drugs: results of systematic reviews, pages 571-83, Copyright (2011), with permission from Elsevier.
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human immunodeficiency virus: epidemiology 
and transmission risks
General details
the HiV virus was discovered in 1983.1 there are currently two groups of viruses which have been isolated (HiV type 1 
and HiV type 2), collectively known as HiV (human immunodeficiency virus).2 in general, HiV type 2 is not found outside 
western and central Africa. HiV type 1 is identified globally. Following infection, the host’s cells transfer the virus to the 
local immune system, including t-cells, macrophages and dendritic cells. Within 10-12 days of infection, HiV RNA can be 
detected in blood by PCR.
During this acute infection (also referred to as primary HiV infection, or the seroconversion illness), HiV RNA levels peak, 
before declining over subsequent weeks.3 Antibodies to HiV usually develop within 3-5 weeks of becoming infected. the 
time period between becoming infected and developing antibodies is referred to as the serological “window period”.2 
Following seroconversion, there is an asymptomatic phase of variable duration.3, 4 During this time, patients are well. later 
in the course of the infection, HiV RNA levels tend to drop. over the subsequent asymptomatic period, of variable duration, 
CD4+ lymphocyte levels gradually decrease. if levels of CD4+ lymphocytes drop below 200-350 cells/μl, the patient is at 
increased risk of developing opportunistic infections. 
Clinical information
the symptoms of acute HiV infection can last for between 7 and 10 days.2 the patient may complain of symptoms 
resembling the “flu”, or mononucleosis infection.3 typical symptoms include fever, maculopapular rash, oral ulcers, 
lymphadenopathy, arthralgia, pharyngitis, malaise, weight loss and myalgia. once these acute symptoms resolve, most 
patient enter an asymptomatic phase. this asymptomatic phase can last more than 10 years.
When CD4+ lymphocyte levels drop below 200-350 cells/μl, the patient is at increased risk of developing opportunistic 
infections5, including pneumocystis pneumonia, oesophageal candidiasis, cerebral toxoplasmosis, and cytomegalovirus, 
amongst others.6 these infections, along with cancers such as kaposi sarcoma, are referred to as AiDS defining conditions.
treatment for patients with HiV infection is with life-long anti-retroviral drugs. this results in a significant reduction in the 
amount of virus in the blood, usually to undetectable levels, and allows for immune recovery.
Transmission
HiV has been isolated from semen, cervical secretions, lymphocytes, cell-free plasma, cerebrospinal fluid, tears, saliva, 
urine and breast milk.1 this does not mean, however, that these fluids all transmit infection since the concentration of 
virus in them varies considerably. Particularly infectious are semen, blood, and possibly cervical secretions. the risk of 
transmission increases with the burden of HiV (i.e. the HiV viral load) in the inoculum.7 
the commonest mode of transmission of the virus throughout the world is by sexual intercourse. other methods of 
transmission are through receipt of infected blood or blood products, donated organs, and semen. transmission also 
occurs through the sharing or reuse of contaminated needles by people who inject drugs (PWiD) or for therapeutic 
procedures, and from mother to child. the virus is also transmitted through breast milk. Healthcare workers (HCW) can be 
infected through needlestick injuries, and skin and mucosal exposure to infected blood or body fluids. 
Prevalence of HIV infection in Ireland, Europe and the world
Ireland
HiV became a notifiable disease in ireland in September 2011. Case based reporting of HiV cases has been in place since 
2001. in 2014, a total of 377 newly diagnosed cases were reported in ireland, a rate of 8.2/100,000. the highest proportion 
was attributed to MSM exposure (49%), followed by heterosexual transmission (33%), and PWiD (7%).  of the 377 cases, 
36.3% were born in ireland and 53.8% were born abroad.8 
Annual numbers of new diagnoses of HiV in ireland have fluctuated between 300 and 400 over the past decade. in recent 
years there has been a change in the predominant modes of transmission – the annual number of new cases among PWiD 
has decreased each year since 2004, up to 2013; the annual number of cases attributed to heterosexual transmission has 
decreased from a peak in 2003; and the number of cases in MSM continues to rise year on year since 2005.8
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Blood donors
of 313,019 first time blood donors tested by the iBtS between 1997 and 2015, 14 (0.0045%) were found to be HiV 
positive. (Personal communication, Dr Joan o’Riordan, iBtS, July 2016).
Pregnant women 
HiV screening is offered routinely to all pregnant women in ireland under a voluntary antenatal HiV testing 
programme that was introduced in 1999. in 2014, the national reported uptake of HiV antenatal screening (from 17 
hospitals) was 99.9%, the rate was 100% in 16 of the hospitals. the HiV prevalence rate among pregnant women 
in ireland was 0.15% in 2014, slightly higher than the rate in 2013 (0.14%). the prevalence of HiV infection among 
pregnant women varied among HSE areas, ranging from 0.05% in HSE West to 0.23% in HSE Dublin Northeast.9
Prisoners and injecting drug users
in 1997, 17% of a group of PWiD in the HSE eastern region, who were attending methadone clinics, tested positive 
for HiV infection.10 A cross sectional study of 307 opiate users attending 21 addiction treatment centres in the HSE 
eastern region was carried out in 2001. the prevalence of anti-HiV was 11%.11 in 2001, the largest tertiary centre for 
HiV infection in Dublin reported a five-fold increase in new HiV diagnoses in PWiD between 1995 and 2000.12 A study 
carried out among socially excluded drug users in 10 European cities in 1998-2000 found a self-reported HiV positive 
prevalence of 24.6% in Dublin, the second highest of the cities.13
in 2014, 27 new HiV diagnoses (7%) were among people who inject drugs (PWiD), representing a 29% increase in the 
number  of diagnoses in 2013 (21). 89% of the cases were resident in HSE East at diagnosis and many of the infections 
were recently acquired at time of diagnosis. injection of newer street drugs, including “snow blow”, amongst 
homeless, chaotic PWiD were common factors in these individuals.8
 A national cross sectional survey of irish prisoners in 1998 showed a prevalence of anti-HiV of 2%. the prevalence was 
3.5% in prisoners who were PWiD.14
Asylum seekers
Screening of asylum seekers in the HSE eastern region 2000-2003 found a prevalence of anti-HiV of 2.2%.15
HIV infection in Europe
in 2013, 29,157 HiV diagnoses were reported by 30 EU/EEA countries with a rate of 5.7 / 100,000 population. the 
male-to-female ratio was 3.3. Young people aged 15-24 accounted for 11%o fall HiV diagnoses reported by this varied 
widely from 6% in Norway to 25% in Romania.16 
MSM accounted for 42% of diagnoses while heterosexual transmission accounted for 32%. transmission due 
to injecting drugs accounted for 5% of diagnoses and for nearly 20% of the cases, the transmission mode was 
unknown.16
Global HIV distribution
At the end of 2010, an estimated 34 million people were living with HiV globally. the annual number of people newly 
infected with HiV continues to decline, although there is stark regional variation. in sub-Saharan Africa, where most 
of the people newly infected with HiV live, the incidence peaked in 1996-1998. However, the annual number of people 
newly infected with HiV has risen in the Middle East and North Africa in the past decade. And in Eastern Europe and 
Central Asia, where the incidence had slowed drastically in the early 2000s, the incidence has been accelerating again 
since 2008.17
the prevalence of HiV among adults (15-49 years) by world (WHo) region is estimated to be as follows: Africa (4.5%), 
Americas (0.5%), Eastern Mediterranean (0.1%), European (0.4%), South-East Asia (0.3%), Western Pacific (0.1%).18
Estimates of HiV prevalence globally among those with a history of PWiD vary.19 this paper by Mathers et al presents 
detailed tables of prevalence of PWiD and of HiV in PWiD by world region. the largest numbers of injectors were 
found in China, the USA and Russia, where mid-estimates of HiV prevalence among injectors were 12%, 16% and 37% 
respectively (see maps, appendix 26).
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Transmission risks
Needlestick injuries
Following a needlestick injury with a needle contaminated with blood from a source known to have HiV, the risk of 
becoming infected with HiV is thought to be between 0.1% and 0.36%.20, 21-23 the risk from needlestick injuries in the 
community is more difficult to estimate and the exact incidence of needlestick injuries and the transmission rate is 
unknown. intravenous drug injections carry a higher risk, with the risk of HiV transmission estimated to be between 
0.63% and 2.4% per injection.24 the risk from a community needlestick where the source is unknown is estimated to be 
between 0.003 and 0.05%, if the local PWiD seropositivity is approximately 1%.25
Several factors influence the rate of transmission. in a study of occupationally associated needlestick injuries, 
seroconversion was associated with factors including whether the needle or device was visibly contaminated with blood 
(odds ratio 10, 95% Ci 4.6-23), the injury was deep (oR 15, 95% Ci 8-26), or if the injury was sustained by a large gauge 
hollow bore needle (oR 14, 95% Ci 4.9-39).22 the health of the source patient is also relevant. if the source patient has 
AiDS, the odds ratio for transmission of HiV is 1.9 (95%Ci 0.8-4.6). it has been demonstrated that if the source patient 
died within 2 months of the needlestick injury, the odds ratio for transmission increased to 4.8 (95% Ci 2.3-10).22
Post-exposure prophylaxis (PEP) is thought to reduce seroconversion by up to 81% (95% Ci 48-94%).22 Commencing PEP 
early after the injury provides the greatest benefit. in animal studies, administration of PEP within 36 hours prevented 
seroconversion. in animals who received PEP at 72 hours after exposure, 25% seroconverted. in contrast, 75% of the 
animals who did not receive any PEP seroconverted by 4 weeks post exposure.26 Additionally, treatment is most effective 
when continued for 28 days. there are documented case reports of HCWs who have become infected with HiV following 
occupational exposure, despite use of PEP, which in one case was commenced within 30 minutes.27
Blood splashes
the risk of transmission associated with splash injuries is less than the risk associated with needlestick injuries, and HiV 
seroconversion following splashes of blood to intact skin has not been reported.23 the risk of HiV transmission associated 
with exposure of non-intact skin and mucous membrane exposure to HiV infected fluid is possible27, but the risk is very 
low.23 Pooled data provided an estimated risk for transmission of HiV via mucous membrane exposure at 0.09%, based on 
one seroconversion from more than 1000 documented exposures.21
Human bites
infection with HiV after a bite from a patient with HiV “is biologically possible, but remains unlikely”.28 Cases of 
transmission have been reported in case reports, but the exact risk of transmission is unknown, and thought to be very 
low.29, 30 in the cases reported, blood was present in the mouth of the biter, and the skin of the recipient was broken. 
PEP is recommended if a patient has been bitten by someone known to be HiV-positive, with a high viral load, if the bite 
breaks the skin.31
Although there are reports of HiV transmission from a dentist who had AiDS to patients, it has never been demonstrated 
that the dentist acquired HiV from any of his patients.32, 33 Cases of other dentists and dental health practitioners who 
developed HiV after presumed occupational contact are reported, but no evidence exists to demonstrate the exact mode 
of transmission.34 Given that injuries to dentists during procedures are common, at a reported rate of 0.9 per 1000 
procedures35, and there are no documented transmissions of HiV to dentists from patients, the rate of transmission 
overall is very low.
Sexual exposures
the risk of transmission of HiV following sexual exposure depends on the type of exposure, the viral load of the source, 
the susceptibility of the host, and the presence of sexually transmitted infections in either the source or the recipient. if 
the index partner also has a genitourinary infection, for instance, the risk of transmission is approximately doubled.36 if 
the recipient has a genitourinary infection, the risk of acquiring HiV is also elevated.37 Effective antiretroviral therapy has 
been shown to be protective in preventing sexual transmission of HiV in a landmark randomised controlled trial 38 and a 
“real world” cohort study.39 the PARtNER study has demonstrated this to be true in male/female and male/male sexual 
encounters across a range of sexual activities, including unprotected receptive vaginal and anal intercourse. 
Heterosexual exposures
overall the risk of transmission of HiV, per unprotected coital act, for receptive vaginal sex and insertive vaginal sex is 1 in 
1000 and 1 in 1219 respectively.40 Correct use of a condom reduces the risk of transmission by 93%-100%.37,41 Circumcision 
has been shown to significantly reduce HiV acquisition in heterosexual males in high prevalence settings.42 the risk of 
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transmission is greater during the initial two and a half months of infection.36,43 the cumulative incidence of transmission of 
HiV to females in couples who practice unprotected anal intercourse is reported as 27.8%, compared to 11.7% transmission 
to females who do not report anal intercourse.37 transmission is very unlikely if the source of the exposure is on effective 
antiretroviral treatment.38, 39
Men who have sex with men (MSM)
overall the risk of transmission of HiV, per unprotected coital act, for receptive anal sex and insertive anal sex is 1 in 90 and 
1 in 666 respectively.40 An Australian cohort study has estimated the per coital risk of HiV to be lower in circumcised MSM 
(0.11, 95% Ci 0.02 - 0.24) versus uncircumcised MSM (0.62, 95% Ci 0.07 - 1.68. 44 transmission is very unlikely if the source 
of the exposure is on effective antiretroviral treatment.39
Orogenital exposures
the risk associated with orogenital contact cannot be accurately predicted, and is considered low, but not zero.45 
Body fluid exposure
the risk associated with exposures to non-blood stained body fluids is thought to be lower than the risk associated with 
blood exposures.20 HiV has been identified in semen, but this is reduced if the index patient is on treatment and blood HiV 
RNA is detected at <400 copies/ml.46 HiV DNA has been extracted from CSF47 and synovial fluid.48 other fluids which it is 
thought could be implicated in HiV transmission are pericardial fluid, amniotic fluid, peritoneal fluid, human breast milk, 
vaginal secretions and pleural fluid. Unless there is visible blood present, faeces, vomitus, urine, nasal secretions, saliva, 
sputum, sweat and tears are not thought to have any infectious potential.49
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HIV transmission risk by exposure type 
Exposure Risk per exposure (unless otherwise stated)
Needlestick Healthcare setting, source patient (serology) 
known
0.1-0.36%.21-23 increased risk if large gauge needle, hollow needle, deep injury, visible blood on the device, needle was in patient’s 
artery/vein, or if the source patient has AiDS (or terminal illness). 
Healthcare setting, source patient unknown, 
or unable to test source 
Risk assessment required of the type of injury and the likely infection status of the source. 
Community needlestick overall low risk and requires a risk assessment of the type of injury, location of the discarded needle (for example if discarded in 
a location where PWiD are known to inject), likely age of the discarded needle and the background prevalence of HiV in the local 
population. 
Mucous membrane exposure to blood 0.09% 21
intact skin exposure to blood No risk23
Human bite Very low risk.29 Risk assessment required. only risk if blood in the mouth of the biter, and significant injury. No risk if no blood in 
mouth of biter, and exposure to saliva only. Case report suggests that if source co-infected with HCV, HCV transmission more likely 
than HiV transmission.50 
Sexual exposure Heterosexual exposure (general) if source on antiretroviral therapy with suppressed viral load transmission rate = 0 (if viral load < 400 copies/ml) 38, 39
increased risk if source patient has recently seroconverted, e.g. within 2.5 months of seroconversion risk of transmission is 
estimated to be 0.0082/coital act (95% Ci 0.0039-0.015).36 
Receptive vaginal intercourse overall  risk is 1 in 1000, which is increased in the presence of cervical ectopy, genital tract trauma, menstruation, genital ulcerative 
disease (in either partner), infectious syphilis and pregancy.40 Male circumcision reduces HiV acquisition.42
insertive vaginal intercourse overall risk is 1 in 1219.40
MSM unprotected receptive anal intercourse overall risk is 1 in 90, increased risk if there is ejaculation within the rectum.40 the PARtNER study has demonstrated zero 
transmissions in HiV serodiscordant couples where the HiV positive individual is on effective antiretroviral therapy.39
MSM unprotected insertive anal intercourse overall risk is 1 in 666.40 the PARtNER study has demonstrated zero transmissions in HiV serodiscordant couples where the HiV 
positive individual is on effective antiretroviral therapy.39
orogenital contact overall very low risk, estimated to be <1 in 10,000 for both receptive and insertive oral sex.40
Remember 
 • There are only 5 reported cases of confirmed HIV transmission from a patient to a healthcare worker in the UK.51
 • There have been no such transmissions between 2004 and 2013, in the UK.52
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Prevalence of HiV worldwide
Source: World Health organisation, 2014.
Prevalence of HiV infection among people who inject drugs
Source: Reprinted from lancet 2008;372(9651), Mathers BM, Degenhardt l, Phillips B, et al. Global epidemiology of injecting drug 
use and HiV among people who inject drugs: a systematic review, pages 1733-45, Copyright (2008), with permission from Elsevier.
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I was exposed to blood or body 
fluids from another person, what 
is the chance that I will develop an 
infection? 
A doctor has looked at your injury and taken 
a detailed history from you on how you got 
your injury. Based on this information, you 
are not at risk of getting a bloodborne virus 
such as hepatitis B, hepatitis C or HiV. 
What do I have to do next? 
if you have a wound, for example, after a 
needlestick injury or a bite injury, follow the 
wound care advice that was given to you. 
keep the wound clean and dry by keeping it 
covered with a plaster or bandage until it is 
healed. 
if your wound was caused by a human bite, 
an antibiotic will be prescribed for you. 
Make sure you finish the full course of the 
antibiotic. 
if you have any concerns about your wound 
after discharge, please attend your own GP 
for follow up. the emergency department 
will be sending a letter to your own doctor 
informing them about your injury and what 
treatment you received.
I was injured by a needle and I kept the 
needle – can it be tested for blood or 
infections? 
testing of needles for blood or infections is of no 
benefit as it is not very reliable and it can be hard 
to test for bloodborne viruses. therefore, it is not 
recommended. 
the needle that you have needs to be carefully 
disposed of into a special bin so that it will not 
cause any more injuries. Ask a member of staff 
about safe disposal of the needle. 
Am I allowed to be a blood donor? 
Based on your injury, there is no risk that you 
will get a bloodborne infection from this injury. 
therefore, you can be a blood donor. However, 
the irish Blood transfusion Service (iBtS) donor 
guidelines require a deferral period before 
donating. For further information, contact iBtS. 
Is there any other follow-up that I 
should know about? 
if you are at risk of getting an injury with blood 
or body fluids again, you may be advised to 
get a vaccine against hepatitis B. 
if you received the 1st dose of hepatitis B 
vaccine in the emergency department or 
occupational health department, you will be 
given instructions about when you should get 
the next two doses of the vaccine. A hepatitis 
B vaccination card will be given to you as a 
reminder of when you should get the next 
dose of the vaccine. 
‘if you have any concerns about 
your wound after discharge, please 
attend your own GP for follow up.’
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What is the chance I will develop 
an infection?
Hepatitis B
if someone is exposed to blood infected with 
hepatitis B virus, e.g. needlestick injury, the 
transmission rate can be as high as 30%. For 
this reason, your hepatitis B immune status will 
have been considered. if you are thought to be 
not immune to hepatitis B infection, you will be 
offered vaccination – either completion of the 
course if you already had one or two doses, or 
the first of three doses of the vaccine if you have 
never been vaccinated against hepatitis B. in 
some circumstances, people may also be offered 
hepatitis immunoglobulin. 
Hepatitis C
Following exposure to blood infected with 
hepatitis C virus, e.g. needlestick injury, the risk 
of developing an infection is about 1.8%.
HIV:
only about 0.3% of those who report a 
needlestick injury from a patient known to be 
infected with HiV will develop HiV. the risk 
of infection following exposure to a splash of 
blood to your eye or into your mouth is lower, 
about 0.09%. Exposure to other body fluids is 
associated with an even lower risk. there is no 
risk associate with blood exposure to intact skin.
 The management of your injury is 
considered on an individual basis 
depending on the nature 
of the injury. 
If I do not know, for example, who 
used the needle before my injury 
or do not know who injured or 
assaulted me, does this change my 
treatment?
You reported an exposure to blood and body fluids 
from an “unknown source”. in this circumstance, 
it is not possible to exclude the possibility 
of infection. the risk that you may develop 
an infection, however, is lower than the risk 
highlighted above. 
What happens next?
You should have been given follow-up 
appointment dates, or advised how to access 
follow-up appointments. Follow-up appointments 
are necessary in order for you to receive test 
results, get additional blood tests done or receive 
further hepatitis B vaccinations. it is important that 
you attend all follow-up appointments. take note 
of follow-up appointment instructions at the back 
of this leaflet. if you have been given hepatitis B 
vaccine, a hepatitis B reminder card will be given 
to you. 
Is there anything I need to do while 
I wait for results of the blood tests? 
the follow-up is not complete until 3 months 
after the injury. in the mean time, if you develop 
symptoms such as fever, any rash, sore throat, 
swollen glands, mouth ulcers, diarrhoea, joint 
or muscle pain, headaches, nausea or vomiting, 
reduced appetite, weight loss or fatigue, please 
contact your doctor and arrange a review 
appointment. 
Am I allowed to be a blood donor 
while I am waiting on the results?
You should avoid donating blood or other body 
fluids, tissues or organs, for the duration of the 
follow-up period, to limit the risk of passing on any 
possible infection. 
Are there any other additional 
precautions that I need to take? 
Depending on the nature of your injury, additional 
precautions may also be necessary. 
•   Pregnancy and breastfeeding should be avoided 
if possible. 
•   Do not share toothbrushes, razors or needles. 
•   Adopt safer sex practices i.e. use a condom for 
the next three months. 
•   There is no need to restrict your work practices 
while awaiting the results of these blood tests. 
If you have any concerns regarding this advice or 
wish to receive counselling, please discuss this 
with your doctor. 
Where will I be attending for my next 
appointment (including contact details)? 
When is this appointment? 
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CHECKLIST 
Testing of source person or recipient 
for hepatitis B/hepatitis C/HIV
this is a checklist for the doctor or nurse providing information to the source or 
recipient for consent prior to testing.
□   Explain why a blood test is required in this blood and/or body fluid exposure 
incident/event 
□  Discuss purpose of test as applicable 
 • Establish baseline status of recipient
 • Establish infection status of source person
 • Follow-up blood test
□  Document individual’s personal risk for hepatitis B, hepatitis C or HIV
□  Specify what blood tests are to be done
 • Hep B surface antigen ± Hep B e antigen, Hep B e antibody, Hep B viral load, 
 • Anti-HBs (if previously vaccinated and no record of post-vaccination titre)
 • Anti-HCV ± Hep C viral load
 • HIV Ag/Ab ± HIV viral load
□   Discuss advantages of testing and implications of positive test result with individual, 
covering the following:
 •  Identification of previously unknown disease and ensuring referral to infectious diseases 
specialist
 •  Protection of sexual partners
 •  Allowing informed planning for the future
 •  Possible requirement to inform insurer of a positive test result as is applicable for an 
existing policy or for a new application
 •  Applicable safe work practices including reporting to own Occupational Health Service
 •  Sharing of toothbrushes, shaving or razor blades, needles
 •  Donation of blood, body fluids or other tissues – need to disclose positive results
 •  Pregnancy and breastfeeding
□  Explain confidentiality in the use of and communication of results
□  Explain that results on source patient may have to be disclosed to recipient 
□  Ensure plan in place to obtain blood results and notify patient of results
□  Affirm that declining consent will not impact on ongoing care (if applicable)
□  Offer individual opportunity for clarification of any concerns
□   Document in presence of patient that informed consent has been given before testing
□   Inform the patient that hepatitis B, hepatitis C and HIV are notifiable diseases and 
positive results will be notified confidentially to the Medical Officer of Health
A downloadable version of this brochure can be found at www.emitoolkit.ie
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Introduction 
An incident has occurred in which 
another person became exposed to 
your blood or body fluid. Because 
of the nature of the exposure, there 
is a need to carry out a blood test 
to check if you have certain viruses 
that can be transmitted if present 
in your blood. These viruses are 
hepatitis B, hepatitis C and human 
immunodeficiency virus (HIV).  A 
negative test result will reduce the 
other person’s anxiety and eliminate 
the need for them to undergo 
unnecessary treatment.
Testing for the viruses
A blood test will be carried out on you in order to 
assess if you already have these viruses. 
The result of this test will be treated as confidential 
and used only for the purposes of confirming your 
infection status at the time of the incident. If your 
test is positive and this was previously unknown to 
you, the results will be sent confidentially to your own 
doctor whose name you provided. The results of your 
blood test may have to be disclosed to the person who 
was exposed to your blood or body fluid.
What does the blood test involve? 
Before the test, you will be provided with information 
to allow you to give your informed consent to the test. 
You will not be tested without your given consent. It 
is similar to a normal blood test that you may have 
had before. It should only take a few minutes and you 
will be advised when to expect the results. You have 
the right to refuse to be tested. If you choose not to be 
tested, your care will not be affected.
What happens if the blood test is 
negative? 
This means that you tested negative for the viruses at 
the time of the blood test. No further testing will be 
required.
What happens if the blood test is 
positive? 
In the event that the blood test is positive for one of 
these viruses and this was previously unknown to 
you, you will be referred to a specialist for follow-up. 
Your own doctor will receive a confidential letter  
outlining your results. 
 
Are there any implications of a 
positive test?
•  If the test is positive for any of these bloodborne 
viruses, you will be referred to a specialist for 
follow up assessment and management. 
•  Depending on the type of insurance policy, you 
may be required to inform your insurer that you 
have tested positive for any of these bloodborne 
viruses where you have an existing policy or when 
making a new application 
•  You will have to inform your sexual partner(s) and 
you should have been given advice regarding the 
need for safer sex practices.
•  You will need to inform relevant agencies if you are 
considering donating blood products or other body 
tissues.
•  You should not share shaving blades or razors, 
toothbrushes and needles.
•  You should get expert advice about pregnancy and 
breast feeding.
•  
diseases and positive results will be notified 
confidentially to the medical officer of health. 
  
Counselling
If you have any concerns regarding this advice or 
wish to receive counselling, please discuss this with 
your doctor.
It is similar to a normal blood test that you may have had 
before. It should only take a few minutes and you will be 
advised when to expect the results.
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HIV 
Post-Exposure 
Prophylaxis (PEP)
INFORMATION LEAFLET 
HIV PEP must be taken 
within 72 hours of your 
exposure as it will not 
be effective if taken 
after 72 hours. 
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What is HIV PEP treatment?
HIV PEP is a post-exposure prophylactic (PEP) 
treatment that is prescribed for you in order to prevent 
HIV infection following a high risk exposure to blood 
or body fluids. The treatment is for 28 days if you are 
prescribed the full course. It is very important that you 
do not miss any doses and complete the 28 day course. 
If you attended the emergency department, you will 
have been given a starter pack of the medications that 
you will need to take. 
In the starter pack there will be only enough 
medications for 3-5 days.  Before the pack 
has finished you should have been seen by an 
appropriate specialist. It is very important that you 
attend all appointments that are arranged for you. 
Do I have to take HIV PEP? 
Based on your type of injury and the potential risk of 
HIV being transmitted to you from the source person/ 
item, it is recommended that you start this treatment 
immediately. 
HIV PEP should be taken as soon as possible after 
your exposure. It will not be effective if taken after 72 
hours. 
If you are HIV positive on your first blood test, your 
HIV PEP medication will be reviewed. 
How long will I be on this 
treatment? 
Generally the treatment will last 28 days and will 
depend on an assessment by the specialist. You will 
also require follow-up blood tests over the next four 
months. Follow up blood tests will be arranged by 
the clinic before you leave. 
What medications will be prescribed?
You will be prescribed medications called truvada® 
and Isentress®, or truvada® and tivicay®. If you are 
pregnant or may become pregnant it is important 
that you let the person prescribing PEP know. In 
general, tivicay® is not recommended for use in early 
pregnancy.
You should take one blue tablet of truvada® once 
a day with food. You should take one pink tablet of 
Isentress® twice a day – take them 12 hours apart if 
you can. You should take one yellow tablet of tivicay® 
once a day. It is important that you take your tablets 
at the same time each day and don’t miss any doses.  
Set reminders on your phone to ensure that you take 
the medication on time. 
Are there any side effects to taking 
these medications?
Yes, they can cause diarrhoea, vomiting, tiredness 
and headaches. Side effects usually disappear after 
a few days but if they worsen talk to your doctor and 
you may need to take time off work or study.
Are the HIV PEP medications safe to 
take with my own medications? 
If you are already on medication for other medical 
conditions, it is really important to let the doctor/
pharmacist giving you PEP know. they will advise 
you if your own medications are safe to take with the 
HIV PEP treatment. It is not recommended to take 
Isentress® with certain antacids (those containing 
aluminium and/or magnesium). talk to your doctor 
about other antacids you can take.      
Are there any special precautions 
to be taken whilst I am on this 
treatment? 
•   Do not share toothbrushes, razors or needles. 
•   Adopt safe sex practices i.e. use a condom for the 
next three months. 
•   If you are pregnant or breastfeeding you must seek 
advice from an obstetrician or HIV/infectious diseases 
specialist.
•   It is not recommended for you to donate blood or 
other body fluids for the duration of your treatment 
and follow-up care. 
 Follow-up Care 
It is very important that you attend all your 
appointments. You should be seen in a specialist 
clinic before the starter pack of medication runs out. A 
referral letter will be sent to the appropriate specialist 
explaining the treatment that you received. It is useful 
to take note of the following: 
Where will I be attending for my next 
appointment (including contact details?) 
When is this appointment?
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THINK
Your guide to contraception
thinkcontraception.ie
Your guide to choosing the right contraception for you. 
When it comes to your sexual health, nobody else is going to do the thinking 
for you. It’s important then to choose contraception that fits your situation and 
lifestyle.
In this leaflet, you’ll find info on how to protect yourself and your partner 
from having an unplanned pregnancy and how to prevent against sexually 
transmitted infections (STIs). You’ll also find descriptions of the main types of 
contraception available. Read on and then have a chat with your doctor and 
your partner  about what’s best for you. And remember, above all, to always 
think contraception. All the methods are very effective – and most are 99% 
effective – when they are used correctly and consistently.
Remember, only abstaining from (avoiding) all sexual contact offers 100% 
protection from pregnancy and STIs.
Disclaimer
The information in this leaflet has been supplied by the Crisis Pregnancy 
Programme in December 2015. It has made every effort to ensure that the 
information is accurate before going to print. Please remember, however, that 
the information in this leaflet does not replace medical advice, diagnosis or 
treatment. If you have questions or concerns or need further information, visit 
your GP, pharmacist (chemist) or local family planning clinic for professional 
advice.
About the HSE Sexual Health and Crisis Pregnancy Programme
The HSE Sexual Health and Crisis Pregnancy Programme is a section of 
the Health Service Executive that is responsible for implementing national 
strategies that promote sexual health and address STIs and crisis pregnancy 
in Ireland.
Age of consent
The age of sexual consent in Ireland is 17 years. 
Top tips
•  Think contraception before you think about having sex! Most 
contraception methods are 99% effective when used correctly and 
consistently. However, only abstaining from (avoiding) all sexual contact 
offers 100% protection from pregnancy and STIs.
•  Different contraceptives suit different people. Discuss your contraceptive 
choices with your GP. You may need to experiment to find the best 
contraception for you.
•  There are long acting methods of contraception available that can be 
more reliable as they do not require you to take a pill every day e.g. 
the coil, the implant. More young adults are using these methods of 
contraception nowadays. These methods can be less expensive in the 
long run.
•  Have an STI check up and discuss contraception with your partner 
before you get intimate.
•  Using ‘dual protection’ (condoms with another method of contraception) 
will help you to have safer sex.
•  Approximately 80% of 18–24 year olds used contraception every time 
they had sex, so plan ahead and carry contraception.
•  Be prepared – research has found that the most common reason why 
people fail to use contraception is because sex is unplanned or they 
were unprepared.
•  Condoms offer the best protection from pregnancy and sexually 
transmitted infections (STIs) - Johnny’s got you covered.
Fertility
Lots of people do not know when a woman is most fertile during her 
cycle (in other words, when pregnancy is most likely to occur).
A woman releases an egg (ovulates) every month 12-16 days before the 
onset of her next menstrual period. This is the most fertile time of her 
menstrual cycle. The time that ovulation occurs within each cycle can 
vary. It can depend on length of the cycle and on a range of external 
factors over which a woman may have no control. Examples of external 
actors could be stress, travel or illness.
*This diagram is based on a 28 day cycle and should only be used as 
a guide. For more information on fertility, talk to a GP or Family Planning 
Clinic.
Fertility
Lots of people do not know when a woman is most fertile 
during her cycle (in other words, when pregnancy is most 
likely to occur). 
A woman releases an egg (ovulates) every month 12-16 
days before the onset of her next menstrual period. This is 
the most fertile time of her menstrual cycle. The time that 
ovulation occurs within each cycle can vary. It can depend 
on length of the cycle and on a range of external factors over 
which a woman may have no control. Examples of external 
factors could be stress, travel or illness.
*This diagram is based on a 28 day cycle and should only be 
used as a guide. For more information on fertility, talk to a GP 
or Family Planning Clinic.
first day of 
cycle begins
next cycle 
begins
1 5 8 1713 18 28
ovulation
most fertile time 
(based on a 28 day cycle)
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Where women have regular, 28 day cycles, ovulation occurs around 
the middle of her cycle. As the egg can survive for  approximately 12-24 
hours and sperm may survive forbetween 5-7 days inside the female 
body, the fertile time can extend from 7-10 days each month. If a couple 
have sexual intercourse or intimate sexual contact during this fertile 
time the egg may be fertilized by a single sperm.
Many women have irregular cycles, so it can be difficult to identify 
their likely fertile time in each cycle. Every woman’s menstrual cycle is 
unique to her. If a woman has sex without using contraception, she 
may become pregnant, even at a time in her cycle when she thought 
she was safe.
Please note that this is general information about fertility which does not 
replace medical advice. If you need further information about fertility, 
talk to your local GP.
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  Condom:  
Male and Female 
how does it work?
This barrier method works by preventing the man’s sperm from 
meeting the woman’s egg.
The male condom is rolled onto a man’s erect penis before sex. 
The female condom lines the woman’s vagina.
how effective is it?
Effectiveness depends on careful and consistent use.  
With careful use, the male condom is 98% effective  
and the female condom 95% effective. 
things to know before choosing this method
• Widely available for sale without a prescription
•  Helps to protect both partners from sexually transmitted  
infections, including HIV
•  Can be used with hormonal contraceptives for additional 
protection
•  Must be correctly and consistently used – using condoms 
properly requires practice
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how effective is it?
Effectiveness depends on careful and consistent use.
With careful us , the male condom is 98% eff c ive
and the female condom 95% effective.
things to know before choosing this method
• Widely available r sale without a prescription
• Helps to protect both partners from sexually transmitted
 infections, including HIV
• Can be used with hormonal contraceptives for additional
 protection
• Must be correctly and consistently used – using condoms
 properly requires practice
• It is impo tant to talk to a doctor who will assess what 
contraceptive option is best for you
how does it work?
This barrier method works by preventing the man’s sperm from meeting 
the woman’s egg.
T male condom is rolled ont  a man’s erect penis before sex.
The female condom lines the woman’s vagina.
how effective is it?
Effectiveness depends on careful and consistent use.
With careful use, the male condom is 98% effective
and the female condom 95% effective.
things to know before choosing this method
• Widely available for sale without a prescription
•  Helps to protect both partners from sexually transmitted infections, 
including HIV
•  Can be used with hormonal contraceptives for additional protection
  rr ctly and consistently used – using condoms properly 
requires practice
•  It is important to talk to a doctor who will assess what contraceptive 
option is best for you
  Combined oral 
contraception:  
the pill
how does it work? 
This pill contains two female hormones (oestrogen and 
progestogen) and is taken every day for three weeks of each 
month. It works mainly by stopping the woman from producing 
an egg.
how effective is it?
If properly used, it is over 99% effective. It is less effective with 
less careful use. It must be taken around the same time every 
day.
things to know before choosing this method
• Not available without prescription
•  Not suitable for women with conditions such as high blood 
pressure or smokers over 35
•  Vomiting, diarrhoea and taking some medicines such as 
antibiotics can interfere with how it works
• Does not protect against sexually transmitted infections
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erone) and is taken every day for three weeks of each
 , migrain  or smokers over 35
 some antibiotics can interfere with how it works
• It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
how does it ork?
This pill contains two female hormones (oestrogen and progesterone) 
and is taken every day for three weeks of each month. It works mainly by 
stopping the woman from producing an egg.
how effective is it?
If properly used, it is over 99% effective. It is less effective with less careful 
use. It must be taken around the same time every day.
things to know before choosing this method
•  Not available without prescription
•  Not suitable for w men with c ditions such as high blood pressure, 
migraine or smokers over 35
•  Vomiting, diarrhoea and taking some medicines such as some 
antibiotics can interfere with how it works
•  Does not protect against sexually transmitted infections
• It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
  Progestogen-only pill:  
the mini-pill
how does it work?
This pill contains one female hormone (progestogen) and is 
taken every day without a break. It works mainly by preventing 
sperm from getting through the fluid at the neck of the womb. 
It may also thin the lining of the womb, which prevents an egg 
from implanting there and may prevent an egg being released.
how effective is it?
Effectiveness depends on careful and consistent use.  
The mini-pill is 96-99% effective with very careful use, but it 
must be taken at the same time every day.
things to know before choosing this method
• Available only with a prescription
•  Useful for women who cannot or do not want  
to take oestrogen
• Can be used when breastfeeding
• May cause irregular periods
• Does not protect against sexually transmitted infections
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• It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
erone) and is
erone-only pi l:
how does it work?
This pill contains one female hormone (progesterone) and is taken every 
day without a break. It works mainly by preventing sperm from getting 
through the fluid at the neck of the womb. It may also thin the lining of the 
womb, which prevents an egg from implanting there and may prevent an 
egg being rel a ed.
how effective is it?
Effectiveness depends on careful and consistent use.
The mini-pill is 96-99% effective with very careful use, but it must be taken 
at the sam  time every day.
things to know b fore choosing this method
• Available only with a prescription
• Useful for women who cannot or do not want to take oestrogen
• Can be used when breastfeeding
• May cause irregular periods
• Does not protect agai st s x lly tr s itted infections
• I t is important that you talk to a doctor who will assess what 
contraceptive option is best for you
  Injectable contraception: 
the hormone injection
how does it work?
A woman receives an injection of a single hormone every 12 
weeks. The hormone works mainly by stopping the woman 
from producing an egg. 
how effective is it?
This method is very effective (over 99%) once the injection is 
given regularly.
things to know before choosing this method
• Injection must be given by a doctor or a nurse
•  Useful for those who find it hard to remember to take  
a pill every day
• May cause irregular bleeding 
• Does not protect against sexually transmitted infections
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st pping the woman from producing an egg.
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N t uitable for long term use
• Does not protect against sexually transmitted infections
• It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
how does it work?
A woman receives an injection of a single hormone (progesterone) every 
12 weeks. The hormone works mainly by stopping the woman from 
producing an egg.
how eff ctive is it?
This method is very effective (over 99%) once the injection is given 
regularly.
things to know before choosing this method
• Injection must be given by a doctor or a nurse
• Usefu for those who find it hard to remember to take a pill every day
• May cause irregular bleeding
• Not suitable for long term use
• Does not protect against sexually transmitted infections
•  It is impor ant hat you talk to a doctor who will asses  what 
contraceptive option is best for you
  Intrauterine system 
(IUS)
how does it work?
The IUS is a small plastic device that is put into the womb and 
releases the hormone progestogen.
It works in several different ways - by stopping sperm from 
meeting the egg, by delaying the egg getting to the womb or 
by preventing the egg from implanting in the womb.
how effective is it?
This is a highly effective method (more than 99% effective).
things to know before choosing this method
•  Works as soon as it is inserted and can stay in place for five 
years
•  Can only be inserted and removed by a specially trained 
doctor
• May cause irregular bleeding for the first few months
• Does not protect against sexually transmitted infections
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erone.
The copper coil is a small copper device that is put into the womb.
Intrauterine contraception works in several different ways -
by stopping sperm from meeting the egg, by delaying the egg 
getting to the womb or by preventing the egg from implanting
in the womb.
how effective is it?
This is a highly effective method (more than 99% effective).
things to know before choosing this method
• Works as soon as it is inserted and can stay in place for three to 
five years
• Can nly be inserted and removed by a specially trained doctor
• The IUS may cause irregular bleeding for the first few months 
but after that time most women have lighter periods and often 
no periods. The copper coil may cause heavier periods in some 
women
• Does not protect against sexually transmitted infections
• It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
contraception 
 and copper coil)
how do they work?
The IUS is a small plastic device that is put into the womb and releases the 
hormone progesterone. The copper coil is a small copper device that is 
put into the w mb.
Intrauterine contraception works in several different ways - by stopping 
sperm from meeting the egg, by delaying the egg getting to the womb or 
by preventing the egg from implanting in the womb.
how effective is it?
This is a highly effective method (more than 99% effective).
things t  know b fore choosing this method
•  Works as soo  as it is i serted an  can tay in place for three to five 
years
•  Can only be inserted and removed by a specially trai ed doctor
•  The IUS may cause irr gular bleeding for the first few months but after 
that time most women have lighter periods and often no periods. The 
copper coil may cause heavier periods in some women
•  Does not protect against sexually transmitted infections
•  It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
 The implant 
how does it work? 
The implant is a small flexible rod that contains the hormone 
progestogen. It is inserted under the skin of the upper arm. 
It works mainly by stopping the woman from producing an egg. 
It also thickens the fluid at the neck of the womb and thins the 
lining of the womb.
how effective is it? 
This method is highly effective (over 99%).
things to know before choosing this method 
• Lasts for up to three years
•  Can only be inserted and removed by a specially  
trained doctor 
• May cause irregular bleeding 
• Does not protect against sexually transmitted infections
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• It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
erone. It is inserted under the skin of the upper arm.
how does it 
The implant is  s ll fl i le rod that contains the hormone progestogen. 
It is inserted under the skin of the upper arm.
It works mainly by stopping the woman from producing an egg. It also 
thickens the fluid at the neck of the womb and thins the lining of the womb.
how effective is it?
This metho  i  i l  ff tive (over 9%).
things to k   sing this method
• Lasts for up to three years
• Can only be inserted and removed by a specially trained doctor
• May cause irregular bleeding
• Does not protect against sexually transmitted infections
•  It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
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how does it work? 
The patch is like a thin plaster that contains two hormones 
(oestrogen and progestogen). A woman wears the patch for 
three weeks out of every four. 
In this way, it works like the combined oral contraceptive pill.
how effective is it? 
This method is 99% effective when used correctly.
things to know before choosing this method 
• Available only with a prescription
•  Has the same effects as the combined oral  
contraceptive pill
• Costs more than the pill
•  Timing may be easier to remember (patch replaced once a 
week)
• Does not protect against sexually transmitted infections
 The patch
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• It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
erone). A woman wears the patch for
how does it work?
The patch is like a thin plaster that contains two hormones (oestrogen and 
progesterone). A woman wears the patch for three weeks out of every 
four.
In this way, it works like the combined oral contraceptive pill.
how effective is it?
This method is 99% effe tive when used correctly.
things to know before choosing this method
• Available only with a prescription
• Has the same effects as the combined oral contraceptive pill
• Costs more than the pill
• Timing may be easier to remember (patch replaced once a week)
• Does not protect against sexually transmitted infections
•  It is important that you talk to a doctor who will assess what 
contraceptive option is best for y u
how does it work? 
The ring contains two hormones (oestrogen and progestogen) 
and is inserted into the vagina for three weeks of every month. 
It works like the combined oral contraceptive pill.
how effective is it? 
This method is 99% effective when used correctly.
things to know before choosing this method 
• Available only with a prescription
• Can be inserted by the woman herself
•  Has the same effects as the combined oral  
contraceptive pill
• Costs more than the pill
•  Timing may be easier to remember (inserted once  
a month)
• Does not protect against sexually transmitted infections
 The vaginal ring
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• It is important that you talk to a doctor who will assess what 
contraceptive option is best for you
erone)
how does it work?
The ring contains two hormones (oestrogen and progestogen) and is 
inserted into the vagina for three weeks of every month. It works like the 
combined oral contraceptive pill.
how effective is it?
This method is 99% effective hen used correctly.
things to know before choosi  t
• Available only with a prescripti
• Can be inserted by the woman herself
• Has the same effects as the combined oral contraceptive pill
• Cost  more than the pill
• Timing may be easier to remember (inserted once a month)
• Does not protect against sexually transmitted infections 
• I t is important that you talk to a doctor who will assess what 
contraceptive option is best for you
How to use a male condom
Condoms are the most common form of contraception used by 18-24 
year olds. Male condoms are really effective when they are used 
properly. They protect against most (but not all) STIs. It takes a little 
practice to use one properly – here are some tips.
•  Make sure you buy a good quality 
condom. Look for the BSI Kitemark 
or CE mark and check the  
expiry date.
•  Be careful that condoms don’t 
tear when you open the packet 
– don’t use your teeth and be 
careful with long nails and 
jewellery.
•  Put the condom on before there is 
any genital contact or penetration 
– there can be semen on the 
penis before ejaculation.
•  Don’t try to put a condom on if the 
penis is not hard.
•  Hold the condom at the head of 
the penis. Pinch the top to get 
rid of any air and with your other 
hand gently roll it down over the 
penis. 
How to use a male condom
Condoms are the most common form of contraception used 
by 18-24 year olds. Male condoms are really effective wh n 
they are us d properly. They protect against most (but not all) 
STIs. It takes a little practice to use one properly – here are 
some tips. 
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•  Use water-based lubricants if 
necessary – they are designed 
especially for use with condoms. 
Most pharmacies stock these 
products close to the condom 
range. Remember that oil-based 
lubricants (massage or baby oil, 
petroleum jelly) and products 
such as body cream can damage 
condoms, making them split. 
•  When pulling out after sex, hold 
the base of the condom. Be careful 
when removing the condom so 
that you don’t spill any semen. 
There will still be semen on the 
penis, so keep it away from the 
vagina.
•  Wrap the condom in a tissue 
and dispose of it safely and 
hygienically (not down the toilet).
A variety of condom types are available. 
If one condom doesn’t feel comfortable, 
check out other condom options.
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•  Make sure you buy a good quality condom. 
Look for the BSI Kitemark or CE mark and check 
the expiry date.
•  Be careful that condoms don’t tear when you 
open the packet – don’t use your teeth and be 
careful with long nails and jewellery.
•  Put the condom on before there is any genital 
contact or penetration – there can be semen 
on the penis before ejaculation.
•  Don’t try to put a condom on if the penis is not 
hard.
•  Hold the condom at the head of the penis. 
Pinch the top to get rid of any air and with your 
other hand gently roll it down over the penis.
•  Use water-based lubricants if necessary – they 
are designed especially for use with condoms. 
Most pharmacies stock these products close to 
the condom range. Remember that oil-based 
lubricants (massage or baby oil, petroleum 
jelly) and products such as body cream can 
damage condoms, making them split.
•  When pulling out aft r sex, hold the base of 
the condom. Be careful when removing the 
condom so that you don’t spill any semen. 
There will still be semen on the penis, so keep 
it away from the vagina.
•  Wrap the condom in a tissue and dispose of it 
safely and hygienically (not down the toilet). 
A variety of condom types are ava labl . If one 
condom doesn’t feel comfort ble, check out 
other condom options
STI screening
It is good sexual health practice to get an STI check 
regularly. Your doctor can arrange tests for you or you 
can visit a family planning clinic or an STI clinic.
What happens at an STI clinic?
You will need to make an appointment for most clinics, 
unless they provide a drop-in service. You don’t have to 
be referred by your GP.
The length of time that you will be at the clinic can vary. 
If you have no symptoms it tends to be shorter and if 
you have a specific problem, it may take a bit longer. STI 
clinics tend to be busy places and you may be waiting 
for a while to be seen. You will be asked questions about 
your sex life. Doctors and nurses working in STI clinics 
are there to help and they have heard it all! It’s a good 
idea to be honest in your answers and worries - don’t 
worry about shocking them - they’ve heard it all before! 
Then you will have a series of tests. Blood tests are used 
to test for HIV, Hepatitis B and syphilis. Swabs and urine 
are used to examine material from a discharge or an 
infected area.
Sometimes you will get some of your results and 
treatment on the same day. After you’ve had your tests 
and treatment (if necessary), you’ll be told how results will 
be made available to you. It’s important that you know 
how results are communicated to you. It’s also important 
that the contact details that you give to the clinic are 
correct otherwise they won’t be able to contact you.
t o o l k i t
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Emergency contraception is more effective the sooner you take it after 
having unprotected sex. Ask a pharmacist for a private consultation 
or talk to your GP or Family Planning Clinic about the best option for 
you. You can also use this time to discuss regular contraception.The 
following table will give you an outline of the choices available.
3 Day Pill
(NorLevo® or Prevenelle®) 
5 Day Pill
(ellaOne®)
The Copper Coil
(Post Coital IUD)
Time limit for use after 
unprotected sex
72 hours (3 days) 120 hours (5 days) 120 hours (5 days)
Effectiveness
Is 99% effective in preventing pregnancy 
if taken within 12 hours after unprotected 
intercourse. It is less effective on day 2 and 
day 3.
Is 99.5% effective but should be 
taken as soon as possible.
Is 99.9% effective but get advice 
as soon as possible.
Available
NorLevo® is available directly from 
pharmacists.
Medical card holders require a 
prescription from a GP (including out of 
hours co-ops) or a Family Planning Clinic.
ellaOne® is available directly from 
pharmacists.
Medical card holders require a 
prescription from a GP (including 
out of hours co-ops) or a Family 
Planning Clinic.
Can be inserted by specially 
trained GPs or Family Planning 
Clinics.
Works by
Delaying ovulation. Delaying ovulation. •  Preventing sperm from joining 
an egg
•  Preventing the fertilised egg from 
attaching to the uterus.
Future protection
After using emergency contraception, it’s 
important to talk to a doctor or pharmacist 
about the following:
•  what to do if you are already using 
regular contraception
•  when you can expect your next period
•  what to do if your period doesn’t come
•  a regular contraceptive option suitable 
for you
After using emergency 
contraception it’s important to talk 
to a doctor or pharmacist about 
the following:
•  what to do if you are already 
using regular contraception
•  when you can expect your next 
period
•  what to do if your period doesn’t 
come
•  a regular contraceptive option 
suitable for you
Can be left in the uterus for up to 
10 years as a regular method of 
contraception
Or
Can be removed if required at 
your next period
Cost
The cost of contraception varies depending 
on what form is most suitable to you, 
what providers are available to you and  
whether or not you have a medical card. 
Talk to a pharmacist, GP or Family Planning 
Clinic for more information on costs.
The cost of contraception varies 
depending on what form is most 
suitable to you, what providers 
are available to you and whether 
or not you have a medical card. 
Talk to a pharmacist, GP or 
Family Planning Clinic for more 
information on costs.
The cost of contraception varies 
depending on what form is most 
suitable to you, what providers 
are available to you and whether 
or not you have a medical card.  
Talk to a pharmacist, GP or 
Family Planning Clinic for more 
information on costs.
Your emergency contraception choices
There are different emergency contraception choices for different 
situations, depending on when you had your last period and how 
long it has been since you had unprotected sex.
3 Day Pill
(NorLev ® or Preven ll ®) 
5 Day Pill
(ellaOne®)
The Copper Coil
(Post C ital IUD)
Time li it for use aft r 
unprotected sex
72 hours (3 days) 120 hours (5 days) 120 hours (5 days)
Effectiv ness
Is 99% effective in preventing pre nancy 
if taken within 12 hours after unprotected 
intercourse. It is less effective on day 2 nd 
day 3.
Is 99.5% effective but should be 
taken s soon as pos ible.
Is 99.9% effective but get advice 
as soon as pos ible.
Available
NorLev ® is available directly from 
pharmacists.
Medical card hol ers requir  a 
prescription from a GP (including out of 
hours co-ops) r a Family Planning Clinic.
ellaOne® is available directly from 
pharmacists.
Medical card hol ers requir  a 
prescription from a GP (including 
out of hours co-ops) r a Family 
Planning Clinic.
Can be i serted by specially 
trained GPs or Family Planning 
Clinics.
Works by
Delaying ovulation. Delaying ovulation. •  Preventing sperm fro  joining 
an egg
•  Preventing the fertilis d egg from 
attaching to the uterus.
Future protection
After using emergency contraception, it’s 
important to talk to a d ctor r pharmacist 
about the following:
•  what to do if you are already using 
regular contraception
•  when you can expect your next p riod
•  what to do if your period doesn’t come
•  a regular contraceptive option suitable 
for you
After using emergency 
contraception it’s important to talk 
to a d ctor r pharmacist bout 
the following:
•  what to do if you are already 
using regular contraception
•  when you can expect your next 
period
•  what to do if your period doesn’t 
come
•  a regular contraceptive option 
suitable for you
Can be left in the uterus for up to 
10 years as a regular method of 
contraception
Or
Can be removed if requir d at 
your next p riod
Cost
The cost of contraception varies depending 
on what form is o t suitable to you, 
what providers are available to you and  
whether or not you have a medical card. 
Talk to a pharmacist, GP or Family Planning 
Clinic for more information on costs.
The cost of contraception varies 
depending on what form is o t 
suitable to you, what providers 
are available to you and whether 
or not you have a medical card. 
Talk to a pharmacist, GP or 
Family Planning Clinic for more 
information on costs.
The cost of contraception varies 
depending on what form is o t 
suitable to you, what providers 
are available to you and whether 
or not you have a medical card.  
Talk to a pharmacist, GP or 
Family Planning Clinic for more 
information on costs.
For more information on emergency contraception visit
thinkcontraception.ie
Emergency contraception facts
• Women of all ages can use emergency contraception to 
prevent unplanned pregnancy if they have had sex without 
using contraception or their contraception has failed.
• Many women who have had a crisis pregnancy did ot 
think to use emergency contraception.
• Emergency contraception is not suitable as a regular 
method of contraception and it does not prevent pregnancy 
in every woman. 
• Many women believe that emergency contraception can 
only be taken 3 times in their lifetimes - there is no evidence 
to support this.
• There is no evidence to suggest that use of emergency 
contraception can cause infertility.
• If you are already pregnant, emergency contraceptive pills 
or the coil will not work.
• Emergency contraception does not provide any protection 
from sexually transmitted infections after having 
unprotected sex.
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Emergency contraception facts
•  Women of all ages can use emergency contraception to prevent 
unplanned pregnancy if they have had sex without using 
contraception or their contraception has failed.
•  Many women who have had a crisis pregnancy did not think to use 
emergency contraception.
•  Emergency contraception is not suitable as a regular method of 
contraception and it does not prevent pregnancy in every woman.
•  Many women believe that emergency contraception can only be 
taken 3 times in their lifetimes - there is no evidence to support this.
•  There is no evidence to suggest that use of emergency 
contraception can cause infertility.
•  If you are already pregnant, emergency contraceptive pills or the 
coil will not work.
•  Emergency contraception does not provide any protection from 
sexually transmitted infections after having unprotected sex.
For more information on emergency contraception visit
thinkcontraception.ie
Your guide to emergency contraception
If you’ve taken a chance or your contraception has failed,
you could be at risk of getting pregnant.
What is emergency contraception?
Emergency contraception is a secondary method or ‘back-up’
contraceptive. It can be used if you want to avoid an unplanned
pregnancy after you have had sex without using contraception
or if contraception has failed (e.g. the condom slipped or you
missed a pill). Emergency contraception is more effective the
sooner you take it after having unprotected sex.
Emergency contraception does not provide any protection from
sexually transmitted infections (STIs). To get advice on STI testing
visit thinkcontraception.ie.
It’s important to think about using a regular method of contraception. 
For information about contraceptive options visit
thinkcontraception.ie
Your guide to emergency contraception 
If you’ve taken a chance or your contraception has failed, 
you could be at risk of getting pregnant.
What is emergency contraception?
Emergency contraception is a secondary method or ‘back-up’ 
contraceptive. It can be used if you want to avoid an unplanned 
pregnancy after you have had sex without using contraception 
or if contraception has failed (e.g. the condom slipped or you 
missed a pill). Emergency contraception is more effective the 
sooner you take it after having unprotected sex. 
Emergency contraception does not provide any protection from 
sexually transmitted infections (STIs). To get advice on STI testing 
visit thinkcontracepti n.ie.
Emergency contraception is more effective the
sooner you take it after having unprotected sex.
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Your guide to emergency contrac pti n 
If you’ve taken a chance or your contraception has failed, 
you could be at risk of getting pregnant.
What is emergency contraception?
Emergency contraception is a secondary method or ‘back-up’ 
contraceptive. It can be used if you want to avoid an unplanned 
pregnancy after you have had sex without using contraception 
or if contraception has failed (e.g. the condom slipped or you 
missed a pill). Emergency contraception is more effective the 
sooner you take it after having unprotected sex. 
Emergency contraception does not provide any protection from 
sexually transmitted infections (STIs). To get advice on STI testing 
visit thinkcontraception.ie.
Emergency contraception is more effective the
sooner you take it after having unprotected sex.
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It’s important to think about using a regular method of 
contraception. For information about contraceptive options visit 
thinkcontraception.ie
Emergency contraception is more effective the
sooner you take it after having unprotected sex.
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It is your right to decide when, with whom, how and where you want to  
have sex.
It is your right to make your own choices.
It is your right not to engage in sexual activity.
It is your right to protect yourself from pregnancy and disease.
It is your right to enjoy yourself.
Only you can protect yourself from unplanned  pregnancy and STIs, so 
make sure you know your stuff and look after yourself.
Facts
Fact:   You can get pregnant even if it’s the first time you have had sex.
Fact:   A woman can get pregnant if the man comes near or around her 
genitals or even if he pulls out before he comes.
Fact:   In 2014, a total of 12,626 cases of sexually transmitted infections 
(STIs) were notified in Ireland (adapted from HPSC, 2014).
Fact:   The most frequently reported STIs were chlamydia, genital warts, 
gonorrhoea and genital herpes (adapted from HPSC, 2014).
Fact:   The majority of STIs notified were among those aged less than 25 
years and men who have sex with men (MSM) (adapted from HPSC, 2014).
Make the right choice for you
Sexually transmitted infections (STIs)
Condoms offer protection against most STIs, but only total abstinence 
from all sexual contact offers 100% protection from pregnancy and 
STIs.
Get advice from your doctor, a family planning clinic or an STI clinic if 
you are worried about STIs or are sexually active and notice any of the 
following symptoms:
• unusual discharge from penis or vagina,
• pain when passing urine,
• unusual sores or blisters in the genital area,
• itching or irritation in the genital area, or
• pain during sex.
Once diagnosed, most STIs (except for HIV) can be cured with treatment. 
But make sure you get treatment early, as some infections can have long-
term effects.
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Free public STI screening services
Carlow STI Clinic.............................................................051 842646
Clare STI Clinic Ennis......................................................061 482382
Cork STI Clinic..............................................................021 496 6844
Donegal
Letterkenny Sexual Health Clinic (GUM)......................074 9123715
Dublin
GUIDE Clinic, St. James’ Hospital, Dublin..................01 416 2315/6
STI Clinic Mater Hospital...............................................01 8032063
Galway
Ballinasloe STI Clinic....................................090 9648 372 (ext 676)
University College Hospital STI Clinic............................091 525200
Kerry STI Clinic Tralee...................................................021 4966844
Laois STI Clinic Portlaoise............................................086 8591273
Limerick STI Clinic...........................................................061 482382
Louth
Dundalk Louth County Hospital GUM.Clinic..............086 8241847
Drogheda Our Lady’s Hospital....................................086 8241847
Mayo STI Clinic............................................094 9021733 (ext 3501)
Monaghan General Hospital GUM Clinic.................086 8241847
Sligo GUM Clinic...........................................................071 917 0473
Tipperary
Clonmel STI clinic............................................................051 842646
Nenagh STI Clinic............................................................061 482382
Waterford STI Clinic........................................................051 842646
Westmeath
Mullingar Midland Regional Hospital........................086 4169830
Unplanned pregnancy? 
Freetext the word ‘list’ to 50444 or
visit positiveoptions.ie for a list of free support services.
crisispregnancyprogramme
www.thinkcontraception.ie
#thinkjohnny
Condoms help protect you 
from preganacy and STIs
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For More 
Information
INFORMATION LEAFLET 
Sexual
Exposurewww.emitoolkit.ie
www.hpsc.ie
www.hse.ie
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What treatments are available for 
these infections? 
if you have not previously been vaccinated 
for hepatitis B, you may be advised to get 
vaccinated against hepatitis B. 
•   The first dose of the vaccine may be given to 
you in the emergency department or SAtU. 
•   You will be told where to get the following 
doses which may be with your GP.
•   You will be given a hepatitis B vaccination 
card which will outline when you should get 
the next doses of the vaccine.
HiV Post Exposure Prophylaxis (PEP): this 
is only recommended for a small number 
of patients and depends on the risk of HiV 
transmission as a result of your sexual 
exposure. the doctor will advise you if this 
treatment is required and provide you with 
more information about what the treatment is.
I am worried about pregnancy?
An emergency contraceptive or ‘morning after pill’ may 
be prescribed for you following a pregnancy test. if you 
are going to take the ‘morning after pill’, an information 
leaflet will be given to you which will describe what it is 
and how it works. 
Am I allowed to be a blood donor? 
You should avoid donating blood or other body fluids for 
the duration of your follow up. 
What other follow-up do I 
need?  
•   If you are being referred to a specialist 
clinic, you will either be given their contact 
details or given instructions with regard to 
appointments. 
•   A referral letter will be sent to the specialist 
clinic explaining the assessment and 
treatment that you have received. 
•   If you have any concerns regarding this 
advice or wish to receive counselling, please 
discuss this with your doctor.
Where will I be attending for my next 
appointment (including contact details?) 
When is this appointment?
How do I know if I have one of 
these infections? 
With your consent, a blood sample may 
be taken in the Emergency Department 
to test for bloodborne viruses (hepatitis 
B, hepatitis C and HiV) and syphilis to 
rule out any infection you may already 
have. Arrangements will then be made for 
you to have blood tests carried out again 
over the next few months in case you 
have become infected as a result of this 
sexual exposure. You will then be referred 
for follow-up to the nearest Sexually 
transmitted infection (Sti)/ Genitourinary 
Medicine (GUM) or infectious Disease (iD) 
Clinic where you will be tested for other 
sexually transmitted infections. 
If you have been sexually assaulted and it has been reported to 
the Gardai, you will be referred to the nearest Sexual Assault 
Treatment Unit (SATU) for treatment. 
Am I at risk of an infection? 
Following an assessment and depending 
on your type of sexual exposure, you may be 
at risk of getting some sexually transmitted 
infections, for example, chlamydia, syphilis 
and gonorrhoea. You may also be at risk for 
bloodborne viruses, such as: hepatitis B, 
hepatitis C and HiV. 
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A downloadable version of this brochure can be found at www.emitoolkit.ie
Private and Confidential 
Date: 
Dear Dr. , 
Re: name; address
DoB: 
Re:  Follow-up for Significant Blood /Body Fluid Exposure
the above named person was involved in a reported blood and/or body fluid exposure incident on 
___________ and attended at this service on _____________. 
this person was the: Source/Recipient of the injury (delete as appropriate).
Relevant patient clinical information attached (tick box as appropriate): 
o  If Recipient - copy of the patient management form detailing the assessment and management of 
the recipient at this service.
o  If Source - copy of the source individual’s blood test reports.
in addition, i wish to confirm the following (tick box as appropriate):
o  Patient’s GP informed
o  infectious diseases notification to Director of Public Health/MoH completed
o other __________________________________________________________________
Please do not hesitate to contact this service should you have further queries or concerns.
Yours sincerely,
Referral letter to Infectious Disease/HIV Physician
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eMI Guidelines - Appendix 35  Referral letter to GP/ occupational health department (reviewed May 2016)
Referral letter to GP or Occupational Health Department 
Private and Confidential 
Date: 
Dear Dr. , 
Re: name; address
DoB: 
Re: Follow-up for Blood /Body Fluid Exposure incident
the above named patient/employee of your organisation was involved in a reported blood and/or body 
fluid exposure incident on ___________ and attended at this service on _____________. this person was the 
recipient of the injury.
the exposure incident was considered to be:
o  Not significant
o  Significant
Please find attached a copy of the patient management form detailing their assessment and 
management at this service. 
Follow-up required - 
o  complete the course of hepatitis B vaccination and test for hepatitis B surface antibody 8 weeks after 
completion of the course of vaccination.
o  carry out a hepatitis B surface antibody test 8 weeks from today’s date.
o  wound dressing.
In addition, I wish to confirm the following – 
o  Referred to infectious Disease Service at _____________________________
o  infectious Diseases notification to Director of Public Health completed
o  other _________________________________________________________________
thank you for your cooperation in this matter and do not hesitate to contact this service should you have 
any queries or concerns.
Yours sincerely,
A downloadable version of this letter can be found at www.emitoolkit.ie
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Sexually Transmitted Infection/Genitourinary 
Medicine Clinics
Youth Health Service,
Penrose House,
Penrose Quay,
Cork City.
tel: 076 108 4150
GMHS,
Baggot Street Clinic, 
18 Upper Baggot St.,
Dublin 4.
tel: 01 669 9553 
GUiDE Clinic,
St James’s Hospital,
James’s Street,
Dublin 8.
tel: 01 416 2315/6 
Mater Hospital,
Eccles Street,
Dublin 7.
tel:  01 803 2063 
louth County Hospital,
Dublin Road,
Dundalk.
tel: 086 824 1847 
Waterford Regional Hospital,
Sti clinic,
Waterford.
tel: 051 842 646 
South tipperary General Hospital,
Clonmel,
Co tipperary.
tel: 051 842 646  
Carlow District Hospital,
Sti clinic,
Athy Road,
Carlow.
tel: 051 842 646 
Useful contact information
Health and Safety Authority
the Metropolitan Building
James Joyce Street
Dublin 1
tel: 1890 289 389
National Virus Reference Lab
UCD National Virus Reference 
laboratory 
University College Dublin 
Belfield 
Dublin 4
tel: 01 716 4401
Consultants in Infectious Diseases/Genitourinary 
Medicine
Position currently vacant
University Hospital limerick
tel: 061 301111
Dr Catherine Fleming
Dr Helen tuite
University College Hospital
Newcastle
Galway
tel: 091 544 544
Professor Mary Horgan
Dr Arthur Jackson
Dr Corinna Sadlier
Cork University Hospital
Wilton
Co Cork
tel: 021 454 6400
Dr Susie Clarke 
Dr Fiona lyons
Prof Colm Bergin
Prof Fiona Mulcahy
Dr Jenny kieran
Dr Ceppie Merry
St James’s Hospital GUiDE Dept 
James’s St 
Dublin 8
tel: 01 416 2315/6, 01 416 2590, 01 416 2507,    
01 416 2402, 01 410 3538
Fax: 01 410 3416
Dr Jack lambert 
Dr Paddy Mallon
Dr Gerard Sheehan
Dr Aoife Cotter
Mater Misericordiae University Hospital,
Eccles Street,
Dublin 7
tel: 01 803 2000
Professor Sam McConkey
Dr Cora McNally
Beaumont Hospital
Dublin 9
tel: 809 3000
Dr Eoin Feeney
St. Vincent’s University Hospital
Elm Park
Merrion Rd.
Dublin 4
tel: 01 221 3363/6029
Paediatric Infectious Diseases
Professor karina Butler
our lady’s Children’s Hospital
Crumlin
Dublin 12
tel: 4096100
Dr Paddy Gavin
Children’s University Hospital
temple Street
Dublin 1
tel: 8784200
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Sexually Transmitted Infection/Genitourinary 
Medicine Clinics (Continued) 
South infirmary Victoria University Hospital,
GUM clinic,
old Blackrock Road,
Cork. 
tel: 021 496 6844 
Regional Hospital,
tralee,
Co kerry.
tel: 021 496 6844 
Mid Western Regional Hospital,
Sti clinic,
Dooradoyle,
limerick.
tel: 061 482 382 
General Hospital,
Nenagh,
Co tipperary.
tel: 061 482 382 
Ennis General Hospital,
Ennis,
Co Clare.
tel: 061 482 382 
Mayo General Hospital,
Castlebar,
Co Mayo.
tel: 094 902 1733 (Extn 3501) 
University Hospital Galway,
Newcastle Rd.,
Galway.
tel: 091 525 200 
Portiuncula Hospital,
Ballinasloe,
Co Galway.
tel: 090 964 8372 (Extn 676) 
Sligo General Hospital,
the Mall,
Sligo.
tel: 071 917 0473 
letterkenny General Hospital,
GUM/Sti Clinic,
letterkenny,
Co Donegal.
tel: 074 912 3715  
St Fintans Hospital,
Dublin Road,
Portlaoise.
tel: 086 859 1273
Monaghan General Hospital,
Monaghan,
Co Monaghan.
tel: 086 824 1847
Sexual Assault Treatment Units (SATUs)
Dublin
Rotunda Hospital, 
Parnell Square, 
Dublin 1
01 817 1736 SAtU@rotunda.ie
out of hours: 
Phone hospital 01 817 1700 ask for SAtU
Waterford
Waterford Regional Hospital, 
Dunmore Road, 
Waterford
051 842 157  wrh.satu@hse.ie 
out of hours: 
Phone Hospital 051 848 000 Nurse Manager on duty 
for hospital
Cork
South infirmary Victoria University Hospital (SiVUH) 
old Blackrock Rd., 
Cork.
021 492 6297 
satu@sivuh.ie
out of hours: 
Phone Hospital 021 492 6100 Nurse Manager on duty 
for hospital
Mullingar
Midland Regional Hospital, 
Mullingar, 
Co. Westmeath
044 939 4239 /086 040 9952
satu.mrhm@hse.ie
out of hours: 
Phone Hospital 044 934 0221 Nurse Manager on 
duty for Hospital
Galway
Hazelwood House, 
Parkmore Rd., 
Galway
091 765 751 / 087 633 8118
satugalway.hsewest@hse.ie
out of hours: 
Phone 091 757 631 Nurse Manager on duty for Merlin 
Park Hospital
Donegal
letterkenny General Hospital 
NoWDoC Premises, 
oldtown, 
letterkenny, 
Co. Donegal
074 9104436 Bleep 777 
087 066 4593 /087 068 1964 
satu.letterkenny@hse.ie
out of hours: 
Phone Hospital 074 912 5888 Nurse Manager on duty 
in the Emergency Dept
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Departments of Public Health
HSE East
Dr Steeven’s Hospital
Dublin 8
tel: 01 635 2145
HSE Midlands
Area office,
Arden Road,
tullamore
Co. offaly
tel: 057 935 9891
HSE North-East
Railway Street,
Navan,
Co Meath
tel: 046 907 6412
HSE West
Finance Building,
Merlin Park,
Galway
tel: 091 775 200
HSE North-West
iona House,
Upper Main Street,
Ballyshannon,
Co. Donegal
tel: 071 985 2900
HSE South
Floor 2, Block 8,
St Finbarr’s Hospital,
Douglas Road
Cork
tel: 021 492 7601
HSE South-East
HSE offices,
lacken,
Dublin Road,
kilkenny
tel: 056 778 4124
HSE Mid-West
Mount kennett House,
Henry Street,
limerick
tel: 061 483 337
Sexual Assault Treatment Units (SATUs) 
(Continued)
Limerick
University Hospital limerick,
St. Nessan’s Rd.,
Dooradoyle,
limerick
out of hours service only:
Contact shannondoc: 1850 212 999
During office hours contact Galway or Cork SAtU.
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